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Abstract 
This dissertation primarily describes chemical-scale studies of G protein-coupled receptors 
and Cys-loop ligand-gated ion channels to better understand ligand binding interactions and the 
mechanism of channel activation using recently published crystal structures as a guide.  These 
studies employ the use of unnatural amino acid mutagenesis and electrophysiology to measure 
subtle changes in receptor function. 
In Chapter 2, the role of a conserved aromatic microdomain predicted in the D3 dopamine 
receptor is probed in the closely related D2 and D4 dopamine receptors.  This domain was found to 
act as a structural unit near the ligand binding site that is important for receptor function.  The 
domain consists of several functionally important noncovalent interactions including hydrogen 
bond, aromatic-aromatic, and sulfur-π interactions that show strong couplings by mutant cycle 
analysis.  We also assign an alternate interpretation for the linear fluorination plot observed at 
W6.48, a residue previously thought to participate in a cation-π interaction with dopamine. 
Chapter 3 outlines attempts to incorporate chemically synthesized and in vitro acylated 
unnatural amino acids into mammalian cells.  While our attempts were not successful, method 
optimizations and data for nonsense suppression with an in vivo acylated tRNA are included.  This 
chapter is aimed to aid future researchers attempting unnatural amino acid mutagenesis in 
mammalian cells. 
Chapter 4 identifies a cation-π interaction between glutamate and a tyrosine residue on loop 
C in the GluClβ receptor.  Using the recently published crystal structure of the homologous GluClα 
receptor, other ligand-binding and protein-protein interactions are probed to determine the similarity 
between this invertebrate receptor and other more distantly related vertebrate Cys-loop receptors.  
We find that many of the interactions previously observed are conserved in the GluCl receptors, 
however care must be taken when extrapolating structural data. 
 vii 
Chapter 5 examines inherent properties of the GluClα receptor that are responsible for the 
observed glutamate insensitivity of the receptor.  Chimera synthesis and mutagenesis reveal the C-
terminal portion of the M4 helix and the C-terminus as contributing to formation of the decoupled 
state, where ligand binding is incapable of triggering channel gating.  Receptor mutagenesis was 
unable to identify single residue mismatches or impaired protein-protein interactions within this 
domain.  We conclude that M4 helix structure and/or membrane dynamics are likely the cause of 
ligand insensitivity in this receptor and that the M4 helix has an role important in the activation 
process. 
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Chapter 1 
Introduction 
 
Chemistry at the synapse 
The brain is the most complex object in nature.  Within a human brain are 
approximately 1011 neurons that make between one and ten thousand connections to each 
other through synapses.  It is at these synapses that most of the information processing in 
the brain occurs.  Connected neurons communicate with each other through a process 
called synaptic transmission.  In this process, an electrical signal, known as an action 
potential, propagates down the axon of a neuron.  Once the electrical signal reaches the 
axon terminal, it stimulates the mobilization of vesicles containing neurotransmitters.  
These vesicles fuse with the cell membrane and release their contents into the synaptic 
cleft, which is the space between the two cells.  Neurotransmitters then diffuse across the 
synapse and bind to neuroreceptors on the second neuron.  Upon binding, these 
neuroreceptors either directly or indirectly produce an electrical signal, which can 
promote or inhibit the firing of an action potential in this second neuron (Figure 1.1).   
Two major classes of neuroreceptors exist at the synapse: G protein-coupled 
receptors (GPCRs) and ligand-gated ion channels (LGICs).  These neuroreceptors are 
found in both the central nervous system and the peripheral nervous system and are 
located on both presynaptic and postsynaptic neurons.  GPCRs are often involved in slow 
synaptic transmission by acting through second messenger pathways, including G 
proteins and β-arrestins, and ligand-gated ion channels are involved in fast synaptic 
transmission through the direct passage of ions across the membrane upon activation. 
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Figure 1.1 Synaptic transmission by neuroreceptors. 
 
These receptors bind a variety of ligands including small aminergics, peptides, and fatty 
acids.  And to add to this complexity, multiple inputs from a diverse array of 
neurotransmitters are received simultaneously at the post-synaptic neuron leading to an 
interplay of signals that gives rise to our higher-order brain processing.  Because of the 
complexity of these neuroreceptors, we are interested in elucidating the binding 
interactions between neurotransmitter ligands and their cognate neuroreceptors, and how 
these binding events lead to cellular signaling.  
 
G protein-coupled receptors 
G protein-coupled receptors are an important class of signaling proteins found 
throughout the eukaryotic kingdom.  These receptors comprise the largest family of 
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membrane proteins and represent an important class of drug targets because of their 
integral role in cellular signaling.  GPCRs are located in all cell types in the human body 
and are involved in a number of intracellular signaling pathways required for proper 
cellular function. 
GPCRs are an evolutionarily and structurally homologous family of integral 
membrane proteins that consist of seven transmembrane helices and a G protein-binding 
 
Figure 1.2: GPCR activation and G protein signaling.  Binding of an agonist to the 
receptor (2) induces a conformational change of the receptor’s helices (3). This 
conformational change causes activation of the heterotrimeric G protein. As a result, 
GDP is exchanged for GTP on the Gα subunit (4), which causes dissociation of the Gα and 
Gβγ subunits from the GPCR (5).  These subunits are then free to interact with 
downstream effector proteins.  The cycle is complete (1) when the agonist dissociates 
from the GPCR, the receptor returns to its resting state conformation, and GTP is 
exchanged for GDP (6) on the Gα subunit. 
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domain created by the three intracellular loops of the receptor.  GPCRs function by 
recognizing an extracellular stimulus (in the form of neurotransmitters, chemokines, 
light, odors, and other signaling molecules) and transducing this signal across the 
membrane to initiate downstream intracellular signaling pathways (Figure 1.2).  Based on 
sequence homology, GPCRs are placed into one of six classes termed A-F.  Class A (or 
the rhodopsin-like GPCRs) is the largest class of GPCRs and has the most solved crystal 
structures.  These receptors are mostly activated by light, neurotransmitters, and 
hormones through binding of the ligand to the transmembrane domain of the receptor.  It 
is this class of GPCRs that contains the well-studied rhodopsin, adrenergic (including β2-
adrenergic receptor), and dopamine receptors. 
Receptor activation occurs via ligand binding (or light activation) and results in a 
series of conformational changes in protein structure, which leads to activation of the 
bound heterotrimeric G protein (Figure 1.3).  Activation of the G protein results in the 
exchange of GDP for GTP and dissociation of the Gα and Gβγ subunits.  These subunits 
are then free to interact with downstream signaling effector proteins, depending on the 
identity of the subunits, resulting in signal transduction.  These pathways include 
activating or inhibiting production of cyclic AMP (Gαs or Gαi/o, respectively), 
phospholipase C-dependent activation of the IP3 pathway (Gαq/11), Rho family GTPase 
signaling (Gα12/13), or hyperpolarization of the membrane for vision (Gαt).  The Gβγ 
subunits are also free to interact with other molecules, and, in the case of Gαi/o-associated 
GPCRs, can result in the opening of GIRK channels2-6. 
Due to the difficulties in obtaining crystal structures for integral membrane 
proteins, GPCRs are under-represented in the Protein Data Bank.  However, recent 
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advances in crystallography have led to the 
elucidation of many new high-resolution 
crystal structures in the last few years7-12.  
Despite these advances, very few of the 
hundreds of known GPCRs have solved crystal 
structures, and we are therefore forced to 
extrapolate from structural data of related 
receptors.  Likewise, while these crystal 
structures provide important structural 
information that was not previously available, the structures are a static image of the 
receptor, which provides minimal information about the activation process.  Attempts 
have been made to capture the receptor in a permanently active conformation through 
either mutagenesis13, the binding of a high affinity agonist12,14, the binding of a G protein 
mimicking “nanobody” to the intracellular surface of the receptor10, or by complexation 
of the receptor with its cognate Gα subunit11.  Despite the promise of these new active-
like structures, they are few and still provide only a static image.  It is also unknown 
whether these structures represent a physiologically relevant active structure or are 
altered through the crystallization process.  The lack of structural characterization of this 
large class of proteins, particularly in the activated state, has required a large effort in the 
form of structure-function studies to elucidate the mechanism of receptor activation as 
well as to probe the ability to target these molecules for therapeutic applications. 
 
 
Figure 1.3. Crystal structure of 
rhodopsin with juxtaposed 
heterotrimeric G protein (PDB IDs: 
1GZM and 1GOT) (taken from 1) 
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Cys-loop receptor ligand-gated ion channels  
The Cys-loop receptors are a subfamily of ligand-gated ion channels and are 
named for a characteristic loop in the extracellular ligand-binding domain formed by a 
conserved disulfide bond.  Receptors in this family include the excitatory, cation-
permeable, nicotinic acetylcholine receptors (nAChRs) and 5-HT3A receptor, and the 
inhibitory, anion-permeable, GABAA, GABAC, glycine, and GluCl receptors.  These 
receptors are pentameric, and are either homomeric with five identical subunits or are 
heteromeric and have between two to four different subunits.  All subunits are composed 
of an N-terminal extracellular ligand binding domain and four transmembrane helices 
(M1-M4), with the second transmembrane helix, known as M2, forming the ion-
conducting pore (Figure 1.4).   
 
Figure 1.4. Structure of a Cys-loop receptor.  (A) Crystal structure of the homomeric 
GluClα receptor (PDB ID: 3RIF).  The ligand binding site is indicated by a yellow star. 
(B) Schematic of a typical Cys-loop receptor subunit.   
!" #"
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Ligand binding occurs at the interface between two subunits in the extracellular 
domain, and the number of ligand binding sites is determined by the identity of the 
subunits in the receptor.  In the absence of an agonist, the receptor exists in a non- 
conducting closed state.  Upon ligand binding, a series of conformational changes occur 
near the binding site, which is translated approximately 60Å to the channel gate in the 
M2 helix.  The net result of these movements is opening of the channel pore and ion 
conduction across the membrane.  The receptor can also transition to a ligand-bound, 
non-conducting state known as the desensitized state. 
Similar to GPCRs, ligand-gated ion channels are integral membrane proteins and 
are therefore difficult to crystallize.  Until recently, only low-resolution cryo-EM 
structures of the torpedo nicotinic acetylcholine receptor15,16 and high-resolution 
structures of acetylcholine binding protein17, a soluble protein homologous to the 
extracellular ligand-binding domain of the full-length nAChRs, were available for 
structural information.  However, in the last few years, a series of high-resolution 
prokaryotic and invertebrate ligand-gated ion channel crystal structures were reported, 
representing major advancements in the field of membrane protein crystallography18-22.  
Of these structures, GluClα, a homopentameric glutamate-gated chloride channel from C. 
elegans, represents the only Cys-loop receptor crystallized to date21.  Therefore, despite 
this recent structural data, there are still no high-resolution crystal structures available of 
vertebrate Cys-loop receptors.  And, also similar to GPCRs, arguments have been made 
about the physiological relevance of the captured states.  As such, structure-function 
studies continue to be an important way to study and better understand the dynamic 
processes of ligand binding and receptor activation. 
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Unnatural amino acid mutagenesis 
While conventional mutagenesis is limited to the 20 naturally occurring amino 
acids, unnatural amino acid mutagenesis affords the ability to incorporate a wide range of 
chemically modified amino acids allowing for a more subtle perturbation of a potentially 
important residue (Figure 1.5).   These unnatural amino acids can be incorporated into a 
protein at a specific site using a method known as in vivo nonsense suppression (Figure 
1.6)23.  This method uses a nonsense (or stop) codon introduced by mutation of the codon 
encoding the amino acid of interest and a suppressor tRNA molecule charged with the
 
Figure 1.5.  Diversity of side chain functionality made possible by unnatural amino acid 
mutagenesis. 
!"#$%#&"#'()
*+,'-%#%./.)
!"#$ %"&$
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*+,'-%#%./.)
Phe Cyclohexylalanine 
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Figure 1.6.  Schematic of site-specific incorporation of unnatural amino acids using 
nonsense suppression. 
 
 
unnatural amino acid to be incorporated.  Normally, the nonsense codon results in 
truncated protein due to premature termination of translation.  However, in the presence 
of the suppressor tRNA (a tRNA with an anticodon engineered to recognize the TAG 
stop codon) a full-length protein containing the appropriate unnatural amino acid at the 
site of interest is produced.  This is made possible by “hijacking” the cellular translational 
machinery, which causes the native polymerase to recognize the supplied suppressor 
tRNA and the stop codon as a match.  
To determine the effect of unnatural amino acid mutagenesis of the receptor, 
mRNA encoding the TAG stop codon at the site for unnatural amino acid incorporation is 
co-injected with the appropriately charged tRNA into Xenopus laevis oocytes. Two- 
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Figure 1.7:  Electrophysiology of receptors containing unnatural amino acids.   (1) Inject 
mRNA and unnatural amino acid charged tRNA into oocyte. (2) Oocyte uses cellular 
machinery to produce receptor with unnatural amino acid. (3) Two-electrode voltage 
clamp techniques are used to measure voltage across the membrane.  (4) This is done 
using K+-containing ND96 (for GPCRs) or Ca2+ free ND96 (LGICs) and an application 
of agonist. (5) Agonist application results in activation of the bound heterotrimeric G 
protein and release of Gβγ, which then bind to and activate GIRK channels or initiate 
direct ion movement through the ion-conducting pore. (6) The resulting outcome of a 
series of increasing agonist applications is an EC50 curve, which provides information 
about the effect of the mutation on agonist binding or function of the receptor24.  
 
electrode voltage clamp (TEVC) techniques are then used to measure the change in 
voltage across the oocyte membrane that results from the opening of the membrane-
expressed ion channels upon agonist activation.  In TEVC, the voltage electrode 
measures the membrane potential of the oocyte while the current electrode injects current 
into the oocyte equal to that passing through the open ion channels to maintain a  
! " 
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Figure 1.8.  Using electrophysiology to quantify receptor functionality. (A) Activation of 
ligand-gated ion channels results in channel opening and passage of ions across the 
membrane. (B) Activation of Gαi/o-coupled GPCRs leads to activation of associated 
GIRK channels through released Gβγ subunits.  (C) Dose-response data are fit to the Hill 
equation giving an EC50 measurement.  Gain- and loss-of-function mutations are 
demonstrated by leftward or rightward shifts from wild type, respectively. (D) As 
increasing concentrations of agonist are applied higher currents across the membrane are 
observed.  These data are fit to the Hill equation. 
 
constant voltage across the membrane (Figure 1.7).  The current applied through the 
current electrode is therefore a direct measure of the sum of currents through all ion 
channels in the membrane.   
LGIC = Direct Readout 
GPCR = Indirect Readout 
!"
#"
$" %"
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The function of the wild type and mutant receptors is assayed by applying 
increasing concentrations of agonist (Figure 1.8).  As higher agonist concentrations are 
applied, more channels open.  This results in dose-dependent increases in current across 
the membrane until this effect becomes saturated at sufficiently high doses.  Any change  
in agonist binding or receptor activity due to incorporation of the unnatural amino acid 
can then be determined through the creation of an EC50 plot by fitting the data to the Hill 
equation.  The EC50 value is the concentration required to elicit a half-maximal response 
and is an equilibrium measurement of agonist binding and channel opening.  An increase 
in EC50 relative to wild type corresponds to a loss-of-function mutation, whereas a 
decrease in EC50 corresponds to a gain-of-function mutation. 
In the case of ligand-gated ion channels, the observed current directly correlates 
to the activity of the channel.  This occurs upon binding of an agonist to the ion channel, 
which causes the channel to open and allow ions to transverse the membrane.  However, 
in the case of GPCRs, a direct output of receptor function cannot be determined by 
measuring the voltage across the membrane because GPCRs are not ion channels.  
Instead, a second messenger system involving G protein-coupled inward-rectifying 
potassium channels (GIRK) is used.  When GPCRs are activated by an agonist, the Gβγ 
dimeric subunit is released from the membrane4-6.  The Gβγ subunit is then free to interact 
with other molecules, and in the case of Gαi/o-associated GPCRs results in the opening of 
GIRK channels2,3.  TEVC can therefore be used to measure GPCR activation through 
movement of potassium ions across the membrane through the GIRK channels. 
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Dissertation work 
 In this dissertation, conventional and unnatural amino acid mutagenesis is used to 
study the function of two distinct classes of neuroreceptors, GPCRs and Cys-loop 
receptor ligand-gated ion channels.  Traditional group suppression methodology was used 
for unnatural amino acid incorporation into X. laevis oocytes and TEVC 
electrophysiology was used as the assay.  The receptors primarily targeted for structure-
function study were the D2 and D4 dopamine receptors (GPCRs), the M2 muscarinic 
receptor (GPCR), and the GluCl receptors (LGICs).  The 5-HT3A receptor was used for 
attempted suppression in mammalian cells. 
 Chapter 2 describes research investigating the role of a conserved aromatic 
microdomain found in the core of the D2-like (D2, D3, and D4) dopamine receptors.  
This was assayed through conventional and unnatural amino acid mutagenesis of these 
aromatic residues and expected interaction partners.  Double mutant cycle analysis was 
used to confirm electrostatic interactions between receptor side chains. 
 Chapter 3 details our attempts at unnatural amino acid suppression in mammalian 
cells.  This chapter outlines our optimization of transfection conditions in HEK293T cells 
as progress toward this goal.  While no suppression was observed with transfected 
acylated tRNA, expression using an in vitro transcribed human serine amber suppressor 
tRNA was observed, indicating the potential for success if transfection conditions can be 
further optimized.  These optimization studies should provide a starting point for future 
researchers attempting to solve this problem. 
 Chapters 4 and 5 are dedicated to the study of GluCl receptors.  In Chapter 4, the 
glutamate-receptor interactions are examined using conventional and unnatural amino 
 14 
acid mutagenesis.  Suppression in the GluClβ receptor proved difficult because of low 
receptor expression levels and a high wild type EC50.  Pore mutations and GluClα/GluClβ 
chimeras were made to minimize these difficulties.  Chapter 5 describes the effects of 
GluClα/GluClβ chimeras on coupling of ligand binding and receptor activation. 
 Short appendices are included describing studies on the light-induced effects of 
Ru(bpy) functionalized poly-unsaturated fatty acids on a voltage-gated ion channel and 
screening of physostigmine analogs synthesized by the Reisman group against a variety 
of neuroreceptors. 
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Chapter 2 
Functionally important aromatic-aromatic and sulfur-pi interactions in the D2 dopamine 
receptor 
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Abstract 
The recently published crystal structure of the D3 dopamine receptor shows a 
tightly packed region of aromatic residues on helices 5 and 6 in the space bridging the 
binding site and what is thought to be the origin of intracellular helical motion.  This 
highly conserved region also makes contacts with residues on helix 3, and here we use 
double mutant cycle analysis and unnatural amino acid mutagenesis to probe the 
functional role of several residues in this region of the closely related D2 dopamine 
receptor.  Of the eight mutant pairs examined, all show significant functional coupling   
(Ω > 2), with the largest coupling coefficients observed between residues on different 
helices, C3.36/W6.48, T3.37/S5.46 and F5.47/F6.52.  Additionally, three aromatic 
residues examined, F5.47, Y5.48, and F5.51 show consistent trends upon progressive 
fluorination of the aromatic side chain.  These trends are indicative of a functionally 
important electrostatic interaction with the face of the aromatic residue examined, which 
is likely attributed to aromatic-aromatic interactions between residues in this 
microdomain.  We also propose that the previously determined fluorination trend at 
W6.48 is likely due to a sulfur-π interaction with the side chain of C3.36.  We conclude 
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that these residues form a tightly packed structural microdomain that connects helices 3, 
5, and 6, thus forming a barrier that prevents dopamine from binding further toward the 
intracellular surface.  Upon activation, these residues likely do not change their relative 
conformation, but rather act to translate agonist binding at the extracellular surface into 
the large intracellular movements that characterize receptor activation. 
 
Introduction 
G protein-coupled receptors (GPCRs) comprise a large class of integral 
membrane proteins activated by a wide range of agonists, including small molecule 
neurotransmitters, peptides, and light, leading to initiation of a wide range of downstream 
signaling cascades.  Much research has been done on this class of molecules to elucidate 
the nature of receptor activation, i.e., how such a wide variety of agonists acts on 
hundreds of different receptors to induce activation of a small family of G proteins1.  The 
recent publication of multiple GPCR crystal structures in both the inactive and active-like 
states complements decades of structure-function studies, resulting in a wealth of 
information about the function of these receptors2-6.  However, much remains unknown 
about the nature of the specific events that cause large conformational changes in the 
cytoplasmic region of the receptor, resulting in activation. 
The recently published high-resolution crystal structure of the human D3 
dopamine receptor (D3R) offers a detailed snapshot of the receptor locked in an inactive, 
antagonist bound conformation4.  This crystal structure shows a tightly packed 
hydrophobic core region of conserved residues that includes a cluster of six aromatic 
amino acids on helices 5 and 6.  Aromatic residues are traditionally over-represented at 
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binding sites, and in the aminergic GPCRs, an important role in agonist binding and/or 
receptor activation has been proposed for residues in this microdomain7-9.  In another 
family of ligand-activated receptors, the Cys-loop (pentameric) family of 
neurotransmitter-gated ion channels, a cluster of aromatics defines much of the agonist 
binding site, usually involving an important cation-π interaction to a protonated amine of 
the agonist10-12.  In the aminergic GPCRs, the protonated amine has long been assumed to 
make a strong ionic interaction with the highly conserved D3.32, and recent crystal 
structures confirm this4,13,14.  A complementary cation-π interaction to the cationic 
portion of agonists is still possible, but in the GPCR crystal structures reported to date, 
the aromatic residues in this microdomain do not seem to interact with any cationic center 
of agonists or antagonists.  Instead, a majority of the aromatic residues in this region are 
located away from the binding site and appear to form a network of aromatic-aromatic 
interactions.   
Aromatic-aromatic interactions are an important class of noncovalent interactions 
that participate in ligand-protein interactions, active site tuning, and protein stability15-17.  
For example, double mutant cycle analysis of two Tyr residues in the bacterial 
ribonuclease barnase demonstrated an important T-shaped aromatic-aromatic interaction 
that contributed -1.3 kcal/mol of interaction energy toward protein stability18.  Similar 
interactions that demonstrate comparable interaction strengths have been observed in 
other proteins19-21.  In addition to aromatic-aromatic dimers, higher order arrangements 
(trimers, tetramers, and larger) of aromatic residues have been observed with high 
frequency in proteins deposited in the Protein Data Bank22.  This indicates a role for 
added stability through long-range interactions that bridge distant regions of the protein.   
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In addition to aromatic-aromatic interactions, the D3R crystal structure suggests a 
putative sulfur-π interaction with one of the aromatic residues in this region, as well as a 
hydrogen bond conserved across the family.  The sulfur-π interaction has been probed in 
biological and model systems, and it has been estimated to contribute between 0.5 and 2 
kcal/mol to binding/stability23, although experimental studies in proteins are limited.  
Studies of hydrogen bonding also indicate a contribution of between 0.5-2 kcal/mol to 
protein stability, however interaction energy data between two polar uncharged residue 
side chains are lacking24,25.  It has also been shown that the strength of a hydrogen bond 
is largely dependent on the polarity of its environment, with hydrogen bonds in the 
hydrophobic interior of proteins up to 1.2 kcal/mol stronger than solvent exposed 
interactions26. 
Given their location and conservation, it seems likely that the residues in this 
region have both an important structural and functional role in receptor activation.  In the 
D3R crystal structure, the residues considered here are located at an important interfacial 
region between helices 3, 5, and 6, which likely serves as a connector domain that 
translates agonist binding in the extracellular region into intracellular helical motion and 
receptor activation.  This region also likely forms the intracellular “floor” of the 
agonist/antagonist binding site and prevents these molecules from binding “lower” in the 
receptor, toward the intracellular space.  In the present work we investigate the 
importance and nature of these noncovalent interactions using double mutant cycle 
analysis and unnatural amino acid mutagenesis in the closely related D2 and D4 
dopamine receptors. 
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Methods 
Molecular Biology.  The human constructs of the DRD2 long form, DRD4 (Missouri 
S&T), and M2 receptors were subcloned into the pGEMhe vector, and GIRK1 and 
GIRK4 were in the pBSMXT plasmid.  Mutagenesis of the DRD2 and M2 receptors was 
performed using Stratagene’s QuikChange protocol, and mutagenesis of the DRD4 was 
performed using Herculase II Fusion polymerase (Stratagene) because of the high GC 
content of the cDNA.  For nonsense suppression experiments, a TAG codon was mutated 
into the site of interest.  The cDNA was linearized using the appropriate restriction 
enzyme (SbfI for DRD2, DRD4, and M2 and SalI for GIRK1 and GIRK4).  mRNA was 
produced from the linearized plasmids by using the T7 mMessage Machine kit (Ambion) 
for DRD2, DRD4, and M2 and the T3 kit (Ambion) for GIRK1 and GIRK4. 
74mer THG73 tRNA was synthesized from a DNA oligonucleotide template 
containing two 5’ methoxy (C2’ position) nucleotides to truncate transcription using 
Ambion’s T7 MEGAshortscript kit27.  Amino acids chemically appended to dCA were 
ligated to the end of the 74mer tRNA using methods previously described28.  Acylation of 
tRNA was confirmed using MALDI mass spectrometry using a 3-hydroxypicolinic acid 
matrix.  The NVOC protecting group on the amino acid was removed through a 5-minute 
irradiation step using a 1 kW Xenon lamp with WG-335 and UG-11 filters. 
 
Oocyte Preparation and RNA Injection.  Stage V-VI Xenopus laevis oocytes were 
harvested and injected with RNA as previously described28.  For nonsense suppression 
experiments, 20 ng of receptor mRNA was coinjected with 10 ng each of GIRK1 and 
GIRK4 mRNA and an equal volume of deprotected ~1 µg/µL tRNA solution 48 hours 
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before recording.  For conventional mutagenesis, 1-5 ng of receptor mRNA was 
coinjected with 10 ng each of GIRK1 and GIRK4 mRNA 48 hours before recording.  For 
some low expressing mutants, receptor and GIRK1/4 mRNA and tRNA (if applicable) 
were injected a second time 24 hours before recording.  Wild type recovery and wild type 
experiments used half the amount of receptor mRNA.  As a negative control, all nonsense 
suppression sites were tested with a full length 76mer tRNA lacking an attached amino 
acid.  In all cases, no significant expression was observed. 
 
Electrophysiology.  All oocyte experiments were performed on an OpusXpress 6000A 
(Axon Instruments) using two-electrode voltage clamp mode.  Recording buffers were 
ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES, 1.8 mM CaCl2, pH 7.5) 
and high K+ ringer (72 mM NaCl, 24 mM KCl, 1 mM MgCl2, 5 mM HEPES, 1.8 mM 
CaCl2, pH7.5).  Solution flow rates were 2 mL/min., drug application flow rates were 2.5 
mL/min. for DRD2 and DRD4 and 4 ml/min. for M2.  Initial holding potential was -60 
mV.  Data were sampled at 125 Hz and filtered at 50 Hz.  An ND96 prewash was applied 
for 10 s followed by high K+ for 50 s to establish basal current and then application of 
agonist in high K+ for 25 s.  Agonist was then washed out with high K+ buffer for 45 s 
and subsequently ND96 for 90 s.  Agonist-induced currents were measured using the 
basal current as the baseline as described previously (Figure 2.1)29.  Acetylcholine and 
dopamine (Sigma-Aldrich) dose solutions were made in high K+ buffer from 1 M stock 
solutions.  A minimum of 8 agonist doses were applied to each cell and a minimum of 
three batches of oocytes were used to give the final data.   
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Figure 2.1.  Sample trace of D2R wild type receptors expressed in Xenopus laevis 
oocytes with a 3.3 µM dopamine application.  An EC50 curve was created by measuring 
the current (Iagonist) at varied dopamine concentrations, normalizing these values to the 
maximum Iagonist value, and fitting the data to the Hill equation.  Basal currents are caused 
by free Gβγ in the cell activating the GIRK1/4 channels and were not included in data 
analysis. 
 
Data Analysis.  Data were fit to the Hill equation,  Inorm = 1/(1 + (EC50/A)) nH, where 
Inorm is the normalized current peak at [agonist] = A, EC50 is the concentration of agonist 
that elicits a half-maximum response, and nH is the Hill coefficient.  EC50 values were 
obtained by averaging the Inorm values for each agonist concentration and fitting those 
values to the Hill equation.  Ω values were calculated using the equation:  
[EC50(mut1,2)*EC50(WT)]/[EC50(mut1)*EC50(mut2)]. 
 
Results 
Mutation Studies of D2R. As noted above, a microdomain of conserved residues on 
helices 3, 5, and 6, important for both agonist binding and receptor activation, has been 
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proposed to exist near the binding site of dopamine in the D2-like dopamine receptors 
(D2R, D3R, and D4R).  The recently published crystal structure of D3R shows a tightly 
packed region of aromatic side chains on helices 5 and 6, along with a key cysteine and 
threonine on helix 3 (Figure 2.2).  For the most part these residues do not directly contact 
the antagonist eticlopride, but rather they appear to form a connector domain between the 
agonist binding site and the intracellular domain of the receptor.  In other GPCR 
structures, aligning aromatic residues are also not in contact with bound 
agonists/antagonists. 
Although GPCRs are not ion channels, we are able to measure an 
electrophysiological readout of receptor activation through G protein-coupled inward-
rectifying K+ (GIRK) channels.  GIRK channels are activated by the binding of Gβγ 
subunits released from Gαi/o-coupled GPCRs upon GPCR activation
30-32.  This assay has 
been described previously for the D2 and M2 muscarinic receptors and provides a 
sensitive readout of Gαi/o-coupled GPCRs expressed in Xenopus laevis oocytes29.   
The assay we use is not applicable to D3R because the receptor has a high binding 
affinity for dopamine and thus prevents adequate washing off of agonist between drug 
applications33.  The residues of interest are however highly conserved across the Gαi/o-
coupled D2-like family with only substitutions of phenylalanine for tyrosine at 5.48 and 
cysteine for phenylalanine at 5.51 in the D4R.  Guided by the D3R crystal structure, we 
evaluated putative pairwise interactions between residues in this microdomain to 
determine whether these residues are functionally coupled using double mutant cycle 
analysis.  We have primarily investigated the closely related D2R, but we have also 
considered the more distantly related D4R. 
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Figure 2.2:  Space filling model of residues in the aromatic microdomain of the D3R 
(PDB 3PBL). Shown are both a side view (A) to position the domain of interest with 
respect to the receptor as a whole, and a top-down view (B). Protein residues are shown 
as space-filling, while the bound antagonist eticlopride is shown as a stick figure.  (C) 
Enlarged view showing the residues considered here. Residues are color-coded according 
to their respective helices. Eticlopride and the highly conserved D3.32 are shown for 
reference. 
 
 
D3.32
C3.36
T3.37 S5.46
F5.47
F5.51
Y5.48
W6.48
F6.51
F6.52
eticloprideA
B
C
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Table 2.1: Conventional mutagenesis of residues in the aromatic microdomain of D2R  
 
Residues of interest were mutated to alanine to determine whether the receptor 
would function in the absence of each side chain (Table 2.1).  Most alanine mutants were 
able to activate GIRK1/4 channels upon exposure to viable concentrations of dopamine 
(< 100 µM), generally with quite substantial shifts in EC50.  However, S5.46A, W6.48A, 
and F6.51A did not produce sufficient responses to applied dopamine.  The more subtle 
mutations S5.46C, W6.48F, and W6.48Y did produce functional receptors, with large but 
measurable shifts in EC50.  F6.51Y did not display a significant shift in EC50 and F6.51W 
did not functionally express, and therefore this site was not examined further (Table 2.2). 
To evaluate potential functional coupling of these residues, double mutant cycle 
analysis was performed using the mutants described in Table 2.1 (Figure 2.3, Table 2.3). 
Mutant cycle analysis is a standard technique used to determine whether the perturbing 
effects of two single mutants are functionally coupled or act independently. This is done 
by calculating a coupling coefficient (Ω = [EC50(mut1,2)*EC50(WT)]/ 
[EC50(mut1)*EC50(mut2)]).  If the two mutations are independent of each other, Ω ~1. 
Mutant EC50 (µM) Hill n  Mutant EC50 (µM) Hill n 
         
WT 0.020 ± 0.001 1.2 ± 0.1 15  F6.51A > 100  10 
C3.36A 0.49 ± 0.03 1.1 ± 0.1 16  F6.52A 0.071 ±0.003 1.4 ± 0.1 19 
T3.37A 1.9 ± 0.2 1.0 ± 0.1 13  C3.36S 0.67 ± 0.04 1.1 ± 0.1 17 
S5.46A No Response   T3.37C 2.1 ± 0.1 1.1 ± 0.1 13 
F5.47A 1.6 ± 0.2 0.9 ± 0.1 14  T3.37V No Response  
Y5.48A 0.50 ± 0.02 1.1 ± 0.1 17  S5.46C 2.4 ± 0.1 1.0 ± 0.1 14 
F5.51A 0.47 ± 0.02 1.1 ± 0.1 11  W6.48F 3.4 ± 0.1 1.0 ± 0.1 16 
W6.48A No Response   W6.48Y 0.65 ± 0.04 1.0 ± 0.1 17 
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Table 2.2: Conventional mutagenesis of D2R 
Mutant (D2R) EC50 (µM) Hill n Fold Shift 
 
Wild type 
 
0.020 +/- 0.001 
 
1.2 +/- 0.1 
 
15 
 
- 
C3.36A 0.49 +/- 0.03 1.1 +/- 0.1 16 25 
C3.36K No response 
C3.36L No response 
C3.36M No response 
C3.36S 0.67 +/- 0.04 1.1 +/- 0.1 17 34 
T3.37A 1.9 +/- 0.2 1.0 +/- 0.1 13 95 
T3.37C 2.1 +/- 0.1 1.1 +/- 0.1 13 105 
T3.37S 0.0050 +/- 0.0003 1.1 +/- 0.1 21 1/4 
T3.37V No response 
S5.46A No response 
S5.46C 2.4 +/- 0.1 1.1 +/- 0.1 14 120 
F5.47A 1.6 +/- 0.2 0.9 +/- 0.1 14 80 
F5.47W 0.34 +/- 0.01 1.3 +/- 0.1 12 17 
F5.47Y 0.051 +/- 0.004 1.3 +/- 0.1 10 3 
Y5.48A 0.50 +/- 0.02 1.1 +/- 0.1 17 25 
Y5.48F 0.020 +/- 0.001 1.0 +/- 0.1 4 1 
Y5.48W No response 
F5.51A 0.47 +/- 0.02 1.1 +/- 0.1 11 24 
F5.51W 0.045 +/- 0.003 1.2 +/- 0.1 12 23 
F5.51Y 0.0051 +/- 0.0007 1.1 +/- 0.1 9 1/4 
F6.44A 0.018 +/- 0.002 1.3 +/- 0.1 6 1/1.1 
W6.48A No response 
W6.48F 3.4 +/- 0.1 1.0 +/- 0.1 16 170 
W6.48Y 0.65 +/- 0.04 1.0  +/- 0.1 17 33 
F6.51A > 100  10 >5000 
F6.51W No response 
F6.51Y 0.11 +/- 0.01 1.2 +/- 0.1 10 6 
F6.52A 0.071 +/- 0.003 1.4 +/- 0.1 19 4 
F6.52W 160 +/- 7 0.9 +/- 0.1 12 8000 
F6.52Y 2.6 +/- 0.9 0.9 +/- 0.1 15 130 
C3.36S/F5.47A 12 +/- 1 1.2 +/- 0.1 14 600 
C3.36S/W6.48F 8.1 +/- 0.4 1.0 +/- 0.1 18 405 
C3.36S/W6.48Y 2.1 +/- 0.1 1.0 +/- 0.1 15 105 
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T3.37C/S5.46C 2.0 +/- 0.1 1.1 +/- 0.1 17 100 
F5.47A/Y5.48A 18 +/- 1 1.2 +/- 0.1 12 900 
F5.47A/F5.51A 5.7 +/- 0.2 1.0 +/- 0.1 11 285 
F5.47A/F6.52A 125 +/- 9 1.3 +/- 0.1 18 6250 
F5.51A/F6.52A 4.6 +/- 0.1 1.1 +/- 0.1 16 230 
 
Mutant cycles using EC50 values have been reported for multiple receptors to signify 
important protein-ligand and residue side chain interactions34-38.  We appreciate, 
however, that the EC50 values presented here result from a complex signaling process, 
and so care must be taken in interpreting the results.  As such, we have rejected the 
common practice of converting Ω values to ∆∆G values (=-RTln(Ω)), as this could be 
pushing the analysis too far. In the present case, an Ω > 1 indicates that the double mutant 
is less functional than predicted from the single mutants, and an Ω < 1 indicates that the 
double mutant is more functional than predicted.  We do not think it is meaningful to 
distinguish these two cases, and simply conclude that if Ω deviates from unity by more 
than a factor of 2, the residues interact significantly.  To facilitate comparisons we report 
Ω values < 1 as fractions, such that a mutant pair with an Ω of 1/5 would have the same 
interaction strength as a mutant pair with an Ω of 5.  
In the D3R crystal structure, the side chain of C3.36 points directly into the face 
of the aromatic ring of W6.48.  Mutant cycle analysis suggests a functionally important 
interaction between the two, with Ω values of 1/14 and 1/10 for the C3.36S/W6.48F and 
C3.36S/W6.48Y pairs, respectively (Table 2.3).  C3.36S was used in place of C3.36A 
due to higher receptor expression levels of the single and double mutants.   
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Figure 2.3:  Mutant cycle analysis of the residues examined in this study. The strongest 
coupling values are observed between residues on different helices.  The Ω values 
between residues are indicated. 
 
 
 
Table 2.3: Mutant cycle analysis of putative pairwise interactions in the D2R 
 
Mutant EC50 (µM) Hill n Ω  
     
T3.37C/S5.46C 2.0 ± 0.1 1.0 ± 0.1 17 1/125 
F5.47A/F6.52A 125 ± 9 1.3 ± 0.1 18 23 
C3.36S/W6.48F 8.1 ± 0.4 1.0 ± 0.1 18 1/14 
C3.36S/W6.48Y 2.1 ± 0.1 1.0 ± 0.1 15 1/10 
F5.47A/F5.51A 5.7 ± 0.2 1.0 ± 0.1 11 1/6.6 
C3.36S/F5.47A 12 ± 1 1.2 ± 0.1 14 1/4.5 
F5.51A/F6.52A 4.6 ± 0.1 1.1 ± 0.1 16 2.8 
F5.47A/Y5.48A 18 ± 1 1.2 ± 0.1 12 1/2.2 
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Other strong side chain couplings were observed between F5.47/F6.52 and 
F5.47/F5.51, indicating the presence of important aromatic-aromatic interactions in this 
region.  The strongest interaction was observed between the putative hydrogen bond pair 
T3.37/S5.46.  We recognize the potential complication of using cysteine mutants to probe 
this interaction, in that a disulfide bond could form and this could impact the mutant 
cycle analysis.  However, the cysteine mutants were the only ones that expressed 
adequately to allow mutant cycle analysis.  Treatment with DTT was inconclusive, 
presumably because of the presence of an important disulfide on the extracellular surface 
between helix 3 and extracellular loop 2.  We are confident however that a hydrogen 
bond exists between these residues due to the overlapping electron density of the oxygen 
atoms of both side chains in the crystal structure.  Both T3.37 and S5.46 were 
individually sensitive to mutation, and no other double mutant of T3.37/S5.46 
functionally expressed.  Weaker coupling energies were observed for the F5.51/F6.52 and 
F5.47/Y5.48 pairs, but there is still evidence for a meaningful interaction. 
 
Nonsense suppression experiments. To further examine the nature of the interactions 
identified through mutant cycle analysis, unnatural amino acid mutagenesis was 
performed.  Mutation of a residue to an unnatural analog can produce a more subtle 
perturbation, avoiding the potential issues that mutating large bulky aromatic residues to 
alanine can cause, such as forming destabilizing cavities.  In the past we have used 
progressive fluorination of aromatic amino acid side chains to especially good effect.  
The surface of the aromatic side chains of Phe, Tyr, and Trp contains a build-up of 
negative electrostatic potential that leads to significant noncovalent interactions that are 
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not possible with simple hydrophobic residues such as Leu, Ile, and Val.  Successive 
fluorination of the aromatic ring diminishes the negative electrostatic potential and thus 
weakens noncovalent interactions.  The strongest of the noncovalent interactions 
involving aromatics is the cation-π interaction, in which a full positive charge is attracted 
to the negative electrostatic potential of the ring39,40.  Fluorination studies have revealed 
over 20 cation-π interactions across a wide range of proteins10-12.  The negative 
electrostatic potential of simple aromatics also gives rise to a number of so-called “polar-
π” interactions, in which the positive end of a bond dipole interacts with the face of the 
ring41.  NH and OH bonds of amines and alcohols/water can interact significantly with 
aromatics42.  The CH bonds of aromatics are also polarized (Cδ–••• Hδ+), and this gives 
 
 
 
Figure 2.4:  EC50 curves for D2R Y5.48Phe, F1Phe, F2Phe, and F3Phe, respectively.  
Data was fit using the Hill equation. 
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Figure 2.5. Fluorination trends of aromatic residues found in the aromatic microdomain 
of the D2R.  A linear trend indicates the existence of an electrostatic interaction with the 
face of the residue examined. 
 
Table 2.4: Unnatural amino acid mutagenesis of aromatic residues in the D2R 
Site Mutant EC50 (µM) Hill n Fold Shift 
      
F5.47 Phe 0.026 ± 0.001 1.1 ± 0.1 19 - 
 F1Phe 0.087 ± 0.006 1.1 ± 0.1 8 3 
 F2Phe 1.0 ± 0.1 1.0 ± 0.1 9 39 
 F3Phe 1.3 ± 0.1 1.0 ± 0.1 12 49 
 Me2Phe 0.35 ± 0.02 1.3 ± 0.1 7 13 
Y5.48 Phe 0.085 ± 0.004 1.3 ± 0.1 13 - 
 F1Phe 0.16 ± 0.01 1.1 ± 0.1 9 1.9 
 F2Phe 0.52 ± 0.06 0.9 ± 0.1 6 6.1 
 F3Phe 1.2 ± 0.1 1.0 ± 0.1 13 14 
F5.51 Phe 0.024 ± 0.001 1.2 ± 0.1 18 - 
 F1Phe 0.045 ± 0.003 1.5 ± 0.1 9 1.6 
 F2Phe 0.059 ± 0.003 1.4 ± 0.1 13 2.0 
 F3Phe 0.087 ± 0.003 1.2 ± 0.1 12 2.8 
W6.48 Trp 0.042 ± 0.004 1.0 ± 0.1 15 - 
 F1Trp 0.12 ± 0.01 1.0 ± 0.1 14 3 
 F2Trp 0.29 ± 0.03 1.0 ± 0.1 11 7 
 F3Trp 0.84 ± 0.06 0.9 ± 0.1 13 20 
 F4Trp 1.8 ± 0.3 0.8 ± 0.1 16 43 
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rise to the familiar aromatic-aromatic interactions, in which the positive periphery of 
aromatic systems and the negative center of aromatics interact in either T-shaped or 
parallel-displaced geometries16,17.  Progressive fluorination should modulate these polar-
π interactions just as it does a cation-π interaction.   
Fluorination of residues F5.47, Y5.48, and F5.51 resulted in a linear fluorination 
trend upon incorporation of Phe analogs containing 1, 2, or 3 fluorines (Figure 2.4, Figure 
2.5, and Table 2.4).  As in previous studies, Y5.48 was probed with fluorinated Phe 
analogues, as fluorinating a tyrosine introduces the complicating feature of modulating 
the pKa of the OH.  The Y5.48F mutation produced only a slight deviation from wild type 
and therefore it is expected that Phe analogs should produce relevant data (Table 2.2). 
These results are indicative of an electrostatic interaction involving the face of the residue 
being fluorinated because fluorination should only significantly diminish the electrostatic 
component of interaction.   
F5.47Cha was previously reported to exhibit a near-wild type EC5029.  This is 
inconsistent with the interpretation that the fluorination trend shown here is a result of an 
electrostatic interaction with the face of this side chain, as substituting cyclohexylalanine 
for phenylalanine should eliminate the electrostatic effect observed at this site.  We have 
found considerable inconsistency in the expression of the F5.47Cha mutant, such that we 
have been unable to reproduce the previously reported results.  As such, we conclude that 
there is a functionally important electrostatic interaction occurring with the face of F5.47.  
We have also previously reported a similar fluorination trend for W6.48 (reproduced here 
in Figure 2.5 and Table 2.4).  Previous fluorination studies of F6.51 and F6.52 in the D2R 
receptor were inconclusive, in part due to complications from steric effects29. 
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D4R.  Fluorination studies in the D4 receptor produced results similar to what was 
observed in the D2R receptor, with the exception of F5.48, where no fluorination trend 
was observed (Table 2.6 and Figure 2.6).  This is surprising, given the homology between 
the receptors, and the fact that all the aromatic residues examined except 5.51 (Cys in 
D4R) are conserved between the two receptors.  It is also interesting to note that C3.36 
and W6.48 show no functional coupling in the D4R receptor, despite the observed 
fluorination trend at W6.48 (Table 2.5).  These data indicate that although the receptors 
show considerable sequence conservation, significant structural/functional differences 
between the two receptors do exist.  This is also supported by the difference in homology 
and pharmacology patterns between receptors.  D2R and D3R display higher sequence 
identity to each other (52%) than either do to D4R (39% and 41%, respectively)43, and 
studies show that the pharmacologies of D2R and D3R are more similar than either are to 
D4R44.  It is therefore likely that the D3R crystal structure provides a less accurate 
depiction of the D4R receptor than it does for the D2R receptor. 
 
M2.  The M2 muscarinic acetylcholine receptor contains a conserved aromatic residue at 
positions 5.47(F), 5.48(Y), 6.48(W), and 6.51(Y).  It was previously determined that the 
M2 receptor did not show evidence of an electrostatic interaction at W6.4829.  In this 
study we show that the M2 receptor also does not exhibit an electrostatic interaction at 
F5.47.  This is not surprising, because the M2 receptor does not have an aromatic residue 
at the 5.51(V) or 6.52(N) positions, providing no aromatic residues to interact with the 
face of F5.47.  We have also done a preliminary evaluation of several other residues that 
contribute to the aromatic cage of the M2 receptor (Y6.51, Y7.39, and Y7.43), but we 
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Figure 2.6:  Fluorination trends of aromatic residues in the D4R.  Solid lines represent 
residues showing a linear fluorination trend, dotted lines indicate poor fitting to a linear 
equation. 
 
 
 
Table 2.5:  Conventional mutagenesis of D4R 
 
Mutant (D4R) EC50 (µM) Hill n Fold shift Ω 
 
Wild type 
 
0.028 +/- 0.001 
 
1.4 +/- 0.1 
 
17 
 
- 
 
F5.48A 0.016 +/- 0.001 1.4 +/- 0.1 12 1/1.7  
C5.51F 0.023 +/- 0.002 1.5 +/- 0.1 14 1/1.3  
C3.36S 0.017 +/- 0.001 1.4 +/- 0.1 13 1/1.7  
W6.48F 0.37 +/- 0.01 1.3 +/- 0.1 12 13  
W6.48Y 0.40 +/- 0.01 1.1 +/- 0.1 15 14  
C3.36S/W6.48F 0.28 +/- 0.01 1.3 +/- 0.1 13 10 1.2 
C3.36S/W6.48Y 0.51 +/- 0.03 1.2 +/- 0.1 12 18 2.1 
D3.32E 2.7 +/- 0.1 0.9 +/- 0.1 13 100  
D3.32N 230 +/- 14 1.2 +/- 0.1 10 8200  
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Table 2.6: Unnatural amino acid mutagenesis of related aminergic receptors 
Receptor/Site Mutant EC50 (µM) Hill n Fold Shift 
 
D4R F5.47 
 
Phe 
 
0.017 ± 0.002 
 
1.3 ± 0.1 
 
19 
 
- 
 F1Phe 0.041 ± 0.005 1.2 ± 0.1 14 2.4 
 F2Phe 0.27 ± 0.01 1.0 ± 0.1 19 16 
 F3Phe 0.72 ± 0.04 1.0 ± 0.1 14 42 
 Cha 0.55 ± 0.04 0.9 ± 0.1 12 32 
 MePhe 0.031 ± 0.003 1.1 ± 0.1 4 1.8 
 Me2Phe 0.10 ± 0.01 1.1 ± 0.1 13 6 
F5.48 Phe 0.018 ± 0.001 1.4 ± 0.1 20 - 
 F1Phe 0.019 ± 0.001 1.4 ± 0.1 12 1.1 
 F2Phe 0.025 ± 0.002 1.7 ± 0.2 13 1.4 
 F3Phe 0.030 ± 0.002 2.0 ± 0.2 12 1.7 
 Cha 0.029 ± 0.002 1.4 ± 0.1 19 1.6 
W6.48 Trp 0.018 ± 0.001 1.3 ± 0.1 32 - 
 F1Trp 0.0080 ± 0.0006 1.2 ± 0.1 20 1/5 
 F2Trp 0.026 ± 0.001 1.2 ± 0.1 21 1.4 
 F3Trp 0.070 ± 0.010 1.0 ± 0.1 18 3.7 
 F4Trp 0.13 ± 0.01 1.3 ± 0.1 11 5.5 
 Nap 0.024 ± 0.002 1.4 ± 0.1 16 1.3 
 MeTrp 0.0078 ± 0.0015 1.1 ± 0.2 4 1/2.5 
F6.51 Phe 0.018 ± 0.001 1.1 ± 0.1 20 - 
 BrPhe 0.093 ± 0.006 1.0 ± 0.1 10 5.5 
 CNPhe 0.16 ± 0.01 1.2 ± 0.1 11 10 
 F1Phe 0.025 ± 0.002 1.2 ± 0.1 14 1.5 
 F2Phe 0.32 ± 0.01 1.1 ± 0.1 16 18 
 F3Phe 0.36 ± 0.02 1.1 ± 0.1 13 20 
 Cha 0.39 ± 0.04 1.1 ± 0.1 13 21 
 Me2Phe 55 ± 7 1.0 ± 0.1 5 3000 
F6.52 Phe 0.019 ± 0.001 1.1 ± 0.1 25 - 
 BrPhe 0.039 ± 0.003 1.2 ± 0.1 12 2 
 CNPhe 0.025 ± 0.002 1.3 ± 0.1 13 1.3 
 F1Phe 0.0072 ± 0.0004 1.4 ± 0.1 14 1/2.5 
 F2Phe 6.0 ± 0.3 0.7 ± 0.1 6 310 
 F3Phe 0.40 ± 0.02 0.9 ± 0.1 12 21 
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M2 F5.47 Phe 0.25 ± 0.02 1.2 ± 0.1 12 - 
 F3Phe 0.31 ± 0.02 1.0 ± 0.1 18 1.2 
 Cha 0.97 ± 0.04 1.0 ± 0.1 13 3.9 
 
have found these residues to be very sensitive to even subtle mutations such as Tyr-to-
Phe, and so we have been unable to evaluate them in ways that parallel the work 
described here. 
 
Discussion 
It has long been appreciated that there are a number of conserved aromatic amino 
acids in class A GPCRs, and many studies have proposed that these residues play a 
crucial role in binding agonists/antagonists.  We have previously probed some of these 
aromatics in the D2R and produced evidence that one highly conserved residue, W6.48, 
makes a direct binding interaction to dopamine.  Our model also proposed a rotation of 
the side chain of W6.48 to facilitate dopamine binding, and indeed this residue has long 
been proposed to play the role of a “rotamer toggle switch” in GPCR activation. 
However, as more and more GPCR crystal structures with agonists/antagonists bound 
have appeared, a pattern has emerged in which drugs bind relatively “high up” (toward 
the extracellular space) in the receptor, at a location where many of the residues of this 
aromatic microdomain cannot directly contact the drug.  Certainly in the D3R structure, 
which serves as the foundation for the present study, W6.48 and other contributors to the 
aromatic microdomain do not directly contact the bound antagonist eticlopride, and the 
side chain of W6.48 has not rotated.  Many other structures of GPCRs show a similar 
conformation for the aligning residue, although in the recent structures of opioid 
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receptors W6.48 does contact bound drug.  Also, in a recent structure of the M2 receptor 
with the antagonist QNB bound, the drug is bound more deeply in the receptor crevice, 
where 5 aromatic amino acids form an “aromatic cage” around the cationic end of the 
drug, as has been seen in a number of ACh binding sites.  However, W6.48 is the only 
residue of the aromatic microdomain considered here that contributes to the aromatic 
cage.  It is interesting, however, that in order to form the aromatic cage of the M2 
receptor, the side chain of W6.48 has rotated to a position not seen in most other GPCR 
crystal structures, but that is similar to what we had previously proposed for D2R. 
Returning to the D3 structure, a cluster of aromatic residues is evident, but it is 
unclear what its functional role might be.  The present work was undertaken with a goal 
of evaluating the functional significance of this microdomain in the dopamine receptor, 
with an emphasis on evaluating possible functional interactions that are implied by the 
structure.  As noted above, our assay system is not compatible with the D3R, and so we 
have investigated the closely related D2R, while also performing more limited studies on 
the more distantly related D4R and M2 receptor. 
 
Residue coupling through mutant cycle analysis.  We considered various pairwise 
interactions involving residues C3.36, T3.37, S5.46, F5.47, Y5.48, F5.51, W6.48, and 
F6.52 (Figure 2.3).  Of the eight pairs considered, six produced clearly meaningful 
interactions (Ω ≥ 4.5), while two others were smaller, but still significant (Ω > 2). 
Especially large coupling coefficients are seen with T3.37C/S5.46C, C3.36S/W6.48F, 
and F5.47A/F6.52A, providing evidence for strong functional coupling between residues 
that directly connect helices 3, 5, and 6.  The notion that this cluster of residues functions 
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as a unit is supported by the long-range coupling seen between F5.51/F6.52 and 
C3.36/F5.47. 
 
Probing aromatic-aromatic interactions using unnatural amino acid mutagenesis.  
While mutant cycle analysis and fluorination of aromatic residues have been previously 
used to examine aromatic-aromatic interactions in proteins45,46, to our knowledge this is 
the first example of using unnatural amino acid mutagenesis to examine the electrostatic 
component of these interactions.  We have successfully incorporated fluorinated 
phenylalanine and tryptophan derivatives at a number of conserved residues in this 
aromatic microdomain of the D2 dopamine receptor.   
We noted above the previously reported strong and consistent response of W6.48 
to fluorination and our earlier interpretation of this as indicating a cation-π interaction. 
However, this interpretation was called into question by the D3R structure.  In that 
structure, W6.48 is not in a position to contact the amine of drugs or other atoms that may 
bear a large partial positive charge, but rather experiences a van der Waals contact with 
the side chain of C3.36, in which the sulfur of the cysteine points directly into the face of 
the Trp side chain.  Mutant cycle analysis establishes a strong coupling between W6.48 
and C3.36, indicating that this interaction is functionally significant.  In the D3R crystal 
structure, W6.48 does make a weak hydrophobic contact with the bound drug eticlopride, 
and so we cannot completely rule out a direct interaction between dopamine and W6.48 
in the activated receptor.  However, it would be difficult to see how such an interaction 
could produce the linear fluorination trend of Figure 2.5, and so we feel that an 
interaction between W6.48 and C3.36 is the more plausible interpretation.  
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Sulfur-arene interactions are in fact quite common in protein crystal structures. 
For example, Met is as likely as Phe or Trp to be near another Trp, with the majority of 
the interactions being to the face of the ring47,48.  While the nature of the interaction is 
primarily dispersive, there is generally considered to be a significant electrostatic 
component as well49.  
We propose that the fluorination of W6.48 is probing this sulfur-arene interaction, 
and removing electron density from the aromatic diminishes the magnitude of the 
interaction.  In addition to a lack of hydrogen atom resolution in the crystal structure, 
computational studies disagree whether the face of aromatic side chains preferentially 
interact with the lone pairs of the sulfur atom or through an SH-π interaction47,49,50.  Our 
fluorination experiments are unable to distinguish between the two scenarios because 
both occur through an electrostatic interaction with the face of W6.48.  Progressive 
fluorination may also impact the dispersion component of the interaction, as F is the least 
polarizable of the elements.  The fact that fluorination of W6.48 in the M2 receptor does 
not produce a comparable trend is consistent with this analysis, as residue 3.36 is valine 
in the M2 receptor, and so no sulfur-arene interaction is possible.  To our knowledge, this 
is the first example of evaluating a sulfur-arene interaction by modulating the 
electrostatic surface of the arene.   Note that the magnitude of the sulfur-arene interaction 
appears to be considerable.  Tetrafluorination of W6.48 (which essentially makes the 
aromatic surface electrostatically neutral) results in a 300-fold shift in EC50.  
We also see linear fluorination plots for residues F5.47, Y5.48, and F5.51, 
indicating noncovalent electrostatic interactions with the faces of these residues.  Given 
the crystallographic results, we propose that fluorination is probing various arene-arene 
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interactions in the D2 receptor.  We emphasize that our assay is a functional one, 
indicating that the noncovalent interactions involving these residues play a significant 
functional role.  In the past we have considered the relative slopes of such fluorination 
plots to be indicative of the magnitude of the electrostatic component of the relevant 
noncovalent interaction.  Here, the relative values of the slopes are F5.47 > W6.48 > 
Y5.48 > F5.51.  These would appear to be consistent with expectations from the D3R 
crystal structure. F5.47 is at the heart of the aromatic region of this microdomain, and it 
makes a parallel stacking interaction with F6.52 and F5.51 and a T-shaped interaction 
with Y5.48.  Y5.48 only makes the single interaction to F5.47.  F5.51 is further away 
from the other aromatics, and the slope associated with it is the smallest we have seen for 
a fluorination plot.  We propose that it makes a weak parallel stacking interaction with 
F5.47.  In our mutant cycle analyses, we paired F5.47 with both Y5.48 and F5.51, and the 
latter produced a larger coupling energy than the former, opposite to the fluorination 
trend.  We are inclined to accept the conclusion from fluorination that the Y5.48•••F5.47 
interaction is stronger than the F5.51•••F5.47 interaction because of the much more subtle 
perturbation introduced by fluorination vs. the highly perturbing arene-to-alanine 
mutation. 
The major interactions probed here, involving residues on helices 3, 5 and 6 
suggest a network of interactions that form a belt in the center of the receptor 
(C3.36/W6.48, F5.47/F6.52, and T3.37/S5.46).  This belt is located between the binding 
site and what is thought to be the origin of intracellular helical motion.  The relative 
orientations of these residues as well as residues in the binding site do not change much 
between the active and inactive structures in the homologous β2 adrenergic receptor.  
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However, a large movement of the side chain of F6.44 past I3.40 as well as the 
appearance of a large bulge at P5.50 are observed, all of which are located one helix turn 
toward the intracellular side of this proposed belt region3.  We therefore propose that the 
residues examined play an important structural role in the activation process, specifically 
serving as a rigid structural unit that prevents dopamine from binding further toward the 
intracellular surface and translates agonist binding into the large intracellular helical 
movement of helices 5 and 6 that occur upon agonist binding.   
 
Conservation in Other Receptors.  While the residues in the transmembrane domain of 
GPCRs are highly conserved, it seems that the functional significance of many residues 
varies from receptor to receptor.  Even within the same receptor family, such as D2R vs. 
D4R, aligning residues studied here do not always respond to functional probes in the 
same way.  This is even more true for the less closely related M2 receptor. It appears that 
considerable caution is in order when making predictions about a GPCR based on 
structural or functional data from even a close relative of the receptor. 
 
Conclusions 
Using the D3R crystal structure as a model, we identified a conserved domain 
located between the agonist binding site and what is thought to be the origin of 
intracellular helical motion.  Residues in this microdomain in the related D2R were 
examined using mutant cycle analysis and unnatural amino acid mutagenesis to 
determine whether putative interactions between residues side chains were functionally 
important.  In this study, we demonstrate 7 functionally important noncovalent 
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interactions between residues on helices 3, 5, and 6.  These interactions include aromatic-
aromatic, sulfur-π, hydrogen bond, and long range interactions, which support the notion 
that this microdomain functions as a unit.  We also show that the largest coupling 
coefficients are observed between residues on different helices, indicating an important 
region of helix connectivity.  
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Chapter 3 
Optimization of DNA and in vitro transcribed tRNA cotransfection into mammalian cells 
for the expression of unnatural amino acids* 
 
*Work done in collaboration with Nyssa Puskar 
Abstract 
 Unnatural amino acid incorporation into proteins in mammalian cells would allow 
for a versatile way to subtly perturb and study mammalian proteins and signaling 
cascades in an endogenous environment.  Unfortunately, the methodology used by this 
lab has not been applied to mammalian cells in a manner that rivals the robust signals 
observed through electrophysiology of ion channels heterologously expressed in Xenopus 
laevis oocytes.  We therefore seek to improve transfection conditions in HEK293T cells 
to enhance protein expression using an in vitro transcribed and acylated tRNA as assayed 
with a membrane sensitive dye and the FlexStation3.  Here, we describe optimized 
cotransfection conditions for in vitro transcribed tRNA and plasmid DNA.  Both double 
transfection using the Neon electroporation system and single transfection with TransIT 
gave robust functional responses to agonist application for wild type and mutant proteins.  
Using these transfection methods we were able to observe functional expression of 
receptors containing a serine residue delivered from an in vitro transcribed human amber 
serine suppressor tRNA, indicating effective transfection of both tRNA and DNA.  
Experiments using in vitro transcribed and acylated tRNA did not result in functional 
responses, indicating further optimization is required for effective delivery of this 
stoichiometric reagent. 
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Introduction 
 Nonsense suppression with unnatural amino acids has been well established as a 
powerful tool to study the structural and functional properties of proteins.  Unnatural 
amino acid mutagenesis enables the site-specific introduction of nearly any chemically 
synthesized amino acid that can pass through the ribosome.  This allows for the 
introduction of much more subtle perturbations or novel functionalities not available in 
the 20 conventional amino acids.  For example, fluorinated aromatic amino acids can be 
used to identify electrostatic interactions with the face of the aromatic side chain1,2, 
proline analogs to measure cis-trans preference3, or α-hydroxy amino acids to examine 
hydrogen bond interactions with the backbone carbonyl or amine4. 
 Two major methods have been developed for the efficient incorporation of 
unnatural amino acids into proteins in a variety of cellular expression systems:  in vitro 
tRNA synthesis/acylation5,6 and engineering of an orthogonal tRNA/synthetase pair7.  
Both methods have their benefits and drawbacks, and are therefore used for different 
purposes.  The orthogonal tRNA/synthetase pair method has been effectively used to 
incorporate amino acids into a variety of expression systems with the ability to synthesize 
higher amounts of protein7-10, however the amino acid side chains that can be 
incorporated are limited by the evolution of a new synthetase for each novel side chain.  
As such, only a small subset of unnatural amino acids can be incorporated by this 
method.  Some permissive synthetases have been developed that allow incorporation of a 
variety of structurally similar unnatural amino acids, for example the pCNF-RS, which 
enables incorporation of 18 phenylalanine derivatives11, however this still represents a 
small amount of possible side chains.  Conversely, the in vitro transcription/acylation of 
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tRNA allows the efficient incorporation of a wide variety of unnatural amino acids, 
limited only by synthetic ability and recognition by the ribosome.  While this method is 
more versatile for side chain functionality, it is limited by both low protein synthesis 
yield and the expression system that can be used (Xenopus laevis oocytes).   
 The ability to functionally express unnatural amino acid-containing proteins in 
mammalian cells is an important goal because it would allow the study of mammalian 
proteins in a biologically relevant environment and enable the introduction of subtle 
perturbations into complete endogenous signaling networks.  Despite the successes of the 
orthogonal synthetase/tRNA system to incorporate unnatural amino acids into 
mammalian cells9, protein expression with transiently transfected in vitro 
transcribed/acylated tRNA has had limited success.  Successful incorporation of an amino 
acid using an in vitro transcribed/acylated tRNA has been demonstrated using 
microelectroporation of CHO cells and cultured neurons12 and chemical transfection 
(Effectene) of COS1 cells13.  Using microelectroporation, only a small number of cells 
are transfected, which limits the detection methods that can be used. The chemical 
transfection method allowed detection of enzymatic activity in cell lysates, however only 
the wild type amino acid was introduced as a proof-of principle experiment.  These 
examples show that transfection of in vitro transcribed/acylated tRNA in mammalian 
cells is feasible, however much work remains to enhance the robustness and versatility of 
this suppression methodology.   
We therefore sought to further develop the suppression methodology to give 
higher protein expression in mammalian cells for easy detection in a 96-well plate format.  
Here we attempt to improve the efficiency of tRNA delivery to the intracellular 
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translation machinery using a variety of transfection reagents and conditions.  Our 
ultimate goal is to functionally express ion channels in a mammalian cell line that have 
an unnatural amino acid incorporated using nonsense suppression with an in vitro 
transcribed and acylated tRNA.  
 
Methods 
Molecular Biology.  The human 5-HT3A receptor in the pcDNA3.1+ vector was 
purchased from Missouri S&T cDNA research center and was subcloned into the 
pGEMhe vector for mRNA transcription.  The mouse α4, α4-GFP, and β2 genes were in 
the pciNEO vector and the mouse β4 gene was in the pcDNA3.1+ vector.  These 
constructs were obtained from the Lester group.  The mouse α1, β1, γ, δ subunits were in 
the pAMV vector and the human α7 and Ric3 genes were in the pcDNA3.1+ vector.  The 
EGFP constructs used were discussed by Monahan et al.12.   
 Amber (TAG) or Frameshift (GGGT) mutations were introduced at the site of 
interest using the QuickChange protocol (Stratagene).  To make mRNA, the cDNA was 
linearized using the appropriate restriction enzyme (NheI for pcDNA3.1+ and NotI for 
pAMV).  mRNA was transcribed from the linearized plasmids by using the T7 mMessage 
Machine kit (Ambion). 
cDNA encoding the THG73, YFaFS, and HSAS tRNAs were in the pUC19 vector 
and have been described previously12,14,15.  74mer THG73 and YFaFS tRNAs were 
synthesized from a DNA oligonucleotide template containing two 5’ methoxy (C2’ 
position) nucleotides to truncate transcription using Ambion’s T7 MEGAshortscript kit16.  
Commercially available amino acids chemically appended to dCA were ligated to the end 
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of the 74mer tRNA using methods previously described17.  Acylation of tRNA was 
confirmed using MALDI mass spectrometry using a 3-hydroxypicolinic acid matrix.  The 
NVOC protecting group on the amino acid was removed through a 5-minute irradiation 
using a 1 kW Xenon lamp with WG-335 and UG-11 filters.  74mer HSAS tRNA was 
synthesized by linearizing the pUC19 vector with FokI and transcribing as above with the 
MEGAshortscript kit (Ambion). 
 
Cell Culture Technique.  HEK293T cells were purchased from ATCC.  Cells were 
grown using DMEM:F12 (1:1) media with GlutaMAX-I (Gibco), 10% heat-inactivated 
fetal bovine serum (FBS) (Sigma), and penicillin/streptomycin (Sigma) at 37 oC and 5% 
CO2  in a humidified atmosphere.  Cells were passaged before confluency reached 90% 
and were discarded after ~35 passages.  Passaging and harvesting cells from 100 mm 
dishes was performed by removing the liquid media above the cells, washing with 5 mL 
of PBS, and applying 1 mL of TrypLE (Gibco) and incubating at 37oC for 5 minutes to 
detach the cells from the plate.  To inactivate the TrypLE, 9 mL of fresh media was 
applied and the cells were mixed by pipetting until homogeneous.  Cells were counted 
using a hemocytometer before seeding to ensure reproducible transfections. 
 Conditions were optimized for cell seeding on 100 mm (Table 3.1) and 35 mm 
(Table 3.2) dishes so that the desired confluency would be obtained on the day of 
transfection.  Optimal confluency and size of dish varied for the different transfection 
protocols.  Our table should therefore serve as a guide for obtaining the correct 
confluency for the transfections described below, and for additional kits that are 
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developed in the future.  Most kits generally required a confluency of 70-90% so those 
seeding conditions are highlighted in the tables below.   
 In all cases, approximately 5 x 104 cells were plated post-transfection per well in a 
96-well plate.  Poly-D-Lysine treated black 96-well plates with flat clear bottoms (BD 
 
Table 3.1: Optimization of HEK293T cell seeding for 100 mm dishes 
Dilution Dilution 
Shorthand 
24 hr 36 hr 48 hr 72 hr 
 
10 million cells/dish 
 
1:1 
 
80% 
 
N/A 
 
N/A 
 
N/A 
7.5 million cells/dish 1:1.5 70% - 100% N/A 
5 million cells/dish 1:2 70% 90% N/A N/A 
3.3 million cells/dish 1:3 25-30% - 60% 80-90% 
2.5 million cells/dish 1:4 20-30% - 50% 80-90% 
2 million cells/dish 1:5 30% - 70% 90% 
1 million cells/dish 1:10 15% - 30% 70% 
 
 
Table 3.2: Optimization of HEK293T cell seeding for 35 mm dishes 
Dilution 24 hr 48 hr 72 hr 
 
100,000 cells/dish 
 
5% 
 
10% 
 
40% 
200,000 cells/dish 10% 20% 50% 
300,000 cells/dish 15% 25% 70% 
400,000 cells/dish 25% 30% 70% 
500,000 cells/dish 35% 50% 100% 
600,000 cells/dish 30% 70% N/A 
700,000 cells/dish 30% 80% N/A 
800,000 cells/dish 40% 90% N/A 
900,000 cells/dish 50% 100% N/A 
1,000,000 cells/dish 60% 100% N/A 
1,500,000 cells/dish 70-100% N/A N/A 
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Falcon) were used for optimal spectroscopic results.  Transfected cells were grown on the 
96-well plate for 24-48 hours before recording on the FlexStation3. 
 
Counting Cells with a Hemocytometer.  To achieve a desired confluency for 
transfection, cells were counted using a hemocytometer and the appropriate amount of 
cells were seeded 1-3 days in advance.  A hemocytometer is a thick glass microscope 
slide with an indent on two sides that creates a chamber for the cells to be counted.  A 
thin cover slide is placed over this section to ensure the volume of the cells remains 
constant for each counting.  The flat area in this chamber contains an etched grid with 
nine 1 mm x 1 mm counting squares (Figure 3.1) that each have a volume of 100 nL at a 
coverslip height of 0.1 mm. 
 To determine the amount of cells in a 100 mm cell culture dish, the growth media 
is removed from the dish and the adhered cells are washed with 5 mL PBS and 
 
 
Figure 3.1:  Hemocytometer 
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dissociated using 1 mL of TrypLE. To inactivate the TrypLE, 9 mL of growth media is 
added and the cells are resuspended until homogenous.  From this cell solution, 10 uL are 
pipetted into the space created by the indent of the hemocytometer and the glass cover 
slip.  The number of cells in each of three non-contiguous 1 mm x 1 mm squares in the 
homocytometer grid are then manually counted under a microscope and averaged 
together to determine the concentration of cells in the original mixture. 
 Conc. of cells  !"##$!" = !"#$%&# # !"##$ !"#$%&'!.! !!! (!"" !") !"! !"!" = Avg.# cells x 10!/mL  
To plate 1,000,000 cells:  1,000,000 cells !"!"# # !"##$ ! !"!  = mL of cells to seed plate 
 
Transfections. A variety of transfections using different commercially available 
transfection reagents were performed to determine the conditions for optimal expression 
of DNA or mRNA and in vitro transcribed tRNA.  Our optimized protocols are described 
below with some notes and their optimization data and relative efficiencies are further 
discussed in the results and discussion section. 
 
PEI.  Polyethylenimine (PEI) (Sigma-Aldrich) is a poly-cationic polymer that interacts 
with the negative charge of nucleic acids.  During transfection, the net-positive complex 
interacts with negatively charged residues on the cell surface and allows the complex to 
pass across cell membranes through endocytosis.  This method can be extremely 
cytotoxic and therefore low concentrations of PEI are used during transfection. 
 HEK293T cells were transfected with PEI in both 100 mm and 35 mm dishes.  
Transfections in 100 mm dishes were suitable for plating an entire 96-well plate while 
 55 
transfections in 35 mm dishes were used for plating 3 columns in a 96-well plate. 
Transfections in 100 mm dishes were performed by adding 10 µg of DNA and 30 µL of a 
1 mg/mL solution of PEI (prepared by dissolving PEI in acidified water and bringing to a 
final pH of 7.0 with NaOH) to 1 mL of DMEM:F12 media.  The DNA/PEI mixture was 
then added to ~70% confluent plates with 9 mL of fresh DMEM:F12 + GlutaMax-I, FBS, 
and penicillin/streptomycin.  After 24 hours, the media with the transfection reagent was 
removed and the cells were washed with 5 mL of PBS.  The transfected cells were treated 
with 1 mL of TrypLE to detach the cells from the plate and incubated at 37oC for 5 
minutes.  The cells were then resuspended in 9 mL of fresh media, transferred to a V-
shaped plastic basin, and 100 µL of transfected cells were plated per well of the 96-well 
plate.   
Transfections in a 35 mm dish were performed by adding 1.5 µL DNA and 9 µL 
of a 1 mg/mL solution of PEI to 0.3 mL of media.  The DNA/PEI mixture was then added 
to the cell dish containing 2.7 mL of fresh media. After 24 hours the media with the 
transfection reagent was removed and the cells were washed with 3 mL of PBS.  The 
transfected cells were treated with 0.3 mL of TrypLE and incubated at 37oC for 5 
minutes.  The cells were then resuspended in 2.4 mL of fresh media and transferred to a 
V-shaped plastic basin.  100 µL of transfected cells were plated per well of the 96-well 
plate.   
The PBS wash, TrypLE treatment, resuspension and plating steps were used for 
all transfections, regardless of the reagent used, to plate transfected cells.  I will simply 
refer to it as plating in future sections.  Additionally, fresh media will refer to 
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DMEM:F12 (1:1) + Glutamax-I, FBS, and penicillin/streptomycin unless otherwise 
specified. 
 
ExpressFect.  ExpressFect (Denville Scientific), formerly known as Hyfect, is also a 
poly-cationic transfection reagent that acts similarly to PEI.  Denville Scientific claims 
that it shows increased transfection efficiency relative to other available transfection 
reagents and that it shows enhanced stability and resistance to serum (FBS) present in 
media.  ExpressFect is also less cytotoxic than PEI.  This reagent is sold in liquid form at 
a concentration of 5 mg/mL and is significantly more expensive than PEI. 
 ExpressFect transfections were performed on 35 mm dishes.  A polymer solution 
and a DNA solution are made independently and combined before adding the complexes 
to the cells. The DNA solution contained 1-2 µg of DNA and 100 µL of DMEM:F12 (no 
FBS/antibiotics) and the polymer solution contained 4 µL of ExpressFect and 100 µL of 
DMEM:F12 (no FBS/antibiotics).  The polymer solution was then added to the DNA 
solution and the mixture was incubated for 20 minutes at room temperature.  During this 
time the media was changed with 1 mL of fresh media added to the 35 mm dish. The 
transfection mix was then added to the media over the cells (60-80% confluent) and the 
transfecting cells were incubated for 4 hours at 37oC 5% CO2.  After 4 hours the cells 
were plated and incubated for 48 hours before recording on the FlexStation3.  No severe 
cytotoxic effects were observed if the transfection reagents were left on the cells for 24 
hours, and in some cases increased expression was observed. 
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TransIT-mRNA.  TransIT (Mirus Bio) is a broad spectrum, low toxicity transfection 
reagent.  It is a non-liposomal reagent that is made up of a lipid/poly-cation mixture.  The 
transfection reagent is supplied along with a “Boost Reagent” that is a proprietary 
compound solution required for successful transfection.  Other transfection reagents in 
the TransIT product line are available that are better suited for DNA or difficult to 
transfect cell lines.  Our interest was to co-transfect plasmid DNA with in vitro 
transcribed and acylated tRNA.  Because the tRNA is the limiting reagent and would 
likely prove more difficult to transfect than DNA, which formulations were originally 
optimized for, we chose the mRNA-optimized product.  Other reagents in the TransIT 
product line may be more successful, however they were not examined in this study.  
Many ratios of Boost:TransIT and varied DNA and tRNA amounts were tested.  Our 
optimized protocol for S61TAG 5-HT3A expression when using HSAS is reported below.  
The optimization data are discussed in the results/discussion section later. 
 All TransIT transfections were performed in 35 mm dishes.  First, 2 µg of DNA 
was added to 250 µL of DMEM:F12 (no FBS or antibiotics).  Then 3.75 µL of Boost 
Reagent was added to this mixture followed by 7.5 µL of TransIT.   The final mixture 
was incubated 2-5 minutes at room temperature while complex formation occurred.  
During the incubation step the media on the cells was changed and 2.5 mL of fresh media 
was added to the cells (60-90% confluent).  The complexes were then added directly to 
the media and cells were incubated in the mammalian incubator for 24 hours.  After 24 
hours the cells were harvested and plated in 96-well plates and allowed to incubate for an 
additional 24 hours.  In some cases we saw increased expression when a “double 
transfection” was performed.  For a double transfection, after 24 hours instead of 
 58 
harvesting and plating the cells, a fresh batch of transfection reagent and DNA and/or 
tRNA was added to fresh media.  This second transfection was incubated in the 
mammalian incubator for 12 hours and then the cells were harvested and plated.  
Recording was still performed after 48 hours.  In some cases, after the first transfection 
many of the cells on the edge of the 35 mm dish flaked off when removing the media, 
presumably due to cell death or poor cell health.  In this case a PBS wash step was 
skipped. 
 
TransMessenger.  TransMessenger (Qiagen) is designed for transfection of cell lines 
with RNA.  It is a lipid-based transfection reagent that is sold with an RNA-condensing 
enhancer and buffer optimized for transfection efficiency.  This transfection method 
works by condensing the RNA and then coating it with the lipid-based transfection 
reagent.  Suppression of S61TAG 5-HT3A with HSAS was not very successful using this 
transfection reagent.  Therefore, our optimized protocol described below includes the 
entire range of DNA and tRNA that was capable of eliciting any 5-HT response.  The 
optimization of DNA and DNA+tRNA expression is described in the results and 
discussion section. 
 For transfection, 4 µL of Enhancer R and 0.5-2 µL of DNA + 2-4 µL of HSAS 
was diluted to a final volume of 100 µL with buffer EC-R. This mixture was incubated at 
room temperature for 5 minutes and then 8 µL of TransMessenger was added.  The final 
mixture was incubated for an additional 10 minutes.  After 10 minutes the media over the 
cells was removed and the cells were washed with PBS.  Finally, 900 µL of DMEM:F12 
(no FBS or antbiotics) was added to the transfection mixture and the total 1 mL of media 
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and transfection complexes were added directly to the cells (80-90% confluent).  Cells 
were incubated with the transfection complexes for 3 hours after which they were washed 
with PBS and plated in a 96-well plate 
 
Lipofectamine RNAiMAX.  Lipofectamine RNAiMAX (Life Technologies) is a lipid-
based transfection reagent optimized for transfection of cells with siRNA.  Lipofectamine 
reagents function by forming liposomes, which are capable of delivering nucleic acids 
through lipofection.  siRNA are small 20-25 nucleotide RNA primers, which we thought 
would more closely relate to tRNA (75-85 nucleotides) than reagents optimized for full 
length mRNA or DNA.  Life Technologies sells other lipofectamine-based reagents 
optimized for DNA and difficult to transfect cell lines.  No expression of S61TAG 5-
HT3A was observed when suppressed with HSAS.  We therefore report the optimized 
procedure for transfection of DNA alone, recognizing that transfection of DNA is 
probably better suited for a different lipofectamine reagent that is optimized for DNA 
transfection. 
 RNAiMAX transfections were performed directly in the 96-well plate to be read 
using suspended cells harvested from 35 mm dishes. We did not try transfecting cells in 
the 35 mm dish as we had in the other transfection methods and suspect that would have 
provided better results.  For the 96-well plate transfection, our best signal was achieved 
by mixing 2 µg of DNA in 600 µL of DMEM:F12 (no FBS or antibiotics) and aliquoting 
25 µL of this mixture into each well in 3 columns (24 wells) of a 96-well plate.  Then 0.3 
µL of RNAiMAX was added per well and the final mixture was incubated for 10 
minutes.  During the 10-minute incubation period, cells from a 35 mm dish were 
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harvested (30-50% confluent) and resuspended in 6.5 mL of fresh media.  After the 10-
minute incubation step was complete, 100 µL of suspended cells were aliquoted into each 
well.  Plates were read after 48 hours. 
Mixing the RNAiMAX with the DNA/media mixture before aliquoting into the 
wells likely would have improved results.  This would lead to more uniformity of 
RNAiMAX per well because of the error associated with pipetting such a small volume 
(0.3 µL), also fewer pipet tips would be used.  Performing these transfections directly on 
adherent cells in the 35 mm dish also would have likely produced better results due to the 
better transfection efficiency of adherent cells versus suspended cells.  These possibilities 
were not tested due to better results with other transfection reagents. 
 
PolyFect.  PolyFect (Qiagen) is an activated dendrimer system optimized for transfection 
of DNA into easy to transfect cell lines (HEK293, CHO, HeLa, and COS).  The 
dendrimers are spherical shaped and have positively charged amino groups at the end of 
the branches.  These positive charges interact with the negatively charged nucleic acids 
and compact the DNA, therefore allowing the complexes to pass across the membrane 
through endocytosis.  None of the methods tested gave good expression of mouse muscle 
(β9’), therefore an optimized protocol is not reported here. 
 
Neon.  The Neon (Life Technologies) is an electroporation device that is designed to 
transfect all cell types by electrically creating small holes in the cell membrane and 
allowing the passage of nucleic acids across the membrane.  We were inspired to try this 
method because of Sarah Monahan’s success with microelectroporation of CHO cells12,  
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and because all of the chemical transfection reagents used failed to result in expression of 
receptors that incorporated in vitro transcribed and acylated tRNAs. 
 For transfections to fill one 96-well plate, two 100 mm dishes of cells (60-90% 
confluent) were treated with 1 mL of TrypLE each and then resuspended in a total 
volume of 10 mL of DMEM:F12 (no FBS or antibiotics).  The cells were added to a 15 
mL Falcon tube and centrifuged for 5 minutes on setting 2 (slow) on the Lester lab 
centrifuge (in their cell culture room).  The media was removed, 5 mL of PBS was added 
to the cells, and the cells were centrifuged for an additional 5 minutes.  The PBS was then 
removed and the cells were resuspended in 50 µL of Buffer R (supplied with the Neon 
transfection kits). 
 Before transfection, 2.7 mL of fresh media was aliquoted into each of four V-
shaped plastic basins.  A clear plastic pipet stage was placed into the transfection system 
and was filled with 3 mL of electrolytic buffer, E buffer.  20 µL of resuspended cells 
were aliquoted into four 0.6 mL Eppendorf tubes and the DNA/tRNA mixture to be 
transfected for 3 columns in the 96-well plate was added to the cells.  Our best results 
used 2 µg of DNA and 4 µg of HSAS for WT recovery and 8 µg for suppression at a 
sensitive site.  It is important to dissolve tRNA in water instead of the 1 mM NaOAc 
normally used after ligations because of the effect it can have on the salt concentration of 
the transfection mixture.  A salt concentration that is too high can cause arcing of the 
cells during transfection, which results in cell death. 
 Once the mixture of cells, DNA, and tRNA is created, 10 µL of cell mixture is 
pipetted into the transfection pipet using the gold tips provided in the Neon transfection 
kit.  Note:  100 µL kits are available for larger scale transfections.  It is important to avoid 
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any air bubbles in the pipet tip because of the potential for arcing.  Once 10 µL are 
successfully pipetted, the tip is placed in the transfection system and the desired protocol 
is selected.  We found that condition 7 (1200 V, 30 ms, 1 pulse) worked best for DNA 
and DNA+tRNA.  In some cases a second transfection of tRNA only, was performed 
after 24 hours using condition 22 (1400 V, 10 ms, 3 pulses).  After transfection the 10 µL 
of transfected cells were added to the media in the V-shaped basin.  Another transfection 
using a second 10 µL of cells and nucleic acid mixture was performed using the same tip.  
In cases of a large volume of DNA and tRNA, a third transfection was performed using 
the remainder of the cell/nucleic acid mixture only if a full 10 µL of mixture remained.  
According to the manufacturer each tip can be used 3 times before it needs to be 
discarded, however we did not test whether the tips could be used more.  New tips were 
always used for different mixtures of DNA/tRNA.  After the transfections were complete, 
the cells were resuspended in the fresh media and 100 µL were plated into each well.  
The plates were read after 48 hours. 
The optimal conditions were obtained by performing one 10 µL transfection for 
each of the 24 stock settings programed into the Neon. Each transfection was plated in 
one column on a 96-well plate resulting in two 96-well plates to read.  This required 4 
100 mm dishes of cells to transfect and the cells to be resuspended in a larger volume of 
Buffer R (240 µL).  Plates were read after 48 hours and the columns with the largest RFU 
values were used for future experiments.  Optimization experiments were performed for 
WT 5-HT3A DNA only, S61TAG 5-HT3A DNA + 74mer HSAS, and a second “double” 
transfection after 24 hours with 74mer HSAS only.  These data can be found in the 
results and discussion section. 
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FlexStation3 recording of ion channels.  The FlexStation3 (Molecular Devices) was 
used for all 96-well plate-based ion channel detection.  To measure receptor function, 
HEK293T cells were transfected using one of the above described transfection methods.   
After a 48 hour incubation period the media above the cells was removed and the cells 
were washed with Flex Buffer (115 mM NaCl, 1 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 
10 mM D-glucose, and 10 mM HEPES at pH 7.5)18.  The cells were then incubated with 
100 µL/well of a 1:10 dilution (unless otherwise specified) of FLIPR Membrane Potential 
Assay Kit (blue) for 30 minutes at 37oC and 5% CO2 and read using the FlexStation3. 
Wells were excited at 530 nm and fluorescence was recorded at 565 nm using a 550 nm 
filter at low photomultiplier tube (PMT) sensitivity after application of 100 µL of agonist 
to the wells.  Fluorescence data were collected every 1.52 seconds for 180 seconds and 
data were analyzed using the SOFTmax Pro software (Molecular Devices) (Figure 3.2).  
The peak values for each well in a column of the 96-well plate were normalized to the 
maximum value and data were fit to the Hill equation to obtain the EC50 and Hill 
coefficient (nH).  The values from a minimum of 3 columns were averaged together to 
result in an EC50 curve with each column representing one n for statistical analysis. 
 
Fluorescent dye experiments.  Serial dilutions (1:1) of rhodamine B (Sigma) were made 
in a 96-well plate using water starting from a stock solution of 50 mM.  The plate was 
assayed for peak fluorescence using the FlexStation3 by exciting the fluorophore at a 
wavelength of 540 nm and measuring the emission at 625 nm with a 610 nm cutoff filter.  
This experiment was performed using the low, medium, and high PMT settings.  Similar 
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Figure 3.2:  Typical FlexStation3 raw data for the 5-HT3A receptor. A) 96-well plate of 
cells transfected with DNA. Wells were treated with 1:1 serial dilutions of agonist with 
decreasing concentration from row A-H. Peak RFUs are shown under the traces. B) 
Compiled fluorescence traces over time of the 8 wells in a single column (Column 7 from 
A) of the 96-well plate. The 8 wells represent responses to agonist concentrations that 
span the EC50 curve. 
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experiments were performed using eosin Y (City Chemical Company) and fluorescein 
(Sigma) using the low PMT setting. 
 
Results and Discussion 
Fluorescent dye experiments.  While the SOFTmax Pro software will select the optimal 
PMT sensitivity for a variety of experiments, runs using the “Flex” tab in the instrument 
settings require the user to select between the high, medium, or low PMT sensitivity.  
When performing nonsense suppression in Xenopus laevis oocytes it is common to obtain 
a significantly weaker signal than when examining the wild type or mutant receptors 
created using conventional mutagenesis.  Therefore, to obtain maximal responses for the 
unnatural amino acid mutagenesis experiments in HEK293T cells, it is important to 
optimize signal detection of the instrument to measure low changes in fluorescence.  
To determine which PMT setting was optimal for our FlexStation3 experiments, 
we tested the response of the instrument over a range of small molecule fluorophore 
concentrations, from 6 nM to 50 mM of rhodamine B, eosin Y, and fluorescein.  We 
found that when measuring moderate to large fluorophore concentrations, the PMT 
became saturated using both the high and medium sensitivity settings and reliable data 
could not be obtained.  When using the high PMT sensitivity setting, the detector became 
saturated at 1.52 µM rhodamine B, which corresponded to a maximum instrument 
response of 300 relative fluorescence units (RFUs). The medium sensitivity setting 
allowed measurement of up to 49 µM rhodamine B and reached a maximum response 
before saturation of 6,500 RFUs.  Decreasing the PMT sensitivity to low allowed 
measurement of up to 0.19 mM rhodamine B (10,000 RFUs) where self-quenching of the 
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fluorophore began to be observed.  High concentrations of eosin y and fluorescein, which 
do not self-quench as strongly as rhodamine B, indicate that the instrument is capable of 
detecting fluorescence signals as high as 50,000 RFUs, well beyond the range of 
fluorescence expected in our membrane potential dye experiments (~500-5,000 RFUs). 
In addition to testing the instrument at high fluorophore concentrations, we also 
measured the instrument response at very low concentrations.  To determine the optimum  
 
Table 3.3:  Fluorescence read-out of rhodamine B solutions using the three PMT 
sensitivities: low, medium, and high. 
 
Rhodamine B 
Concentration 
(µM) 
Low PMT 
Setting 
Medium 
PMT 
Setting 
High PMT 
Setting 
 
0.763 
 
191.47 
 
144.91 
 
124.55 
0.381 77.67 65.71 47.34 
0.191 44.83 27.18 22.21 
0.095 20.88 16.13 12.56 
0.048 17.04 8.56 6.44 
0.024 10.07 5.52 4.34 
0.012 7.88 4.64 2.89 
0.006 5.87 3.42 2.25 
  
sensitivity setting for low fluorescence read-out, we assayed a 96 well plate with low 
concentrations of rhodamine B (< 1 µM) using the high, medium, and low PMT 
sensitivity settings (Table 3.3).  The data from these experiments indicate that the low 
PMT setting provides the highest fluorescence read-out for low concentrations of 
fluorophore, and that this setting is optimal for both measuring high (detector saturation) 
and low (detector sensitivity) fluorescence.  No advantage for using the medium or high 
 67 
PMT setting was determined, therefore all experiments were performed using the low 
PMT sensitivity setting. 
 
Optimization of mRNA transfections.  For X. laevis oocyte experiments, receptor 
expression at the membrane is achieved through microinjection of receptor mRNA.  To 
determine if transfection with mRNA would give larger responses than DNA in 
HEK293T cells, we examined the expression of three receptors, muscle type (β9’), α7 
(with or without RIC3), and 5-HT3A using the mRNA transfection kit, TransMessenger.  
Cells transfected with receptor mRNA showed an increase in fluorescence upon 
application of acetylcholine (ACh) to the muscle type receptor.  The EC50 and Hill 
coefficient values measured by the FlexStation are similar to what are observed in X. 
laevis oocytes using the OpusXpress (Figure 3.3), however the responses were small (< 
100 RFUs) and many data points had to be discarded to get a good fit.  No fluorescence 
was observed in response to application of ACh to the α7 receptor or 
5-hydroxytryptamine (5-HT) to the 5-HT3A receptor.  While in vitro poly-adenylation 
would likely improve mRNA stability and therefore receptor expression, producing 
mRNA is significantly more expensive than DNA and larger responses are elicited from 
DNA transfection experiments.  This is especially true because the cell line we have 
chosen to use, HEK293T cells, is designed to amplify transfected plasmid DNA, which 
gives DNA transfection an additional benefit. 
 
Optimization of DNA transfections – wild type.  Before experiments with unnatural 
amino acids were attempted, we first sought to optimize transfection and incubation 
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Figure 3.3:  Data from TransMessenger transfection of the muscle type nAChR mRNA 
using the FlexStation fit to the Hill equation. 
 
conditions for cells transfected with wild type DNA alone.  We tested a variety of 
conditions using seven different commercially available transfection methods: PEI 
(Sigma-Aldrich), ExpressFect (Denville Scientific), TransIT (Mirus Bio), RNAiMAX 
(Life Technologies) TransMessenger (Qiagen), Polyfect (Qiagen), and Neon (Life 
Technologies).  We primarily focused on the 5-HT3A receptor, because it is not known to 
have difficulties being transported from the endoplasmic reticulum to the membrane and 
because it has five identical subunits, which removes complications of stoichiometry 
changes.  Some experiments however were performed using other Cys-loop receptors 
including the muscle type (α12β1δγ) and neuronal α4β4, α4β2, and α7 nicotinic 
acetylcholine receptors (nAChRs).  These experiments will be discussed first. 
 HEK293T cells transfected with α4β2, muscle type, and α7 nAChR DNA using 
PEI and ExpressFect resulted in no increase in fluorescence in response to application of 
ACh.  It has been shown previously that the α4β2 nAChR is retained in the ER due to the 
lack of an ER export motif and the presence of an ER retention motif in the M3-M4 loop 
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region of the β2 receptor19.  To test whether this was the case in our experiments we 
transfected cells with a 1:1 ratio of α4-GFP and either β2 or β4 (not retained in the ER).  
The expression pattern of the two receptors was visualized using confocal microscopy of 
the tagged green fluorescent protein (GFP) subunits (Figure 3.4).  The images obtained  
 
 
Figure 3.4:  Confocal microscopy of α4-GFP/β2 and α4-GFP/β4 receptors in HEK293T 
cells transfected using ExpressFect.  An ER exit site in the α4-GFP/β4 receptor is 
indicated by a red arrow. 
 
show the α4β2 subunit heavily expressed in the ER whereas the α4β4 subunit is 
expressed both in the ER and at the membrane.  GFP-tagged receptors can be observed 
exporting from the ER via ER exit sites (bright spots in the image). 
 We therefore concluded that our experimental results with the FlexStation agree 
with previously published data about the α4β2 neuronal receptor.  We did not have GFP 
tagged constructs of the α7 and the muscle type receptors and therefore were not able to 
determine why these receptors did not exhibit functional expression using the 
FlexStation.  Because the α4β4 receptor exhibited robust signals, we tested a variety of  
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Table 3.4:  Functional data from the α4:β4 transfection ratios tested 
α4:β4 
Ratio 
EC50 (µM) Hill n Average 
Max RFU 
 
2000:1 
 
1.8 ± 0.2 
 
1.2 ± 0.1 
 
6 
 
40.4 
1000:1 1.5 ± 0.2 1.1 ± 0.2 5 52.9 
500:1 0.75 ± 0.04 1.7 ± 0.1 17 104.4 
200:1 0.70 ± 0.02 1.5 ± 0.1 17 106.2 
100:1 0.72 ± 0.07 1.1 ± 0.1 20 144.6 
50:1 0.70 ± 0.05 1.2 ± 0.1 20 155.4 
30:1 0.65 ± 0.04 1.2 ± 0.1 20 163.8 
10:1 0.66 ± 0.04 1.2 ± 0.1 21 125.0 
3:1 0.75 ± 0.07 1.1 ± 0.1 19 80.1 
1:1 3.1 ± 0.2 1.0 ± 0.1 23 67.0 
1:3 5.5 ± 0.6 2.6 ± 0.5 2 47.3 
1:10 7.5 ± 1.6 3.8 ± 3.2 2 16.1 
 
transfection ratios of the two subunits to obtain pure populations of different 
stoichiometries (Table 3.4).  It has previously been shown in X. laevis oocytes that pure 
populations of different stoichiometries can be obtained by biasing injection ratios of 
mRNA20.  Here, we wanted to determine whether this principle held in mammalian cells 
and if we could detect changes in stoichiometries as well as the difference between pure 
and mixed populations using the FlexStation. 
Interestingly, we found that the agonist sensitivities for the different 
stoichiometries are switched in the HEK293T cells relative to X. laevis oocytes.  We see 
the formation of a low sensitivity stoichiometry when the transfection ratios were biased 
toward the β4 subunit (presumably (α4)2(β4)3) and a higher sensitivity receptor when the 
transfection ratios are biased toward the α4 subunit (presumably (α4)3(β4)2).  Upon 
heavily biasing the transfection ratios toward α4 (≥ 1,000:1) we see the appearance of a 
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medium sensitivity receptor with a Hill coefficient of approximately 1.1, which is likely 
indicative of the formation of a third stoichiometry, the (α4)4(β4)1 receptor.  While we 
were able to bias the transfection ratios to make pure populations of what is likely the 
(α4)3(β4)2 receptor, the transfection ratio needed to do so varied from batch to batch.  The 
need to optimize our transfection conditions for every transfection batch indicated that 
the range needed to make a pure population was small.  This would likely complicate 
both conventional and unnatural amino acid mutagenesis experiments in the future 
because of the need to optimize subunit bias for each mutant.  We therefore sought to 
optimize expression conditions for a homopentameric receptor, the 5-HT3A receptor, to 
avoid potential stoichiometry issues. 
 Since we anticipated a large loss of receptor expression when incorporating 
unnatural amino acids via nonsense suppression, we first wanted to optimize expression 
of the wild type receptor and cell health.  To determine which transfection kit, 
transfection method, and incubation times were optimal for DNA transfection we tested a 
variety of conditions using seven different commercially available transfection kits.  
First, we tested the PEI and ExpressFect transfection reagents, because our collaborators 
in the Lummis and Lester labs had previously used them to successfully express 
membrane receptors in mammalian cells.  
The PEI reagent was by far the most inexpensive reagent tested in these studies.  
Transfections with both PEI and ExpressFect gave comparable max RFU values as 
detected by the FlexStation (Figure 3.5) and the data obtained resulted in similar EC50 
and Hill coefficient values when fit to the Hill equation (EC50 of 0.31 µM and nH of 3.9 
 72 
 
Figure 3.5:  Data from 5-HT3A transfections of HEK293T cells using ExpressFect (left) 
and PEI (right) fit to the Hill equation. 
 
for cells transfected with ExpressFect and EC50 of 0.28 µM and nH of 3.8 for cells 
transfected with PEI). These EC50 values are lower than what is observed using 
electrophysiology, however the data match well with published EC50 values for the 5-
HT3A receptor measured using fluorescent membrane potential dyes21. 
 In addition to the PEI and ExpressFect transfection methods, we tested additional 
transfection kits to determine whether we could further enhance signals measured by the 
FlexStation.  First, we sampled three different RNA transfection kits: TransMessenger, 
RNAiMAX, and TransIT.  Despite the fact we were looking to transfect DNA in these 
initial experiments, our final goal was to transfect DNA along with tRNA for suppression 
with unnatural amino acids.  Unlike plasmid DNA, the tRNA is a stoichiometric reagent, 
and therefore efficient delivery of the tRNA in the future might be the limiting factor.  
The first step for optimizing DNA and tRNA cotransfections was to find the ideal 
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transfection and growth conditions for DNA alone using these three transfection kits 
(Tables 3.5-3.7). 
 
Table 3.5:  Transfection of HEK293T cells with 5-HT3A DNA using the TransMessenger 
transfection reagent.  Average Max RFUs were determined from three columns in a 96-
well plate.  The conditions for the highest RFU signal are highlighted in red. 
 
 
WT DNA (µg) TransMessenger (µL) Avg Max RFU 
 
0.1 
 
8 
 
207.6 
0.5 8 366.0 
2 8 346.8 
2 4 No Response 
2 8 376.0 
2 16 287.5 
4 8 310.0 
4 16 361.7 
 
 
 
Table 3.6:  Transfection of HEK293T cells with 5-HT3A DNA using the RNAiMAX 
transfection reagent.  Average Max RFUs were determined from three columns in a 96-
well plate.  The conditions for the highest RFU signal are highlighted in red. 
 
WT DNA (µg) RNAiMAX (µL) Avg Max RFU 
 
Vary DNA, constant RNAiMAX 
0.02 7.5 82.3 
0.1 7.5 141.5 
0.5 7.5 209.1 
2 7.5 270.6 
Constant DNA, vary RNAiMAX 
2 2.5 162.0 
2 7.5 146.1 
2 15 163.3 
2 30 42.9 
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Table 3.7:  Transfection of HEK293T cells with 5-HT3A DNA using the TransIT 
transfection reagent.  Average Max RFUs were determined from three columns in a 96-
well plate.  The conditions for the highest RFU signal are highlighted in red. 
 
WT DNA (µg) Boost Reagent (µL) TransIT (µL) Avg Max RFU 
 
0.02 
 
5  
 
7.5 
 
No Response 
0.1 5 7.5 107.0 
0.5  5 7.5 308.9 
2 5 7.5 467.6 
2 1.25 2.5 408.1 
2 3.75 7.5 497.8 
2 7.5 15 541.8 
2 15 30 563.5 
 
 From these optimization experiments it was determined that the highest 
transfection efficiency conditions for all three methods involved transfection of 2 µg of 
DNA.   For both the TransMessenger and RNAiMAX transfection kits, a moderate 
amount of transfection reagents were found to give the highest signal, likely because of 
cell health issues at high concentrations of reagent.  Conversely, expression using the 
TransIT transfection kit continued to increase with higher concentrations of the 
transfection reagent, showing moderate expression increases with each doubling of the 
transfection reagent.  For this particular reagent, cell health did not appear to be an issue.  
Of the three RNA transfection reagents tested, TransIT gave the highest fluorescence 
signal overall (565 RFU vs. 376 RFU for TransMessenger and 270 RFU for RNAiMAX).  
Likewise, all three RNA transfection reagents gave higher average RFU signals than 
either ExpressFect or PEI (218 RFU and 232 RFU, respectively).  It is important to note, 
however, that transfections with ExpressFect were done with 1 µg of DNA and PEI with 
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1.5 µg of DNA.  Increasing DNA concentrations to 2 µg would likely give higher RFU 
signals, which could change the relative efficiencies of the transfection reagents. 
 The final chemical transfection reagent that we tested was the DNA transfection 
kit, PolyFect.  We performed similar optimization experiments as for the mRNA 
transfection kits and were not able to find a transfection method that gave any 
fluorescence response to applied agonist.  Most conditions tested resulted in massive cell 
death, and those with living cells resulted in no functional expression.  The PolyFect kit 
was therefore not used in any further experiments. 
In addition to the chemical transfection methods described above, we also tested 
transfection efficiencies by electroporation using the Neon Transfection System.  The 
Neon software has 24 pre-programmed settings for cellular electroporation that vary the 
voltage delivered, time of voltage application, and number of voltage pulses.  These 24 
settings were applied to resuspended HEK293T cells + DNA and were each plated in a 
single column of a 96-well plate.  Upon assaying the two 96-well plates from this 
experiment, it was shown that settings 6, 7, and 8 gave the highest RFUs upon application 
of agonist (Table 3.8).  These settings correspond to a single 30 ms pulse length with a 
voltage application of between 1,100-1,300 V.  Although the maximum RFU value was 
technically higher for transfection condition 6 (1,100 V, 1 pulse, 30 ms), we selected 
condition 7 (1,200 V, 1 pulse, 30 ms) as our optimum transfection method because it fell 
in the middle of three high signals.  We thought that selecting this method might 
minimize potentially strong negative effects from batch-to-batch variability that could 
shift the optimal transfection setting in either direction.  Next, using setting 7 on the 
Neon, we optimized expression levels for incubation time and amount of DNA 
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Table 3.8:  Optimization of 5-HT3A receptor expression using the Neon electroporation 
method.  The best setting conditions are highlighted in red. 
 
Condition Voltage 
(V) 
Width 
(ms) 
# 
Pulses 
Max 
RFU 
Condition Voltage 
(V) 
Width 
(ms) 
# 
Pulses 
Max 
RFU 
 
1 
 
0 
 
20 
 
1 
 
n/a 
 
13 
 
1100 
 
20 
 
2 
 
242 
2 1400 20 1 294 14 1200 20 2 311 
3 1500 20 1 299 15 1300 20 2 280 
4 1600 20 1 174 16 1400 20 2 115 
5 1700 20 1 130 17 850 30 2 265 
6 1100 30 1 342 18 950 30 2 254 
7 1200 30 1 341 19 1050 30 2 301 
8 1300 30 1 322 20 1150 30 2 238 
9 1400 30 1 216 21 1300 10 3 265 
10 1000 40 1 321 22 1400 10 3 273 
11 1100 40 1 298 23 1500 10 3 270 
12 1200 40 1 256 24 1600 10 3 87 
 
 
Table 3.9:  Optimization of DNA transfection conditions and incubation lengths.  
Amount of DNA transfected is for three columns in a 96-well plate. 
 
DNA (µg) 1 Day Incubation, 
Avg Max RFU 
2 Day Incubation, 
Avg Max RFU 
 
1 
 
145.0 
 
232.0 
2 300.1 359.7 
4 137.4 309.3 
8 185.1 304.5 
 
transfected.  We found that a two-day incubation resulted in higher expression levels for 
all DNA transfection amounts with 2 µg of DNA giving the highest signal (Table 3.9). 
 
Conventional mutagenesis.  After transfection conditions were optimized for the wild 
type 5-HT3A receptor, we next attempted to assay conventional mutants.  We were 
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interested in both the effect on expression upon introducing detrimental mutations and the 
ability of the FlexStation to measure shifts in EC50.  To introduce a large loss-of-function 
mutation, we sought to remove or modulate the side chain that participates in the crucial 
cation-π binding interaction (W183) with the agonist22.  The W183A and W183Y 
mutations had been previously shown in HEK293 cells to give large loss-of-function fold 
shifts in the mouse 5-HT3A receptor (166 and 22 fold, respectively)23.  Using the human  
 
Table 3.10: Data from conventional mutagenesis of both the human and mouse 5-HT3A 
receptors.  Mouse 5-HT3A data was previously determined in a different study23. 
 
 Human 5HT3A Mouse 5HT3A 
 EC50 (µM) Fold Shift Hill EC50 (µM) Fold Shift 
 
Wild Type 
 
0.28 ± 0.01 
 
- 
 
3.84 ± 0.42 
 
0.24 
 
- 
W183A 180 ± 7 652 2.47 ± 0.21 39.8 166 
W183Y 34.5 ± 1.9 125 2.49 ± 0.25 5.25 22 
 
 
 
 
Figure 3.6: Data from 5-HT3A mutant receptors (W183A and W183Y) fit to the Hill 
equation. 
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5-HT3A construct we observed larger (652 and 125, respectively) fold shifts with data that 
fit well to the Hill equation (Table 3.10, Figure 3.6).  These data indicated that we were 
able to measure large fold shifts using our transfection methods and assay.  Interestingly, 
we did not observe a significant loss of signal amplitude at saturating agonist doses.  The 
maximum RFUs given for the W183A and W183Y mutants were 223 and 207 RFUs, 
respectively compared to 218 RFUs for the wild type receptor using the ExpressFect 
transfection reagent. 
 
Optimization of DNA and tRNA cotransfections:  suppression with the human 
serine amber suppressor.  To optimize DNA and tRNA cotransfection into HEK293T 
cells, we first began by finding ideal transfection conditions for a model DNA/tRNA 
suppression pair.  The human serine amber suppressor (HSAS) is the endogenous serine 
tRNA found in human cells, however the anticodon has been mutated to recognize the 
amber stop codon (TAG).  In the cell, this tRNA is recognized by the endogenous serine 
tRNA synthetase, which charges the unacylated tRNA with the natural amino acid serine.  
The HSAS tRNA is expected to give significantly higher receptor expression than the 
orthogonal acylated tRNAs commonly used for unnatural amino acid mutagenesis 
because it is recognized by the cellular machinery and is not a stoichiometric reagent.  
Therefore, to determine the ideal transfection conditions of DNA and tRNA, we began 
our optimizations with DNA and in vitro transcribed tRNA cotransfection using plasmid 
DNA with a TAG codon at the site of interest and the HSAS tRNA. 
 To examine whether an amino acid could be incorporated by this methodology, 
we first sought to visualize serine incorporation into enhanced green fluorescent protein  
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Figure 3.7:  Confocal microscopy of serine suppression in eGFP using the HSAS tRNA. 
A) Wild type eGFP expression B) eGFP expression from HSAS suppression at A37TAG 
using the Neon transfection system.  Confocal image is at both the laser power used to 
image wild type eGFP and a higher laser power to better image suppression efficiency C) 
Suppression of eGFP using ExpressFect. 
 
(eGFP).  We chose A37 as the site for suppression because it is located at the beginning 
of the protein before the residues that make up the GFP chromophore.  Therefore, if the 
HSAS tRNA is transfected at a concentration lower than is required for sufficient protein 
synthesis or if the in vitro transcribed tRNA is not stable and/or recognized by host 
machinery, protein synthesis will be truncated before the chromophore can be formed and 
no fluorescence will be observed.  We found that HEK293T cells cotransfected with 
HSAS and A37TAG eGFP plasmid resulted in observed fluorescence by confocal 
microscopy using both ExpressFect and the Neon.  Although fluorescence was detected, 
indicating serine suppression at the A37 site, eGFP expression was significantly lower for 
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the suppression experiments than for wild type eGFP (approximately <1%) (Figure 3.7).  
Expression was slightly higher for the cells transfected using ExpressFect. 
 Once we were able to confirm that an amino acid could be incorporated into a 
high expressing protein using cotransfection of an in vitro transcribed tRNA and plasmid 
DNA, we next sought to test suppression efficiency in a neuroreceptor.  First, we 
attempted to incorporate serine via wild type recovery at the S61 site in the 5-HT3A 
receptor.  Assuming 2 µg remains the ideal amount of DNA for maximal expression, we 
used a variety of transfection methods to determine which method gave the highest 
transfection efficiency and how much cotransfected tRNA was required (Table 3.11).  No 
expression was observed when using PEI, indicating that this transfection method might 
not allow efficient transfection of RNA.  Expression of 5-HT3A was, however, observed 
when cells were transfected with ExpressFect and the Neon.  Expression using 
ExpressFect was strongly variable from batch-to-batch, showing some expression with 
high concentrations of HSAS on some days and none on others.  Expression using the 
Neon was more consistent, and expression was highest for transfection conditions using 
low amounts of HSAS.  Response could be slightly increased by using a larger 
concentration of membrane potential dye (1:2 vs. 1:10) (Table 3.12). Maximum 
expression was approximately three-fold lower than the wild type signal, which is 
expected when using suppression.  However, the ability to detect a signal and measure an 
EC50 value indicates potential viability using the suppression methodology. 
 We also tested the RNA transfection kits: TransMessenger, RNAiMAX, and 
TransIT for their ability to cotransfect plasmid DNA and in vitro transcribed RNA.  No 
expression was observed using RNAiMAX (Table 3.13).   However, we did observe 
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functional 5-HT3A receptor expression in cells transfected using TransMessenger (Table 
3.14) and TransIT (Table 3.15).  The highest expressing transfection conditions using 
TransMessenger required more transfection reagent than TransIT (16 µl vs. 7.5 µL per 35 
mm dish) and gave lower wild type recovery signals (120 vs. 350 RFUs).   
When using TransIT, we observed higher wild type receptor expression with 
increasing concentrations of TransIT (up to 30 µL), however in the presence of tRNA, 
higher TransIT concentrations had the opposite effect.  We therefore determined that 
 
Table 3.11: 5-HT3A expression of S61TAG DNA cotransfected with HSAS tRNA.   Data 
is shown for three columns of cells transfected using PEI, ExpressFect, and Neon 
electroporation. 
 
DNA (µg) HSAS 
(µg) 
Neon, 
Avg Max 
RFU 
PEI,  
Avg Max 
RFU 
ExpressFect,  
Avg Max 
RFU 
ExpressFect,  
Avg Max 
RFU 
   
11/15/10 
 
11/15/10 
 
11/15/10 
 
12/1/10 
2 (WT) 0 297.1 195.7 320.5 309.5 
2 (S61TAG) 2 93.8 No Response No Response No Response 
2 (S61TAG) 4 37.7 No Response 80.9 No Response 
2 (S61TAG) 8 No Response No Response 78.3 No Response 
 
 
 
Table 3.12:  5-HT3A receptor expression of S61TAG DNA cotransfected with HSAS 
tRNA using a 1:2 dye dilution. 
 
DNA (µg) HSAS (µg) Neon, 
Avg Max 
RFU 
 
2 (WT) 
 
0 
 
371.5 
2 (S61TAG) 2 112.4 
2 (S61TAG) 4 121.4 
2 (S61TAG) 8 91.9 
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transfection conditions using 2 µg of DNA (and 4 µg of tRNA if applicable), 3.75 µL of 
Boost Reagent, and 7.5 µL of TransIT were optimal for receptor expression in the case of 
wild type recovery and a balance of expression and cost effectiveness in the case of wild 
type.  The TransIT transfection reagent gave the highest overall wild type and wild type 
recovery signals of all methods and conditions tested.  We therefore believe that this 
reagent is superior for both DNA transfection and RNA/DNA cotransfection. 
In addition to wild type recovery, we also sought to incorporate a serine residue 
via suppression at a critical site in the receptor designed to perturb receptor function.  For 
this we chose W183, the cation-π site crucial for ligand binding.  We had previously 
shown using conventional mutagenesis that mutations at the W183 site (W183A and 
W183Y) resulted in a large loss-of-function mutations (652 and 125-fold, respectively), 
therefore we assumed a similar loss of function for the W183TAG(Ser) mutation. Using 
electroporation, we were able to obtain functional receptors with an EC50 of 370 µM 
5-HT, which demonstrates a 1,200-fold shift relative to wild type.  Expression of the 
mutant receptors was approximately three-fold lower than that for wild type recovery at 
S61 (Table 3.16).  Introducing a functionally detrimental mutation in all of the five 
subunits can likely account for this loss of expression.  No expression was observed using 
PEI, similar to what was observed for wild type recovery. 
 
Optimization of DNA and tRNA cotransfections:  unnatural amino acid 
mutagenesis.  Using the transfection methods previously optimized for DNA and HSAS 
tRNA cotransfection, we next sought to incorporate an amino acid from an in vitro 
transcribed and acylated tRNA.  Suppression with in vitro acylated tRNA has been 
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Table 3.13:  Wild type recovery by cotransfection of HSAS and S61TAG plasmid DNA 
using RNAiMAX 
 
DNA (µg) HSAS (µg) RNAiMAX (µL) Avg Max RFU 
 
2 (WT) 
 
0 
 
15 
 
113.8 
2 (S61TAG) 0 15 No Response 
2 (S61TAG) 4 15 No Response 
2 (S61TAG) 8 15 No Response 
 
 
Table 3.14:  Wild type recovery by cotransfection of HSAS and S61TAG plasmid DNA 
using TransMessenger 
 
  
DNA (µg) HSAS (µg) TransMessenger 
(µL) 
Avg Max RFU 
 
Constant DNA, vary HSAS, constant TransMessenger 
2 (WT) 0 8 274.7 
2 (S61TAG) 2 8 No Response 
2 (S61TAG) 4 8 No Response 
2 (S61TAG) 8 8 No Response 
Vary DNA, constant HSAS, vary TransMessenger 
0.5 (S61TAG) 4 8 42.5 
1 (S61TAG) 4 8 47.2 
0.5 (S61TAG) 4 16 74.1 
1 (S61TAG) 4 16 120.4 
Constant DNA, vary HSAS, using 16 mL TransMessenger 
2 (WT) 0 16 208.4 
2 (S61TAG) 2 16 63.8 
2 (S61TAG) 4 16 No Response 
2 (S61TAG) 8 16 No Response 
Constant DNA, vary HSAS, using 32 mL TransMessenger 
2 (WT) 0 32 181.8 
2 (S61TAG) 2 32 69.9 
2 (S61TAG) 4 32 52.9 
2 (S61TAG) 8 32 No Response 
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Table 3.15:  Wild type recovery by cotransfection of HSAS and S61TAG plasmid DNA 
using TransIT 
 
5HT3A DNA (µg) HSAS (µg) Boost Reagent 
(µL) 
TransIT 
(µL) 
Avg Max 
RFU 
  
DNA constant, vary HSAS and Boost:TransIT 
2 (WT) 0 7.5 15 471.1 
2 (S61TAG) 4 7.5 15 113.1 
2 (S61TAG) 8 7.5 15 94.6 
2 (S61TAG) 8 15 30 Cells Died 
Vary DNA, constant HSAS, vary Boost:TransIT 
0.5 (S61TAG) 4 3.75 7.5 95.2 
1 (S61TAG) 4 3.75 7.5 91.1 
0.5 (S61TAG) 4 7.5 15 44.8 
1 (S61TAG) 4 7.5 15 73.2 
Constant DNA, vary HSAS, using 2.5 µL TransIT 
2 (WT) 0 1.25 2.5 167.7 
2 (S61TAG) 2 1.25 2.5 No Response 
2 (S61TAG) 4 1.25 2.5 37.4 
2 (S61TAG) 8 1.25 2.5 33.5 
Constant DNA, vary HSAS, using 7.5 µL TransIT 
2 (WT) 0 3.75 7.5 489.0 
2 (S61TAG) 2 3.75 7.5 162.9 
2 (S61TAG) 4 3.75 7.5 353.5 
2 (S61TAG) 8 3.75 7.5 340.0 
 
 
 
Table 3.16:  Conventional mutagenesis of the 5-HT3A receptor using HSAS serine 
suppression at W183.  Results are compared between PEI and electroporation. 
 
DNA (µg) HSAS (µg) Neon,  
Avg Max RFU 
PEI,  
Avg Max RFU 
 
2 (WT) 
 
0 
 
180.6 
 
73.9 
2 (W183TAG) 0.5 No Response No Response 
2 (W183TAG) 2 14.9 No Response 
2 (W183TAG) 4 33.5 No Response 
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effectively used to incorporate unnatural amino acids into receptors in X. laevis oocytes, 
and its implementation in mammalian cells is the ultimate goal of this project.  To 
achieve sufficient nucleic acid delivery, we tested a variety of optimized transfection 
methods that have been previously described in this chapter.  
Unlike the HSAS experiments where an endogenous tRNA was used to 
incorporate its cognate natural amino acid, suppression with unnatural amino acids 
requires the use of an orthogonal tRNA.  For a tRNA to be orthogonal, it must not be 
reaminoacylated with its associated natural amino acid by the host synthetases after 
delivery of the desired unnatural amino acid.  This prevents background expression of 
receptors lacking the unnatural amino acid and facilitates investigation of the desired 
mutation.  Unfortunately, because the tRNA is not recharged with another amino acid in 
vivo, the unnatural amino acid-containing tRNA is a stoichiometric reagent.  In X. laevis 
oocytes, this leads to lower expression levels of receptors containing an unnatural amino 
acid relative to wild type or conventional mutants.   
To determine whether we could effectively incorporate an unnatural amino acid 
into receptors in HEK293T cells, we cotransfected cells with DNA and acylated tRNA 
previously developed for unnatural amino acid mutagenesis in X. laevis oocytes: 
Tetrahymena thermophila G73 (THG73) or the yeast phenylalanine frameshift suppressor 
(YFaFS)15.  Orthogonal suppressor tRNAs are often derived from distantly related 
organisms and we believed that the tRNAs used in X. laevis oocytes would also be 
orthogonal in mammalian cells.  We did not observe any response to applied agonist for 
cells transfected using any of the methods tested (Tables 3.17-3.19 for THG73-W at 
W183TAG and Table 3.20 for YFaFS-W at W183GGGT).  Because suppression with 
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alpha-hydroxy amino acids often gives higher expression levels in X. laevis oocytes, 
likely due to reduced hydrolysis of the amino acid during incubation, we also attempted 
to suppress with tryptophan α-hydroxy (Wah) at the W183 site (Table 3.21) and Sah at 
the S61 site (data not shown).  In both cases, no receptor expression was observed 
indicating that while hydrolysis may be a problem, other issues likely prevent adequate 
unnatural amino acid incorporation.   
Although we were not able to measure functional expression of mutant 5-HT3A 
receptors suppressed with in vitro acylated tRNA on the FlexStation, we wanted to 
determine visually whether any mutant protein was being produced.  We therefore sought 
 
Table 3.17:  Attempted wild type recovery at W183 using in vitro transcribed THG73-W 
tRNA and W183TAG plasmid DNA.  Cells were transfected by Neon electroporation. 
  
W183TAG DNA (µg) THG73-W tRNA (µg) Avg Max RFU 
 
Constant DNA 
2 0 No Response 
2 2 (THG73-76mer) No Response 
2 0.1 No Response 
2 0.5 No Response 
2 1 No Response 
2 2 No Response 
2 4 No Response 
Constant tRNA 
1 2 No Response 
2 2 No Response 
4 2 No Response 
8 2 No Response 
16 2 No Response 
32 2 No Response 
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Table 3.18: Attempted wild type recovery at W183 using in vitro transcribed THG73-W 
tRNA and W183TAG plasmid DNA.  Cells were transfected by ExpressFect. 
 
W183TAG DNA (µg) THG73-W (µg) ExpressFect,           
Avg Max RFU 
 
0.5 
 
1.25 
 
No Response 
1 1.25 No Response 
2 1.25 No Response 
5 1.25 No Response 
 
 
 
Table 3.19: Attempted wild type recovery at W183 using in vitro transcribed THG73-W 
tRNA and W183TAG plasmid DNA.  Cells were transfected by PEI. 
 
W183TAG DNA (µg) THG73-W (µg) PEI, Avg Max RFU 
 
Vary DNA, wide range of tRNA 
0.5 0.5 No Response 
1 0.5 No Response 
1 2 No Response 
1 3 No Response 
tRNA constant (1 µg) 
0.25 1 No Response 
0.5 1 No Response 
1 1 No Response 
2 1 No Response 
Vary DNA and tRNA, but keep total nucleic acid constant (1 µg)  
0.25 0.75 No Response 
0.75 0.25 No Response 
0.1 0.9 No Response 
0.9 0.1 No Response 
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Table 3.20:  Attempted wild type recovery at W183 using in vitro transcribed YFaFS-W 
tRNA and W183GGGT plasmid DNA.  Cells were transfected by Neon electroporation 
 
Trial Date W183GGGT DNA (µg) YFaFS-W tRNA (µg) Avg Max RFU 
 
Trial 1 
 
2 (WT) 
 
0 
 
572.6 
2 8 (YFaFS-76mer) No Response 
2 8 No Response 
Trial 2 2 (WT) 0 301.2 
2 8 (YFaFS-76mer) No Response 
2 4  No Response 
2 8 No Response 
Trial 3 2 (WT) 0 443.7 
2 8 (YFaFS-76mer) No Response 
2 4 No Response 
2 8 No Response 
 
 
 
Table 3.21: Attempted mutagenesis at W183 using an α-hydroxy acid.  Cells were 
transfected with in vitro transcribed THG73-Wah tRNA and W183TAG plasmid DNA.   
 
DNA (µg) tRNA (µg) Neon,  
Avg Max RFU 
TransIT,  
Avg Max RFU 
 
2 (WT) 
 
0 
 
645.7 
 
407.5 
2 (W183TAG) 4 No Response No Response 
2 (W183TAG) 8 No Response No Response 
2 (W183TAG) 12 No Response No Response 
 
to incorporate an in vitro acylated amino acid into eGFP to avoid the need for 
suppression and assembly of five subunits per receptor and high surface expression of 
functional receptors for FlexStation analysis with the voltage-sensitive dye.   
To visually observe suppression efficiency, we imaged HEK293T cells transiently 
transfected with mutant eGFP using confocal microscopy (Figure 3.8).  Cells transfected 
with wild type eGFP showed robust fluorescence indicating efficient DNA transfection 
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and protein synthesis.  Conversely, cells transfected with A37TAG eGFP DNA showed 
very low fluorescence indicating truncation of protein translation early during protein 
synthesis, which is expected for a nonsense mutation in cells that lack a corresponding 
suppressor tRNA.  When cells were cotransfected with A37TAG eGFP DNA and an in 
vitro transcribed suppressor tRNA (76mer THG73), a slight increase in expression was 
observed.  The increase in observed signal is indicative of a small amount of in vivo 
acylation and full-length protein synthesis, therefore providing evidence that both the 
DNA and tRNA are successfully cotransfected.  Unfortunately, when cells were 
cotransfected with A37TAG eGFP DNA and THG73-Ala, no additional expression was 
observed.  This suggests that the in vitro acylated amino acid is not being delivered to the 
growing peptide and is instead likely hydrolyzed during Neon electroporation or the 48 
hour incubation period. 
 
 
Figure 3.8:  Confocal microscopy of HEK293T cells transfected with eGFP using Neon 
electroporation. A) Wild type eGFP, 2.5% laser power 90% saturation B) A37TAG 
DNA, 41% laser power 96% saturation C) A37TAG DNA with 76mer THG73 tRNA, 
41% laser power 96% saturation D)  A37TAG DNA with THG73-Ala, 41% laser power 
96% saturation 
 
 
Double transfections.  To enhance expression, we sought to determine whether a second 
transfection 24 hours after the first led to better agonist responses, similar to what is 
performed in X. laevis oocytes for difficult-to-express mutants.  For this, we tested our 
A B C D 
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two most successful DNA and tRNA cotransfection methods: TransIT and Neon 
electroporation.  For TransIT double transfections, we tested the effect on expression of a 
second application of transfection reagents and either DNA and tRNA or tRNA only.  We 
determined that a second transfection of DNA did not lead to enhanced expression 
because the expression of the wild type receptor was not changed compared to the singly 
transfected cells (Table 3.22).  We did however observe an increase in receptor 
expression upon a second transfection of tRNA only for all S61TAG + HSAS conditions 
tested, further supporting that tRNA is the limiting reagent for suppression.  While a three 
to six-fold increase in receptor expression was observed for serine incorporation at 
S61TAG, no expression was observed using the orthogonal THG73-W tRNA (Table 
3.23).  This indicates that while a second transfection increases the pool of intracellular 
tRNA without negatively affecting cell health, a larger acylated tRNA population is still 
required. 
Next, to determine whether a second transfection using electroporation gave 
enhanced signals relative to the TransIT transfection method, we performed a series of 
double transfections using the pre-programmed instrument settings.  The first transfection 
 
Table 3.22:  Double TransIT transfection of HEK293T cells with S61TAG DNA and 
HSAS tRNA.  Both a second transfection with DNA and tRNA and tRNA only were 
performed. 
 
DNA (µg) HSAS (µg) Boost 
Reagent 
(µL) 
TransIT 
(µL) 
2X 
(DNA+HSAS) 
Avg Max RFU 
2X  
(HSAS only) 
Avg Max RFU 
 
2 (WT) 
 
0 
 
3.75 
 
7.5 
 
621.6 
 
626.0 
2 (S61TAG) 2 3.75 7.5 46.2 177.7 
2 (S61TAG) 4 3.75 7.5 51.9 321.4 
2 (S61TAG) 8 3.75 7.5 85.0 390.1 
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Table 3.23:  Double TransIT transfection of HEK293T cells with W183TAG DNA and 
THG73-W tRNA.  Both a second transfection with DNA and tRNA and tRNA only were 
performed. 
 
W183TAG 
DNA (µg) 
tRNA (µg) Boost 
Reagent 
(µL) 
TransIT 
(µL) 
2X 
DNA+tRNA 
Avg Max 
RFU 
2X  
tRNA only 
Avg Max 
RFU 
 
2  
 
8 (THG73-
76mer) 
 
3.75 
 
7.5 
 
No Response 
 
No Response 
2  2 (THG73-W) 3.75 7.5 No Response No Response 
2  4 (THG73-W) 3.75 7.5 No Response No Response 
2  8 (THG73-W) 3.75 7.5 No Response No Response 
 
 
 
Table 3.24:  Optimization of Neon double transfection of S61TAG DNA and HSAS 
tRNA.  Data represents cells first transfected using condition 7 and a second transfection 
24 hours later using the specified instrument setting.  Condition 1 represents singly 
transfected cells. 
 
Condition Max RFU Condition Max RFU 
 
1 (single) 
 
17.4 
 
13 
 
No Response 
2 161.1 14 118.8 
3 158.1 15 209.8 
4 170.5 16 278.4 
5 193.4 17 54.0 
6 172.6 18 135.9 
7 219.2 19 223.5 
8 264.5 20 279.7 
9 315.7 21 260.1 
10 216.8 22 390.0 
11 253.7 23 273.1 
12 277.1 24 183.1 
 
was performed as previously described using 2 µg of S61TAG DNA and 4 µg of HSAS 
tRNA and electroporation with condition 7.  We found that a second transfection with 4 
µg of tRNA after a 24 hour incubation gave enhanced agonist-induced signals for all 
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conditions tested, except condition 13, relative to cells transfected a single time 
(condition 1) (Table 3.24).  The highest expressing second transfection condition was 
found to be condition 22 (1400 V, 10 ms, 3 pulses) as determined by maximum RFU.  
When the same double transfection conditions were applied to W183TAG DNA and 
THG73-W tRNA no expression was observed (Table 3.25). 
 
Table 3.25:  Neon double transfection of HEK293T cells with W183TAG DNA and 
THG73-W tRNA or tRNA only. 
 
DNA (µg) tRNA (µg) Nucleic Acid 
Double 
Transfected 
Avg Max RFU 
 
2 (WT) 
 
0 
 
DNA only 
 
Instrument disrupted, 
data lost 
2 (W183TAG) 8 (THG73-76mer) tRNA only No Response 
2 (W183TAG) 8 (THG73-W) tRNA only No Response 
2 (W183TAG) 8 (THG73-W) tRNA + DNA No Response 
 
tRNA stability.  To determine whether the lack of suppression efficiency by in vitro 
acylated tRNA was due to significant hydrolysis of the amino acid upon transfection 
and/or incubation at 37oC, stability tests were performed.  The integrity of the acylated 
tRNA was examined by MALDI-TOF analysis before and after typical transfection 
conditions for the two most efficient methods: TransIT and Neon electroporation.  To 
ensure that MALDI-TOF analysis is sensitive enough to detect a mass loss in the range of 
an amino acid, we measured the mass of the tRNA before and after deprotection of the 
NVOC protecting group.  Analysis shows a mass loss of 238, which corresponds to the 
expected 239 mass loss of the NVOC group (Figure 3.9).  We are therefore confident that 
MALDI-TOF analysis would be sensitive enough to measure the mass loss of a large 
amino acid such as tryptophan (204 g/mol). 
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Next, we wanted to simulate the transfection conditions experienced by the 
deprotected tRNA in our above-described methods.  For the simulated TransIT 
transfection, tRNA was deprotected for 10 minutes and incubated in the presence of the 
TransIT transfection reagents at 37oC for 24 hours.  A mass loss of 206 was observed 
between the non-deprotected untreated tRNA and the deprotected TransIT-treated tRNA 
(Figure 3.10).  This mass corresponds better to the NVOC protecting group than both the 
NVOC and W side chain (239 vs. 442) indicating that W is likely not hydrolyzed during 
transfection.  Likewise, we subjected tRNA to a 10 minute deprotection step followed by 
Neon electroporation using protocols 7 and 22, to represent the Neon transfection 
conditions used in our experiments.  MALDI-TOF analysis shows a mass loss of 195 and 
305, respectively (Figure 3.11).  Both of these mass values are closer to the mass of the 
NVOC protecting group, however the broadness of the peak may obscure definitive 
assignment.  To increase the sharpness of the mass peak, the treated tRNA was 
subsequently run through a BD Biosciences CHROMA SPIN-30 DEPC-H2O desalting 
column.  Column purification resulted in a low concentration of purified tRNA and 
therefore no mass data was able to be obtained. 
 
Dye optimization.  To determine the concentration of membrane potential dye that 
elicited the largest fluorescence signal in response to applied agonist, a variety of dye 
dilutions were tested.  The different dye concentrations were tested on the wild type 
5-HT3A receptor expressed by both PEI transfection of wild type DNA and Neon 
transfection of S61TAG DNA and in vitro transcribed HSAS tRNA (Table 3.26).   
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Figure 3.9: MALDI-TOF analysis of THG73-W tRNA A) before and B) after NVOC 
deprotection. 
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Figure 3.10: MALDI-TOF analysis of THG73-W incubated with TransIT transfection 
reagents A) before NVOC deprotection and transfection and B) after transfection 
conditions. 
 96 
 
 
 97 
 
Figure 3.11:  MALDI-TOF analysis of THG73-W electroporation with the Neon 
transfection system A) before NVOC deprotection and electroporation, B) after 
deprotection and electroporation with condition 7, and C) after deprotection and 
electroporation with condition 22. 
 
Optimization of wild type and wild type recovery experiments was performed to 
determine the best dye dilutions for both high and low receptor signals. 
 It was found that the 1:2 dye dilution (5 mL of dye + 5 mL of Flex buffer), 
relative to the manufacturer’s protocol, elicited the maximal response for both the high 
and low expressing receptor populations.  Using the full-strength dye recommended by 
Molecular Devices elicited a comparable high signal relative to the 1:2 dilution, however 
it required twice as much dye, which is not cost effective.  Therefore it was determined 
that using the 1:2 dilution of membrane potential dye was the optimal concentration for 
all experiments involving the 5-HT3A receptor.  For cost-effectiveness it is also possible 
to use lower concentrations of dye down to a 1:10 dilution (1 mL of dye + 9 mL Flex 
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Table 3.26:  Optimization of membrane potential dye concentration for assaying 5-HT3A 
receptors 
 
Dye Dilution 5-HT3A wild 
type 
5-HT3A S61TAG 
+ HSAS 
 Max RFU Max RFU 
 
1:1 
 
986.86 
 
83.55 
1:2 994.67 83.46 
1:5 616.73 53.02 
1:10 466.11 42.12 
 
buffer) for high receptor expressing conditions such as experiments assaying wild type 
receptor function. 
 
Conclusions and Future Directions 
 In conclusion, we were able to optimize cotransfection conditions for in vitro 
transcribed tRNA and plasmid DNA into HEK293T cells.  We found that the highest 
expression of functional receptors was observed when cells were transfected with the 
TransIT-mRNA transfection reagent or through a double transfection with the Neon 
electroporation system.  Both conditions gave comparable results, however transfection 
with TransIT required less total nucleic acid.  Additionally, we found that transfection 
with plasmid DNA gave larger functional expression than transfection with mRNA.  
Coupled with the lower cost of making large quantities of DNA than mRNA, we believe 
that DNA is superior to mRNA for all mammalian cell experiments. 
 Cotransfection of HSAS tRNA and plasmid DNA gave robust signals for both 
wild type recovery and conventional mutagenesis experiments, indicating that in vitro 
transcribed tRNA is successfully transfected into cells.  However, when using the 
stoichiometric, orthogonal, and acylated tRNAs (THG73 and YFaFS), we did not observe 
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any functional expression of receptors, indicating low protein synthesis.  Therefore, 
despite our initial success with HSAS, further optimization and troubleshooting is 
required for the ultimate goal of unnatural amino acid mutagenesis in mammalian cells.  
Some possible issues that could be arising are listed and discussed below: 
1) Lack of tRNA post-transcriptional modifications:  The majority of in vivo tRNA 
processing steps are not required for an in vitro transcribed tRNA because a 
mature tRNA lacking leader, trailer, and intron sequences is initially synthesized 
and the terminal CA is added upon acylation with dCA-amino acid.  The in vitro 
transcribed tRNA does however lack several conserved post-transcriptional 
modifications added by a variety of enzymes in the cell.  These enzymes and their 
resulting modifications vary between species and tRNA molecules, however the 
modifications have been shown to be important for tRNA stability, anticodon 
recognition, and binding by host translational machinery24.  While many of these 
modifications are conserved between species, it is likely that many human (or 
other mammalian) enzymes will not recognize bacterial, protozoan, or yeast 
tRNA due to variations in tRNA sequence and structure.  Therefore, if crucial 
modifications are not introduced, the orthogonal tRNA may be recognized as 
foreign and degraded or not be tightly bound by elongation factor-1α (EF-1α) as 
a required preliminary step to ribosome delivery.  Interestingly, the orthogonal 
synthetase/tRNAs evolved for use in mammalian cells employ a bacterial tRNA.  
These tRNAs bind their cognate synthetase, which is an early step in elongation 
factor recruitment.  Therefore, these orthogonal tRNA molecules may either be 
modified appropriately by host machinery, can be directly handed off to EF-1α to 
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facilitate incorporation into the growing peptide, or may suggest that these 
modifications are not necessary during over-producing conditions.   
2) tRNA not recognized by elongation factors or the ribosome:  Prior to 
incorporation of an amino acid by an endogenous tRNA: the mature tRNA 
molecule binds its cognate synthetase, is acylated with its corresponding amino 
acid, is handed off to elongation factors, and is finally passed off to the ribosome 
by the elongation factor.  Because the orthogonal tRNAs used in these studies 
cannot (by design) bind to any of the endogenous synthetases, it is possible that 
binding by the elongation factors is impaired.  Without the synthetase to hand off 
the acylated orthogonal tRNA to the elongation factor, the tRNA may remain in 
solution long enough that the degradation rate is higher than the binding rate to 
the elongation factors.  To overcome this issue, over-expressing the elongation 
factor EF-1α may allow for a larger population of acylated tRNA to be 
sequestered from degradation pathways and shuttled to the ribosome for 
incorporation.  Alternatively, a “dummy” synthetase could be used that lacks 
enzymatic activity (cannot acylate the tRNA), but is capable of binding the tRNA 
and elongation factors for hand-off. 
3) Transfection/incubation temperature:  Mammalian cells are transfected/incubated 
at significantly different temperatures than X. laevis oocytes: 37oC vs. 18oC, 
respectively.  The higher incubation temperature may lead to denaturing of the 
tRNA or an increase in the stringency for binding interactions.  For example, 
although the orthogonal tRNAs bind elongation factors sufficiently well in X. 
laevis oocytes, the added temperature might provide enough energy to break the 
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non-ideal noncovalent interactions that hold together the exogenous 
tRNA/endogenous elongation factor complex, therefore decreasing translation 
efficiency.   
4) Hydrolysis of amino acid from the tRNA:  The increased incubation temperature 
of mammalian cells might also lead to increased hydrolysis of the in vitro 
acylated amino acid off of the tRNA.  Similar to oocyte experiments, the amino 
acid is deprotected by UV irradiation before transfection.  Once deprotected, the 
amino acid becomes a labile group that can be hydrolyzed in water.  In addition to 
higher incubation temperatures, the transfection time is longer for mammalian 
cells than for oocytes.  In an oocyte experiment, the tRNA is directly injected into 
the cell where it is can be rapidly bound by elongation factors and shuttled to the 
ribosome for incorporation into the growing peptide.  Conversely, in mammalian 
cells, the tRNA is mixed with transfection reagent and applied externally to cells.  
Over a period of 24 hours the transfection reagent/DNA/tRNA complexes diffuse 
across the cell membrane delivering nucleic acid to the 
transcriptional/translational machinery.  During these 24 hours, any tRNA that is 
external to the cell is not protected by elongation factors and is therefore 
susceptible to hydrolysis.  Use of α-hydroxy acids and/or pre-incubation with 
purified EF-1α might lead to decreased hydrolysis rates. 
5) Low concentration of stoichiometric tRNA reagent:  Because the tRNA is applied 
external to cells rather than through direct injection, higher amounts of tRNA are 
required to achieve a comparable concentration of intracellular tRNA as we use in 
oocyte experiments.  Unfortunately, a proportional increase in transfection 
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reagent is required for higher concentrations of nucleic acid, which leads to a 
decrease in cell viability.  In a typical oocyte experiment, assuming 50 nL of 1 
µg/µL tRNA is injected into an oocyte with a diameter of 1 mm, the concentration 
of tRNA inside the cell is 95.5 µg/mL.  We were able to transfect a maximum of 8 
µg of tRNA in a 35 mm dish with 3 mL of media over the cells, which amounts to 
2.67 µg/mL of tRNA in solution.  This concentration is approximately 35-fold 
less than that used in a typical oocyte experiment and is likely a major 
contribution to the lack of protein expression.    
6) Misfolded/denatured/hydrolyzed by transfection reagents:  It is possible that 
during complexation with the transfection reagent the tRNA is denatured or 
misfolded from its normal structure.  Therefore, upon delivery to the cytoplasm, 
the single stranded unmodified RNA would likely appear as foreign to the cell 
and would be quickly degraded.  Most transfection reagents are designed and 
optimized for nucleic acids without a defined structure such as: DNA, mRNA, or 
siRNA.  It is possible that a new class of transfection reagents might be required 
to more effectively transport tRNA across the membrane. 
 
Acknowledgements 
 I would like to thank Sarah Lummus, A.J. Thompson, and Shawna Frazier for 
teaching me all I know about cell culture and use of the FlexStation.  I would also like to 
thank Crystal Dilworth for helping us with the confocal experiments. 
 
 
 
 103 
References 
 
1. Daeffler, K.N., Lester, H.A., and Dougherty, D.A., Functionally Important 
Aromatic-Aromatic and Sulfur-pi Interactions in the D2 Dopamine Receptor. J 
Am Chem Soc, 2012. 134(36): p. 14890-14896. 
2. Zhong, W.G., Gallivan, J.P., Zhang, Y.O., Li, L.T., Lester, H.A., and Dougherty, 
D.A., From ab initio quantum mechanics to molecular neurobiology: A cation-pi 
binding site in the nicotinic receptor. Proceedings of the National Academy of 
Sciences of the United States of America, 1998. 95(21): p. 12088-12093. 
3. Limapichat, W., Lester, H.A., and Dougherty, D.A., Chemical Scale Studies of 
the Phe-Pro Conserved Motif in the Cys Loop of Cys Loop Receptors. Journal of 
Biological Chemistry, 2010. 285(12): p. 8976-8984. 
4. Xiu, X., Puskar, N.L., Shanata, J.A., Lester, H.A., and Dougherty, D.A., Nicotine 
binding to brain receptors requires a strong cation-pi interaction. Nature, 2009. 
458(7237): p. 534-537. 
5. Nowak, M.W., Gallivan, J.P., Silverman, S.K., Labarca, C.G., Dougherty, D.A., 
and Lester, H.A., In vivo incorporation of unnatural amino acids into ion channels 
in Xenopus oocyte expression system. Methods Enzymol, 1998. 293: p. 504-529. 
6. Noren, C.J., Anthonycahill, S.J., Griffith, M.C., and Schultz, P.G., A General-
Method for Site-Specific Incorporation of Unnatural Amino-Acids into Proteins. 
Science, 1989. 244(4901): p. 182-188. 
7. Liu, C.C. and Schultz, P.G., Adding New Chemistries to the Genetic Code. 
Annual Review of Biochemistry, Vol 79, 2010. 79: p. 413-444. 
8. Santoro, S.W., Wang, L., Herberich, B., King, D.S., and Schultz, P.G., An 
efficient system for the evolution of aminoacyl-tRNA synthetase specificity. 
Nature Biotechnology, 2002. 20(10): p. 1044-1048. 
9. Liu, W.S., Brock, A., Chen, S., Chen, S.B., and Schultz, P.G., Genetic 
incorporation of unnatural amino acids into proteins in mammalian cells. Nature 
Methods, 2007. 4(3): p. 239-244. 
10. Chin, J.W., Cropp, T.A., Anderson, J.C., Mukherji, M., Zhang, Z.W., and Schultz, 
P.G., An expanded eukaryotic genetic code. Science, 2003. 301(5635): p. 964-
967. 
11. Young, D.D., Young, T.S., Jahnz, M., Ahmad, I., Spraggon, G., and Schultz, 
P.G., An Evolved Aminoacyl-tRNA Synthetase with Atypical Polysubstrate 
Specificity. Biochemistry, 2011. 50(11): p. 1894-1900. 
12. Monahan, S.L., Lester, H.A., and Dougherty, D.A., Site-specific incorporation of 
unnatural amino acids into receptors expressed in mammalian cells. Chemistry & 
Biology, 2003. 10(6): p. 573-580. 
13. Kohrer, C., Xie, L., Kellerer, S., Varshney, U., and Rajbhandary, U.L., Import of 
amber and ochre suppressor tRNAs into mammalian cells: A general approach to 
site-specific insertion of amino acid analogues into proteins. Proceedings of the 
National Academy of Sciences of the United States of America, 2001. 98(25): p. 
14310-14315. 
14. Saks, M.E., Sampson, J.R., Nowak, M.W., Kearney, P.C., Du, F., Abelson, J.N., 
Lester, H.A., and Dougherty, D.A., An engineered Tetrahymena tRNAGln for in 
 104 
vivo incorporation of unnatural amino acids into proteins by nonsense 
suppression. J Biol Chem, 1996. 271(38): p. 23169-23175. 
15. Rodriguez, E.A., Lester, H.A., and Dougherty, D.A., In vivo incorporation of 
multiple unnatural amino acids through nonsense and frameshift suppression. 
Proceedings of the National Academy of Sciences of the United States of America, 
2006. 103(23): p. 8650-8655. 
16. Kao, C., Zheng, M., and Rudisser, S., A simple and efficient method to reduce 
nontemplated nucleotide addition at the 3 ' terminus of RNAs transcribed by T7 
RNA polymerase. Rna-a Publication of the Rna Society, 1999. 5(9): p. 1268-
1272. 
17. Nowak, M.W., Gallivan, J.P., Silverman, S.K., Labarca, C.G., Dougherty, D.A., 
and Lester, H.A., In vivo incorporation of unnatural amino acids into ion channels 
in Xenopus oocyte expression system. Ion Channels, Pt B, 1998. 293: p. 504-529. 
18. Lummis, S.C.R., Thompson, A.J., Bencherif, M., and Lester, H.A., Varenicline Is 
a Potent Agonist of the Human 5-Hydroxytryptamine(3) Receptor. Journal of 
Pharmacology and Experimental Therapeutics, 2011. 339(1): p. 125-131. 
19. Srinivasan, R., Pantoja, R., Moss, F.J., Mackey, E.D.W., Son, C.D., Miwa, J., and 
Lester, H.A., Nicotine up-regulates alpha 4 beta 2 nicotinic receptors and ER exit 
sites via stoichiometry-dependent chaperoning. Journal of General Physiology, 
2011. 137(1): p. 59-79. 
20. Puskar, N.L., Xiu, X.A., Lester, H.A., and Dougherty, D.A., Two Neuronal 
Nicotinic Acetylcholine Receptors, alpha 4 beta 4 and alpha 7, Show Differential 
Agonist Binding Modes. Journal of Biological Chemistry, 2011. 286(16): p. 
14618-14627. 
21. Price, K.L. and Lummis, S.C.R., FlexStation examination of 5-HT3 receptor 
function using Ca2+ and membrane potential-sensitive dyes: Advantages and 
potential problems. Journal of Neuroscience Methods, 2005. 149(2): p. 172-177. 
22. Beene, D.L., Brandt, G.S., Zhong, W., Zacharias, N.M., Lester, H.A., and 
Dougherty, D.A., Cation-pi interactions in ligand recognition by serotonergic (5-
HT3A) and nicotinic acetylcholine receptors: the anomalous binding properties of 
nicotine. Biochemistry, 2002. 41(32): p. 10262-10269. 
23. Thompson, A.J., Lochner, M., and Lummis, S.C.R., Loop B Is a Major Structural 
Component of the 5-HT(3) Receptor. Biophysical Journal, 2008. 95(12): p. 5728-
5736. 
24. Phizicky, E.M. and Hopper, A.K., tRNA biology charges to the front. Genes & 
Development, 2010. 24(17): p. 1832-1860. 
 
 
 105 
Chapter 4 
Functional Evaluation of Key Interactions Evident in the Structure of the Eukaryotic  
Cys-loop Receptor GluCl 
 
Abstract 
 The publication of the first high-resolution crystal structure of a eukaryotic Cys-
loop receptor, GluClα, has provided valuable structural information on this important 
class of ligand-gated ion channels (LGIC).  However, limited functional data exists for 
the GluCl receptors.  Before applying the structural insights from GluCl to mammalian 
Cys-loop receptors such as nicotinic acetylcholine and GABA receptors, it is important to 
establish that conserved functional features of this receptor class are present in the more 
distantly related GluCl receptors.  Here, we seek to identify these ligand-binding 
interactions, including the frequently observed cation-π interaction.  Our studies were 
performed in the homologous GluClβ receptor because GluClα is not activated by 
glutamate in Xenopus laevis oocytes. Mutagenesis of the signal peptide and pore lining 
helix was performed to enhance functional expression and sensitivity to applied ligand, 
respectively.  Conventional and unnatural amino acid mutagenesis indicate a strong 
cation-π interaction between Y206 and the protonated amine of glutamate as well as other 
important ionic and hydrogen bond interactions between the ligand and the binding site, 
as predicted by the crystal structure.   
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Introduction 
The Cys-loop receptors are a family of pentameric ligand-gated ion channels 
involved in fast synaptic transmission.  They are the target of a variety of native 
neurotransmitters, along with therapeutics targeting, among others, Parkinson’s disease, 
Alzheimer’s disease, schizophrenia, pain, and nicotine addiction in humans1-3.  Members 
of this family include the excitatory, cation-permeable, nicotinic acetylcholine receptors 
(nAChRs) and 5-HT3A receptors, and the inhibitory, anion-permeable, GABAA/C and 
glycine receptors.  These receptors possess conserved structural elements, including an 
extracellular ligand binding domain, four transmembrane helices of which one, M2, 
forms the channel pore, and the eponymous disulfide loop in the extracellular domain. 
Until recently, structural models of Cys-loop receptors were based on the low 
resolution cryo-EM structures of the Torpedo marmorata nAChR4,5 or the high resolution 
X-ray crystal structures of acetylcholine binding proteins6, soluble proteins homologous 
to the extracellular, ligand-binding domain of the full length receptor.  However, recent 
developments in membrane protein crystallography have led to a wealth of new high-
resolution structures including two homologous bacterial ligand-gated ion channels,  
ELIC and GLIC7-9, and most recently, GluClα, from Caenorhabditis elegans10.  
GluCl represents a true, eukaryotic Cys-loop receptor, although there is no 
mammalian homologue. It is an anion-permeable channel, and it displays 34% sequence 
identity to its closest human homolog, the α1 glycine receptor. The GluClα receptor was 
crystallized in the presence of the native orthosteric ligand, glutamate, as well as the 
positive allosteric modulator, ivermectin, a broad-spectrum antiparasitic clinically used 
for the treatment of river blindness in humans and animal parasites in veterinary  
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Figure 4.1.  Crystal structure of GluClα crystallized in the presence of glutamate and 
ivermectin (PDB ID: 3RIF)10.  Both ligands bind at the interface of two identical subunits 
with glutamate binding at the extracellular orthosteric ligand binding site and ivermectin 
at an allosteric site in the transmembrane region.  The primary (+) and complementary (-) 
subunits are indicated in green and blue, respectively. 
 
medicine3,11-13 (Figure 4.1).   Both ligands were shown to bind at the interface of two 
subunits of which the primary (+) subunit contributes loops A-C and the complementary 
(-) subunit loops D-F to the orthosteric glutamate binding site. 
While the GluClα structure represents a milestone in the study of Cys-loop 
receptors, relatively few functional studies on this receptor have been reported. In 
contrast, a large number of wide-ranging functional studies of mammalian Cys-loop 
receptors have been reported1,14,15. In our own labs we have developed a series of 
functional probes based on unnatural amino acid mutagenesis that provide high precision 
information on drug-receptor interactions and protein structural features. These include a 
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cation-π interaction between the protonated amine of endogenous ligands and one of 
several conserved aromatic amino acids in the binding site, which has been demonstrated 
in all Cys-loop receptors studied to date16.  In addition, several hydrogen bonding 
interactions, including hydrogen bonds to the protein backbone, have been established to 
be important in several Cys-loop receptors. 
In the present work we set out to determine whether key structural features of the 
C. elegans GluClα receptor have functional consequences that parallel those seen in 
mammalian Cys-loop receptors. Mutagenesis was performed on the closely related 
GluClβ receptor because the GluClα receptor is not activated by glutamate in the absence 
of ivermectin in Xenopus laevis oocytes17. Every ligand-binding residue considered here 
is conserved in the two forms, however residues in the M2 helix vary between receptors.  
To facilitate these studies, the receptor had to be optimized for expression in Xenopus 
oocytes, by altering the signal peptide and by introducing a mutation in the pore-lining 
regions. Our studies find functional significance for many of the key features of the 
GluClα receptor structure, and also highlight the challenges of probing binding 
interactions in invertebrate receptors. 
 
Methods 
Molecular biology.  The mammalian codon optimized GluClβ receptor from C. 
elegans18 was subcloned into the pGEMhe vector and the stop codon of the receptor was 
mutated from TAG to TGA.  Mutagenesis of the GluClβ receptor was performed using 
the QuikChange protocol (Stratagene), and for nonsense suppression experiments, a TAG 
codon was mutated into the site of interest.  The cDNA was linearized using SbfI (New 
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England Biolabs) and mRNA was produced from the linearized plasmids by using the T7 
mMessage Machine kit (Ambion). 
74mer THG73 tRNA was in vitro transcribed from a DNA oligonucleotide 
template containing two 5’ methoxy (C2’ position) nucleotides to site-specifically 
truncate transcription by the T7 MEGAshortscript kit (Ambion)19.  Amino acids 
chemically appended to dCA were ligated to the 74mer tRNA, resulting in full-length 
acylated tRNA, using methods previously described20.  Acylation of tRNA was 
confirmed using MALDI mass spectrometry using a 3-hydroxypicolinic acid matrix.  The 
NVOC protecting group on the amino acid was removed immediately prior to injection 
through a 5-minute irradiation step using a 1 kW Xenon lamp with WG-335 and UG-11 
filters. 
 
Chimeras.  Chimeras were synthesized by mutating in an EcoRI restriction enzyme site 
(GAATTC) in both the GluClα and GluClβ receptors at the desired cut site.  First, the 
inherent EcoRI site in the GluClα M3-M4 loop (ATGAATTCC) was removed using 
silent mutations (ATGAACAGC) to eliminate undesired cutting.  The mutated receptors 
were then cut with EcoRI and HindIII (5’ of the encoded gene) and the fragments 
separated by gel electrophoresis on a 1% agarose gel.  The resulting bands were isolated 
and purified using a gel extraction kit (Qiagen) and the desired GluClα and GluClβ 
fragments were ligated together using DNA ligase.  The engineered EcoRI restriction site 
was then mutated back to the wild type α/β or β/α sequence and mRNA was produced as 
described above.   
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Oocyte preparation and injection.  Stage V-VI Xenopus laevis oocytes were harvested 
and injected with RNA as previously described20.  For nonsense suppression experiments, 
37.5 ng of receptor mRNA was coinjected with excess deprotected ~1 µg/µL tRNA 
solution both 48 hours and 24 hours before recording.  For conventional mutagenesis, 
12.5 ng of receptor mRNA was injected 48 hours before recording.  As a negative 
control, all nonsense suppression sites were tested with a full length 76mer tRNA lacking 
an attached amino acid to ensure no read-through expression was observed. 
 
Data Collection and analysis.  All oocyte experiments were performed on an 
OpusXpress 6000A (Axon Instruments) using two-electrode voltage clamp mode.  The 
recording buffer was calcium-free ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5 
mM HEPES, pH 7.5).  The initial holding potential was -60 mV.  Data were sampled at 
125 Hz and filtered at 50 Hz.  A calcium-free ND96 prewash was applied for 30 s (1 
mL/min.) followed by application of agonist for 15 s (4 mL/min.).  Agonist was then 
washed out with calcium-free ND96 buffer for 116 s (3 mL/min.).  Agonist-induced 
currents were measured from the baseline.  Glutamate dose solutions were made in 
calcium-free ND96 buffer from a 50 mM (pH 7.5) stock solution.  The maximum dose of 
100 mM glutamate was made from the glutamate-HCl salt in water and brought to a pH 
of 7.5. 
Data were fit to the Hill equation, Inorm = 1/(1 + (EC50/A)) nH, where Inorm is the 
normalized current peak at [agonist] = A, EC50 is the concentration of agonist that elicits a 
half-maximum response, and nH is the Hill coefficient.  EC50 values were obtained by 
averaging the Inorm values for each agonist concentration and fitting those values to the 
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Hill equation.  ΔΔG values were calculated by the equation ΔΔG=-RTlnΩ, where Ω=  
[EC50(mut1,2)*EC50(WT)]/[EC50(mut1)*EC50(mut2)]. 
 
Results and Discussion 
Mutagenesis of pore lining residues to increase the sensitivity of GluClβ to 
glutamate.  Mutation of the pore lining residues on the M2 helix of Cys-loop receptors 
has had dramatic effects on ligand sensitivity21-23, open channel duration21,24, and receptor 
desensitization22,25.  Specifically, mutation of a conserved hydrophobic residue in the 9’ 
position (i.e., the 9th residue from the N-terminus of helix M2, Figure 4.2) has been used 
in nicotinic acetylcholine receptors (nAChRs) to increase ligand sensitivity and current 
size, thereby facilitating measurement of low expressing and large loss-of-function 
mutations26-28.  Similar to many nAChRs, the GluClβ homomeric receptor gives small 
current responses to applied glutamate and demonstrates a relatively high wild type EC50 
of 0.35 mM (Table 4.1).  The high EC50 value is problematic for measuring loss-of-
function mutations for many reasons.  Glutamate is not soluble at concentrations higher 
than 50 mM in buffered solution, and while a hydrochloride salt increases this solubility, 
it also dramatically increases the osmolarity of the solution to several times greater than 
the running buffer29.  Also, at high concentrations of glutamate, currents are observed in 
uninjected oocytes, which may be due to non-specific activation of endogenous receptors 
or osmotic response.  These currents, while small, complicate measurement of low-
expressing mutants.  Also, in high expressing mutants, rapid desensitization of GluClβ 
occurs at concentrations greater than 100 mM, prohibiting further measurements.  
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Therefore, to enable measurement of low expressing and large loss-of-function mutants, 
it is important to lower the EC50 of the wild type receptor.   
 Unlike 9’ mutations in individual nAChR subunits, mutation of the L9’ residue in 
GluClβ to either alanine or phenylalanine led to constitutive activation of the receptor, 
characterized by large baseline currents (>1 µA), and no additional response to applied 
glutamate.  A similar increase in basal activation 
of GluClαβ heteromers was previously observed 
in GluClαL9’X-βWT receptors, along with a 
decrease in the amplitude of the ligand response 
in HEK293 cells23.  An exception to this was the 
GluClαL9’F-βWT receptor, which demonstrated 
increased sensitivity to ivermectin and glutamate 
(not shown) with no loss of signal amplitude.  
The gain-of-function phenotype was not 
observed in GluClαL9’F homomers and is not 
observed here in GluClβL9’F homomers, 
indicating the effect may be specific to the 
heteromeric receptor.   Similar observations have 
been reported in other Cys-loop receptors 21,29.  
All receptors with 9’ mutations that give large 
functional responses and an increase in ligand 
sensitivity are heteromeric receptors, where 
fewer than five individual subunits contained the 
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Figure 4.2.  The M2 pore lining 
helix of GluClβ.  View from (A) 
the top of the receptor and (B) 
from the side.  Residues in the 
ion-conducting pore are 
highlighted in blue and the 
location of the 0’ arginine and 20’ 
alanine are indicated.  Side chains 
of the GluClα crystal structure 
were mutated to the 
corresponding GluClβ side chains 
in PyMol. 
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9’ mutation.  In the cases where all five subunits had 9’ mutations, either in homomeric 
or multiply mutated receptors, small ligand-induced responses and high resting currents 
were observed, indicative of receptor activation in the absence of agonist.  Therefore, to 
create a receptor with increased sensitivity to glutamate and no significant loss of current 
amplitude, other pore-lining residues, potentially with a lesser effect on channel gating, 
were targeted for mutagenesis. 
 The GluClα crystal structure (PDB ID: 3RIF) indicates that the pore-lining 
residues are at the -2’, -1’, 2’, 6’, 9’, 10’, 13’, 17’, and 20’ positions in the M2 helix 
(Figure 4.2).  These residues physically shape the channel and influence the conductance 
and the equilibrium between inactive and active conformations through the presence or  
 
Table 4.1: GluClβ M2 helix mutations 
 
Mutation EC50 (mM) Hill n Imax (µA) Fold shift 
WT 0.35 +/- 0.01 2.5 +/- 0.2 20 0.4-4 - 
AG-2',-1'PA 0.46 +/- 0.01 1.8 +/- 0.1 10 12-66 1.3 
A2'S 0.63 +/- 0.01 2.0 +/- 0.1 12 0.6-6 1.8 
A2'T No response 
T6'A Very low response 
T6'S 0.0080 +/- 0.0005 2.4 +/- 0.3 27 0.06-8 1/44 
L9'A Constitutively active 
L9'F Constitutively active 
L9'V No response 
T10'A 0.013 +/- 0.001 2.8 +/- 0.1 14 2-28 1/27 
T10'S 0.011 +/- 0.001 2.5 +/- 0.1 14 0.3-4 1/32 
T13'A 0.038 +/- 0.001 2.8 +/- 0.1 11 0.1-6 1/9 
T13'S No response 
A17'G >5 
 
10 
 
  
A17'S 0.23 +/- 0.01 2.5 +/- 0.1 10 0.6-12 1/1.5 
A17'T 0.058 +/- 0.001 2.8 +/- 0.1 13 0.3-13 1/6 
A20'S No response 
A20'T 0.11 +/- 0.02 1.7 +/- 0.1 14 0.5-48 1/3 
T6'S/T10'S Constitutive activity - some glutamate response 
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absence of steric bulk and polarity of the side chains30.  In this study, to modulate these 
properties of the receptor, the pore-lining residues were mutated to amino acids of 
varying size and polarity (Table 4.1).  Constitutive activity was only observed in 
mutations at the 9’ site, whereas mutations to the other residues had varied effects on 
receptor EC50 and current across the membrane.  Of the mutations tested, the T6’S 
mutation led to the greatest increase in receptor sensitivity (44-fold), followed by 
mutation of the T10’ residue to either alanine or serine (27 and 32-fold, respectively), and 
the T13’A mutation (9-fold).  The T6’A and T13’S mutants were not functional.  These 
results indicate that smaller residues near the pore constriction facilitate channel opening, 
and that while polarity of the 6’ side chain is required, it is not important at the 10’ or 13’ 
positions.  The double mutant T6’S/T10’S gave low agonist response and high leak 
currents indicative of agonist-independent openings as was observed in the L9’A and 
L9’F mutants.  
 To ensure that the T6’S mutation does not affect measurement of other side chain 
substitutions, a distal loss-of-function mutation was incorporated into the wild type and 
T6’S containing receptor for comparison.  This mutation, Y206F, is located in the 
extracellular domain of the receptor at the glutamate binding site and disrupts an 
important hydrogen bond between itself and a nearby threonine side chain, T203 (see 
below).  The loss-of-function observed in the T6’S/Y206F mutant was 12.5-fold 
compared to 12.3-fold in the single Y206F mutant.  These values are not significantly 
different and therefore indicate that the T6’S mutation is multiplicative and should not 
affect measurement of binding site interactions (Table 4.2).  No effect on signal 
amplitude was observed in T6’S-containing receptors.  Because of the large increase in 
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glutamate sensitivity and a demonstrated lack of coupling between the T6’S mutation and 
the ligand binding site, it was determined that incorporation of T6’S as a background 
mutation is ideal for measuring large loss-of-function mutations to the GluClβ receptor. 
 
Table 4.2.  Multiplicative effect of the T6’S mutation 
Mutation EC50 (mM) Hill n Imax (µA) Fold Shift 
WT 0.35 +/- 0.01 2.5 +/- 0.2 20 0.4-3.9 - 
T6'S 0.0080 +/- 0.0005 2.4 +/- 0.3 27 0.06-8 - 
Y206F 4.3 +/- 0.1 2.4 +/- 0.1 13 0.2-8  12.3 
T6'S/Y206F 0.10 +/- 0.01 2.6 +/- 0.3 14 0.14-7 12.5 
 
Of the other mutations tested, only small shifts in EC50 were observed.  
Mutagenesis of the -2’ and -1’ residues to be like the GluClα receptor (AG to PA) 
resulted in no shift of EC50, but a large increase in current through the channel.  It is also 
interesting to note that while the A2’S mutation had minimal effect on receptor function, 
the A2’T mutation abolished sensitivity of the receptor to glutamate.  The converse 
mutation in GluClα, T2’A, was previously shown to restore glutamate sensitivity to an 
otherwise glutamate-insensitive channel17.  It is therefore likely that the 2’ residue plays 
an important role in the coupling of ligand binding to receptor activation.  
 
Optimization of receptor expression.  It has been shown previously that surface 
expression of the GluClβ homomeric receptor in HEK293 cells is low relative to the 
homomeric GluClα and the heteromeric GluClαβ receptors, because it is retained in the 
endoplasmic reticulum (ER) more so than other GluCl receptors23.  We observe this 
functionally in X. laevis oocytes, with approximately 10-fold enhanced currents of the 
heteromer relative to the GluClβ homomeric receptor (data not shown).  Data for the  
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Figure 4.3.  Sequence alignment of GluClα and GluClβ.  Sites for chimera synthesis and 
receptor mutagenesis are indicated:  α signaling peptide chimera spliced at red line, α 
signaling peptide + α1 helix spliced at orange line, M3-M4 loop spliced between green 
lines, C terminus spliced at purple line, and putative ER retention RxR motifs and ER 
export LxxLE motif are highlighted in black boxes.  Sequence alignment was made using 
Clustal Omega. 
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Figure 4.4.  Effects of mutations and chimeras on GluClβ functional expression.  (A) 
Schematic of chimeras examined and (B) average and median currents from X. laevis 
oocytes expressing the specified mutant receptor. 
 
homomeric GluClα receptor are not available because this receptor is not gated by 
glutamate in X. laevis oocytes17.  The relatively low receptor expression of GluClβ does 
not affect studies of wild type GluClβ or conventional mutants, however expression 
becomes an issue when attempting to incorporate unnatural amino acids by nonsense 
problematic to distinguish between a receptor that does not respond to the applied 
glutamate concentrations and a receptor that is expressed too poorly to detect.  To avoid  
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Table 4.3:  Effects of receptor mutagenesis on functional expression.  All mutations have 
the T6'S mutation unless otherwise noted. 
Mutation EC50 (µM) Hill n Imax (µA) 
Median 
(µA) 
Average 
(µA) 
Fold 
Change 
Median 
Fold 
Change 
Average 
WT 11 +/- 1 3.0 +/- 0.1 19 0.1-4 1.1 1.1 - - 
RRR_AAA 14 +/- 1 2.8 +/- 0.1 15 0.1-4 1.0 1.4 1 1 
RSR_AAA 14 +/- 1 2.6 +/- 0.1 15 0.1-3 0.6 0.6 -2 -2 
RRR/RSR_AAA 15 +/- 1 2.8 +/- 0.1 20 0.8-10 4.5 4.1 4 4 
LXXLE 14 +/- 1 3.2 +/- 0.1 12 0.02-0.23 0.1 0.15 -11 -8 
M3-M4 loop No response 
α signal peptide  
(no T6'S) 980 +/- 20 1.9 +/- 0.1 16 3-14 8.9 8.7 9 8 
α signal peptide 
+ α1 (no T6'S) 110 +/- 10 2.6 +/- 0.2 14 0.2-6 1.0 1.4 1 1 
M4-C term β/α No response 
 
this issue, we sought to increase receptor expression without affecting the receptor’s 
function. 
To enhance functional surface expression of GluClβ receptors, point mutants or 
chimeras with GluClα segments were made in regions of the receptor previously shown 
to affect Cys-loop receptor trafficking and expression levels (Figure 4.3)31-37.  These  
regions include the signal peptide, the C-terminus, and the intracellular M3-M4 loop, 
which contains two RxR putative ER retention motifs in the GluClβ receptor.  Chimeras 
were made with GluClα since it does not accumulate in the ER and because of the high 
similarity between the receptors, which minimizes the chance of affecting receptor 
function.  Of the mutations and chimeras examined, only GluClβ with the α signal 
peptide and the RSR/RRR_AAA mutant (replacement of all six residues in the two ER 
retention motifs with alanine) gave enhanced expression relative to the wild type receptor 
(Figure 4.4 and Table 4.3).  Conversely, introduction of a putative ER export motif 
(LxxLE) in the M3-M4 loop decreased expression, and the M3-M4 loop and α C-
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terminus chimeras resulted in non-functional receptors.  Mutation of either RxR motif 
singly to AAA had no effect on receptor expression and replacement of the GluClβ α1 
helix with the corresponding segment from GluClα neutralized the increased expression 
observed upon introduction of the GluClα signal peptide.  Removal of both RxR ER 
retention motifs enhanced expression approximately 4-fold whereas the α signal peptide 
chimera had approximately 8-fold enhanced expression.  The α signal peptide chimera 
gave currents comparable to other Cys-loop receptors, and therefore mutant receptors not 
responding to glutamate at the applied concentrations are assumed to be non-functional 
rather than inadequately expressed.  No shift in EC50 was observed for any of the 
chimeras or mutants examined, with the exception of a less than three-fold loss of 
function of the α signal peptide chimera.  
 
Evaluating Potential Cation-π Interactions.  A cation-π interaction between agonist 
and receptor is a universal feature of Cys-loop receptors. These binding sites are rich in 
aromatic residues, and in most nAChRs and the 5HT3A receptor, a Trp on loop B 
provides the π system. Receptors for smaller agonists such as GABA and glycine do not 
typically have Trp residues, and the cation-π interaction is formed to a Phe or Tyr. Along 
with loop B, aromatics on loops A and C have been shown to make cation-π interactions 
to agonists. 
To facilitate visualization of the discussed residues in the GluClα crystal 
structure, the residue identifier for the corresponding GluClα amino acid is included after 
the GluClβ number (ex. Y206(200) corresponds to Yβ(α)).  The GluClα numbering is 
included for the first mention of the residue only. The glutamate-bound GluClα crystal 
structure suggests a strong cation-π interaction between Y206(200) on the C loop and the 
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protonated amine of glutamate (Figure 4.5).  
The crystal structure also indicates the 
potential for a weaker, but still significant, 
electrostatic interaction between the α carbon 
of the ligand (which carries a substantial 
positive charge) and the face of Y156(151), 
located on the B loop.  These aromatic 
residues are conserved among Cys-loop 
receptors and have been previously shown to 
participate in important cation-π interactions 
in other receptors with their corresponding 
ligands26,38-41.  Additionally, a phenylalanine, 
F96(91), on loop A and a tryptophan on the D 
loop of the complementary face are conserved members of the aromatic binding box. 
However, these residues are not predicted to participate in an electrostatic interaction 
with the ligand or any other residue.  A major difference between the GluCl receptors and 
other Cys-loop receptors is the absence of a second aromatic residue on the C loop (C1).     
We have established a general protocol for evaluating cation-π interactions16, in 
which the aromatic of interest is substituted with electron withdrawing groups that are 
known to diminish the cation-π binding ability of the ring (Figure 4.6). A clear 
correlation between cation-π binding ability and receptor function, as reported by EC50, 
indicates a functionally significant cation-π interaction. An especially convenient system 
is a series of progressively fluorinated phenylalanine derivatives, which systematically  
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Figure 4.5.  The glutamate binding site 
and predicted electrostatic interactions 
between the ligand and its surrounding 
amino acids.   The primary subunit is 
colored in green and the 
complementary subunit in blue. 
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Figure 4.6.  Chemical structures of amino acids used in this study.  
 
 
Table 4.4.  Unnatural amino acid mutagenesis of aromatic binding site residues.  Data 
were obtained from a receptor containing the α signal peptide for enhanced functional 
expression.  All mutants have the T6’S background mutation. 
 
Mutation EC50 (mM) Hill n Imax (µA) Fold Shift 
 
WT 0.93 +/- 0.02 1.8 +/- 0.1 26 2-13 - 
T6'S 0.013 +/- 0.001 2.7 +/- 0.2 17 2-13 - 
F96TAG           
Phe 0.012 +/- 0.001 2.8 +/- 0.3 12 0.1-4 - 
F1-Phe 0.080 +/- 0.002 2.8 +/- 0.2 7 0.1-0.5 7 
F2-Phe 0.0047 +/- 0.0001 4.1 +/- 0.5 12 0.04-1 1/3 
F3-Phe 0.039 +/- 0.001 2.4 +/- 0.2 11 0.06-0.6 3 
Y156F 15 +/- 1 2.3 +/- 0.2 15 1-5 - 
Y156TAG 
    
  
Phe 17 +/- 1 1.7 +/- 0.1 15 1-4 - 
OMe-Phe No response  
F1-Phe 14 +/- 1 2.0 +/- 0.1 20 0.1-5 1/1.2 
F2-Phe 49 +/- 3 1.8 +/- 0.1 13 0.2-4 3 
F3-Phe 65 +/- 5 1.7 +/- 0.1 11 0.3-2 4 
Cha No response 
Y206F 0.25 +/- 0.01 2.7 +/- 0.1 17 0.6-17 - 
Y206TAG 
     Phe 0.25 +/- 0.01 2.5 +/- 0.1 20 0.06-12 - 
F1-Phe 1.4 +/- 0.1 2.8 +/- 0.5 15 0.4-6 6 
F2-Phe >100 
 
20 0.1-1 
 OMe-Phe 0.64 +/- 0.01 2.9 +/- 0.1 11 0.3-6 3 
Br-Phe 1.5 +/- 0.1 3.1 +/- 0.1 11 1-13 6 
CN-Phe 43 +/- 1 2.7 +/- 0.1 19 0.8-7 172 
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Table 4.5. Unnatural amino acid mutagenesis of aromatic binding site residues.  Data 
were obtained from a receptor containing the wild type signal peptide.  All mutants have 
the T6’S background mutation.  
 
Mutation EC50 (mM) Hill n Imax (µA) Fold Shift 
 
WT 0.35 +/- 0.01 2.5 +/- 0.2 20 0.4-4 - 
T6'S 0.0080 +/- 0.0005 2.4 +/- 0.3 27 0.06-8 - 
Y156F 6.4 +/- 0.4 1.6 +/- 0.1 17 1-4 800 
Y156TAG 
    
  
Phe 4.8 +/- 0.3 1.6 +/- 0.1 7 0.2-2 - 
F3-Phe 32 +/- 2 1.4 +/- 0.1 7 0.06-0.4 7 
Y206F 0.10 +/- 0.01 2.6 +/- 0.3 14 0.14-7 - 
Y206TAG 
    
  
Phe 0.16 +/- 0.01 3.0 +/- 0.2 8 0.07-0.30 - 
F1-Phe 0.64 +/- 0.01 2.8 +/- 0.1 9 0.04-0.34 4 
F2-Phe >100 
 
8 0.1-0.6 >250 
OMe-Phe 0.56 +/- 0.01 1.8 +/- 0.1 11 0.1-1.4 4 
Br-Phe 0.98 +/- 0.03 2.5 +/- 0.1 15 0.08-6 6 
CN-Phe 19 +/- 1 2.8 +/- 0.2 14 0.8-6 119 
Me-Phe 0.098 +/- 0.003 2.4 +/- 0.1 12 0.05-7 1/1.8 
 
lower the cation-π binding ability. Such a study shows no electrostatic interaction 
between the ligand and either F96 or Y156, as indicated by the very small losses-of-
function upon incorporation of F3-Phe, a highly electron-deficient ring system (Table 
4.4).   
In contrast, electron-withdrawing groups added to Y206 strongly impacted 
receptor function. As before, we study substituted Phe analogues to avoid complications 
associated with lowering the pKa of a Tyr residue when electron-withdrawing groups are 
added. Most telling is the large effect for 4-CN-Phe vs 4-Br-Phe. The two substituents 
present a similar steric perturbation, but only CN is strongly deactivating in a cation-π 
interaction. We were unable to study the series of fluorinated Phe derivatives that we 
have previously employed because 3,5-F2-Phe gave receptors that did not reach their 
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maximal response upon application of our 
highest concentration of glutamate, 100 
mM. There is apparently a strong steric 
penalty for substituents in the meta 
position at residue 206, where the side 
chains of T201(195) and T203(197) could 
be impacted, as incorporation of 3,5-Me2-
Phe also resulted in nonfunctional 
receptors. As such, our study is restricted 
to 4-substituted Phe derivatives.  With 
this more limited data set, a linear plot of 
calculated cation-π binding energy and 
the ratio of the mutant EC50 to the wild type could be obtained (Figure 4.7). Although this 
is a limited data set, we feel the correlation of Figure 5, along with the very large CN/Br 
ratio (~20) makes a compelling case for a cation-π interaction to Y206.  
 In addition to the 3,5-F2Phe mutation, full turnover of the dose-response curve 
was not seen for 4-CN-Phe in the α signal peptide-containing template (Figure 4.8).  The 
α signal peptide was required to obtain suppression data at the F96 and Y156 sites, 
however suppression data could be obtained for both the wild type and α signal peptide-
containing Y206 mutations.  Data was obtained in both templates for Y206 mutations to 
ensure that the signal peptide did not affect receptor function (Tables 4.4 and 4.5).  To 
estimate an EC50 value, obtained data were fit to the Hill equation. As shown in Figure 5, 
very similar results are obtained for receptors with either the α or the β signal peptide, 
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Figure 4.7.  Plot of cation-π binding 
energy vs. mutant receptor loss-of-function 
at Y206.  A linear trend is indicative of an 
electrostatic interaction with the face of the 
residue examined.  Data for both the wild 
type and α signal peptide-containing 
templates are plotted together and indicate 
no effect of altering the signal peptide on 
receptor function  
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providing evidence that altering the signal peptide has no effect on receptor function and 
boosting confidence in the EC50 values obtained for the receptors with the α signal  
 
Figure 4.8.  EC50 plots of mutant receptors that demonstrate a large loss-of-function. (A) 
Y206CNPhe with the α signal sequence (B) Y206CNPhe with the WT β signal sequence 
(C) Y156F2Phe (D) Y206F2Phe with the α signal sequence (E) Y206F2Phe with the WT 
β signal sequence (F)Y156F3Phe with the α signal sequence (G) Y156F3Phe the WT β 
signal sequence. 
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peptide.  The Y206 3,5-F2-Phe mutant in both constructs began to respond to glutamate 
but did not near the turnover point.  These data were fit to the Hill equation (Figure 4.8), 
but we do not believe that the resulting EC50 value is an accurate indication of receptor 
function.  We have therefore reported this mutation as having an EC50 of >100 mM.  The 
D loop tryptophan was not examined because it is not located near the binding site in the 
crystal structure. 
 
Probing other Noncovalent Interactions. In addition to a strong cation-π interaction, 
other noncovalent interactions between glutamate and the receptor were identified.  Two 
arginine residues on the complementary subunit, R40(37) and R59(56), were predicted by 
the crystal structure to form ionic interactions with the main chain carboxylate and the 
side chain carboxylate of glutamate, respectively (Figure 4.5).  These interactions are 
confirmed through receptor mutagenesis.  The R59 residue appears to be more sensitive 
to mutagenesis than R40 because R59 could not tolerate mutation to alanine, whereas 
R40A demonstrated a large but measurable loss-of-function of approximately 140-fold 
(Table 4.6). Mutagenesis of either residue to glutamate resulted in a non-functional 
receptor.  The importance of a stabilizing positive charge on the complementary face of 
the binding site is further demonstrated by mutagenesis of a nearby lysine residue, 
K176(171), on the F loop of the complementary subunit.  This residue is predicted to be 
4.5 Å from the side chain of glutamate and does not participate in a functionally 
important ligand binding interaction, as indicated by the small 2-fold loss-of-function 
upon mutagenesis to alanine.  Interestingly, however, mutagenesis of this lysine residue 
to glutamate resulted in a large 70-fold loss-of-function, indicating either the repulsive  
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Figure 4.9.  Predicted hydrogen bond interactions between the primary and 
complementary subunits near the ligand-binding site in the 3RIF crystal structure.  
Residues on the primary face are shown in green, residues on the complementary face in 
blue, and glutamate in white. Hydrogen bond network between (A) the C loop of the 
primary subunit and the F loop of the complementary subunit the B loop of the primary 
subunit and the E loop of the complementary subunit (B) the B loop of the primary 
subunit and the E loop of the complementary subunit.  
 
 
Table 4.6.  Conventional mutagenesis of binding site residues.   All mutants have the 
T6’S background mutation. 
 
Mutation EC50 (mM) Hill n 
Fold 
Shift Ω 
ΔΔG 
(kcal/mol) 
WT (T6’S) 0.0080 +/- 0.0005 2.4 +/- 0.3 27 - 
  R40A 1.1 +/- 0.1 2.1 +/- 0.1 17 140 
  R40E No response   
 R59A No response   
 R59E No response   
 K176A 0.017 +/- 0.001 2.2 +/- 0.1 17 2 
  K176E 0.54 +/- 0.02 1.8 +/- 0.1 14 70 
  Y206A No response 
  Y206F 0.10 +/- 0.01 2.6 +/- 0.3 14 13 
 
  
T203A 0.64 +/- 0.01 2.3 +/- 0.1 19 80 
 
  
T203A/Y206F 0.21 +/- 0.01 2.2 +/- 0.1 18 26 1/37 2.1 
Q174A 0.11 +/- 0.01 2.4 +/- 0.2 14 14 
 
  
N202A 0.010 +/- 0.001 3.3 +/- 0.2 16 1.25 
 
  
Q174A/Y206F 0.92 +/- 0.04 2.2 +/- 0.2 13 115 0.67 0.23 
Y156A No response   
 Y156F 6.4 +/- 0.4 1.6 +/- 0.1 17 800 
  S126A 4.7 +/- 0.1 2.5 +/- 0.1 22 590 
  S126A/Y156F No response   
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effect of introducing a negative charge near the carboxylates of the ligand or interference 
of the ligand-binding interactions with R40 or R59. 
 Two inter-subunit hydrogen bond networks are predicted by the GluClα crystal 
structure: one between the C loop of the primary subunit and the F loop of the 
complementary subunit and another between the B loop of the primary subunit and the E 
loop of the complementary subunit (Figure 4.9).  Motivation to study the former comes 
from previous studies in the muscle-type nAChR, where an inter-subunit hydrogen bond 
between an aspartate side chain (γD174/δD180) on the complementary subunit and a 
backbone nitrogen (αS191) on the β-hairpin turn of the C loop was shown to be important 
for channel gating42.  This backbone nitrogen was later shown to be optimally positioned 
by a hydrogen bond network initiating from a neighboring vicinal disulfide bond 
(αC192/αC193) on the C loop43.  While the GluCl receptors, as well as all non-α 
nAChRs, lack this vicinal disulfide, other structural motifs may have evolved to perform 
the same function.   
The GluClα crystal structure predicts an intra-subunit hydrogen bond between the 
side chains of T203(197) and Y206(200) on loop C in approximately the same relative 
position as the vicinal disulfide.  Additionally, a glutamine, Q174(169), is located two 
residues away from the aspartates on the F loop in the γ and δ subunits of the nAChR and 
is poised to interact with the side chain of an asparagine on the β-hairpin turn of the C 
loop, N202(196).  While these interactions are different than those observed in the 
muscle type nAChR, they have the potential to be functionally analogous.   
To analyze these potential interactions, mutant cycle analysis was performed.  
The data indicate a strong functional coupling between the side chains of T203 and Y206 
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with a coupling strength of 2.1 kcal/mol (Table 4.6), between the T203A and Y206F 
mutants. A 14-fold loss-of-function was observed for the Q174A mutant, providing 
evidence that this side chain is important for receptor function. Interestingly, the N202A 
mutant gives wild type receptors, despite a clear hydrogen bond between Q174 and N202 
in the crystal structure. No functional coupling was observed between Y206 and Q174.  
These findings do not support a long-range functional coupling between structural and/or 
ligand-binding elements on the C loop and an inter-subunit hydrogen bond with the F 
loop, as was observed in the nAChR.  The only other polar neighbor of Q174 is an 
asparagine also on the complementary subunit, N36(33), suggesting that no functionally 
important inter-subunit interaction exists between the C loop of the primary subunit and 
the F loop of the complementary subunit. It is possible that the salt-bridges formed 
between the two arginine residues on the complementary subunit and the carboxylates of 
the ligand are sufficient to shape the ligand binding site on the complementary side and 
an additional interaction between the C and F loops would be redundant.  These strong 
interactions are absent in the nAChRs because acetylcholine is neutral on the side that 
binds the complementary subunit, and additional interactions may be necessary to hold 
the binding site together. 
While the functional coupling between the side chains of T203 and Y206 is likely 
unrelated to the effects caused by the vicinal disulfide, it provides support for the ligand-
binding interactions previously discussed and predicted by the crystal structure.  T203 is 
predicted to act as a hydrogen bond donor to the side chain carboxylate of glutamate and 
as a hydrogen bond acceptor to the hydroxyl of Y206.  The hydrogen bond between Y206 
and T203 likely strengthens the cation-π binding energy of the tyrosine due to an increase 
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in electrostatic potential on the ring system, caused by the electron donating properties of 
the acidic phenol.  These effects were previously predicted with gas phase calculations of 
phenol and formamide, a hydrogen bond acceptor, where a hydrogen bond significantly 
enhanced a cation-π interaction in the gas phase44.  This may account for why tyrosine, a 
weaker cation-π binder than tryptophan in isolation, is capable of forming such a strong 
cation-π interaction with glutamate in this receptor and why tyrosines are overrepresented 
in cation-π interactions in Cys-loop receptors relative to phenylalanine.  It can also be 
argued that the hydrogen bond exists to position Y206 in an orientation optimal for a 
strong cation-π interaction.  It is important to note that the cation-π interaction determined 
here was measured with phenylalanine derivatives that lack the hydrogen bond to T203.  
Data indicate a cation-π binding strength similar to other primary amines as indicated by 
the slope of the cation-π plot38,40,41,45. Regardless of mechanism, we experimentally 
observe the importance of this hydrogen bond with the Y206F mutation, which results in 
a 13-fold loss of function.  The directionality of hydrogen bonding predicted by the 
crystal structure is confirmed by incorporation of 4-MeO-Phe at Y206.   This mutation 
does not reverse the loss-of-function seen in the Y206F mutant, and therefore provides 
evidence that Y206 is acting as a hydrogen bond donor.  The T203A mutation resulted in 
an 80-fold loss-of-function, likely caused by breaking both its interaction to glutamate 
and Y206. 
 In addition to inter-subunit interactions between the C and F loops, the crystal 
structure suggests a hydrogen bond interaction between the side chains of Y156 on the B 
loop of the primary subunit and S126 on the E loop of the complementary subunit.  
Mutagenesis of these residues individually to remove the polar side chain resulted in a 
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large loss-of-function of 800-fold and 590-fold, respectively (Table 4.6).  These large and 
similar losses-of-function indicate that an interaction between the two side chains is 
likely to occur and is important for receptor function, however functional coupling could 
not be determined because the EC50 of the double mutant could not be measured.  The 
high EC50 values of the single mutants are near the limit of our detection, and therefore 
any additional loss-of-function would be difficult to measure because of the high 
glutamate concentrations required.   
In other anion-selective Cys-loop receptors where a tyrosine is found at the 
aromatic position on loop B, different effects are observed upon mutagenesis of the 
tyrosine to phenylalanine.  In the glycine receptor, this residue is naturally a 
phenylalanine, and therefore a hydrogen bond with the complementary subunit is not 
possible.  In the GABAC receptor, a less than 5-fold loss of function is observed upon 
mutagenesis of tyrosine to phenylalanine40.  However, in the GABAA receptor, a large 
400-fold loss-of-function was observed, similar to that seen here in the GluClβ receptor45.  
Interestingly, substitution of tyrosine with 4-MeO-Phe was able to recover the receptor to 
wild type EC50 in GABAA, indicating that the tyrosine acts as a hydrogen bond acceptor, 
whereas in GluClβ, substitution with 4-MeO-Phe led to a non-functional receptor 
indicating that it acts as a donor.  These data suggest that the interactions between the 
primary and complementary subunits vary, even between highly related receptors, and 
that a hydrogen bond at this site is not a universal feature of Cys-loop receptors.     
In summary, a series of interactions were examined in the GluClβ receptor that 
were predicted by the crystal structure of the homologous GluClα receptor.  Unnatural 
amino acid mutagenesis indicates a strong cation-π interaction with a tyrosine residue on 
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loop C, Y206.  This ligand-binding interaction is a conserved feature of the mammalian 
Cys-loop receptors studied to-date, and is found here in a distant invertebrate homolog.  
While this interaction shows that many of the features between distant classes of Cys-
loop receptors are conserved, many interactions were found that are receptor-specific.  
An inter-subunit hydrogen bond between loops C and F shown to be important in the 
muscle type nAChR is absent in GluClβ.  Conversely, an important inter-subunit 
interaction between loops B and E in GluClβ is absent in many more closely related 
anion-selective homologs.  These data indicate that while the crystal structure of a 
receptor can serve as a good model for other homologous receptors, care must be taken 
when extrapolating structural information. 
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Chapter 5 
M4 helix properties in the GluClα receptor tune the coupling of ligand binding and 
channel gating 
 
Abstract 
 Despite the ability of the GluClα receptor to bind glutamate, the receptor is not 
activated by glutamate in the absence of allosteric modulators such as ivermectin. In 
contrast, the homologous GluClβ homomeric and GluClαβ heteromeric receptors are 
efficiently activated by glutamate.  The ability of GluClα to bind glutamate indicates that 
the receptor’s dysfunction is due to a lack of coupling between the ligand-binding domain 
and the transmembrane pore-forming domain.  Through the synthesis of a series of 
GluClα/β chimeras, it was found that by modifying the C-terminal residues of GluClα, 
including the C-terminal half of the M4 helix, glutamate sensitivity could be restored.  
The C-termini of GluCl subunits are short disordered sequences that are positioned to 
interact with the extracellular domain of the receptor, specifically the Cys-loop, which is 
characteristic of this class of proteins.  Additional chimera and mutagenesis studies have 
failed to provide evidence for a defective C-terminus-Cys-loop interaction in GluClα.  
Instead, membrane-protein interactions or M4 helix structure/dynamics may be 
responsible for this decoupling.  
 
Introduction 
 Fast synaptic transmission occurs through the propagation of an electrical signal 
by a class of ligand-gated ion channels known as the Cys-loop receptors.  In these 
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receptors, a ligand-binding event in the extracellular domain initiates a cascade of 
receptor movements that ultimately results in the opening of the pore lining M2 helix and 
the flow of ions across the membrane.  These two domains are located over 40 Å apart in 
the folded receptor, and the mechanism by which this signal is propagated is not yet fully 
understood1,2.  
 The activation process is thought to occur in a wave-like manner with discreet 
domain movements that ultimately lead to an increase in ion permeability across the 
membrane3.  These movements initiate at the ligand-binding site and propagate step-wise 
toward the transmembrane region4,5.  Proper communication in the form of structural 
compatibility between the extracellular and transmembrane domains is crucial for the 
coupling of ligand binding and channel gating6,7.  Many of the regions shown to be 
important for successful channel gating are found at the interface of the two domains 
including the pre-M1 linker8,9, the “pin in socket” interaction between extracellular loop 
2 and the M2-M3 loop10-12, the Cys-loop13, and the extracellular C-terminal domain14,15.  
Additionally, maintaining an overall charge pattern at the interface between the two 
domains was shown to be important for gating16.  
 In addition to these interfacial regions, other factors and regions distant from the 
binding site have been shown to be important for the creation of functional receptors and 
the coupling of ligand binding to channel gating.  These factors include the lipid 
composition surrounding the receptor17 and the properties of the transmembrane 
regions18, of which proper tuning is required for receptor assembly and ligand-induced 
activation.  The fourth transmembrane helical domain, TM4, has been implicated as a 
lipid-sensing domain that serves to translate the information of the surrounding 
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membrane to the rest of the receptor17,19.  It has also been suggested to serve as a hinge in 
the gating mechanism20.  Linear free-energy analysis of the muscle-type nAChR supports 
concurrent motion of TM4 helix residues along with residues on the mid-section of TM2 
(13’, 11’, 7’, and 3’) that are estimated to move in the middle of the gating process4,21, 
therefore supporting the importance of this helix in the gating mechanism.   
Disruption of regions important for channel gating can lead to receptors with 
lower ligand efficacy or in the most extreme case, to receptors that are nonfunctional.  
Decoupling of ligand-binding and channel gating events can occur through point 
mutations to residues important for gating22-24, varied properties of receptor domains25,26, 
or through modulation of the lipid bilayer surrounding the receptor17,27.  In Xenopus 
laevis oocytes, the homomeric GluClα receptor is shown to be insensitive to its native 
ligand, glutamate, in the absence of an allosteric modulator that stabilizes the open 
conformation, ivermectin24.  The receptor is known to have a functional binding site 
because the receptor was crystalized with glutamate bound in the presence of ivermectin, 
and additional channel activation can be elicited by glutamate after application of 
ivermectin2.  Functional response to glutamate in the absence of ivermectin can be 
regained with a point mutation of a TM2 helix pore-lining residue, T2’A24, or by 
expressing the channel in an alternate heterologous expression system such as HEK293 
cells28.  These findings support a mechanism of glutamate-insensitivity that involves 
dysfunction of the gating mechanism rather than ligand-binding event.  It also suggests 
that membrane effects might play a role in this decoupling. 
In this study, chimeras between GluClα and the homologous GluClβ receptor, 
both from Caenorhabditis elegans, were created to determine regions of the receptor 
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responsible for this decoupling.  The 
GluClβ receptor was selected because it is 
the closest homolog to GluClα and is fully 
activated by glutamate in X. laevis oocytes.  
GluClα/β chimeras implicate the C-terminal 
half of the M4 helix of GluClα as having 
defective properties that prevent channel 
activation (Figure 5.1).  Mutagenesis of 
amino acids in this region indicates that no 
individual residue is responsible for this 
effect, but rather the properties of the entire 
helix are involved.  Removal of a putative cholesterol binding motif near the C-terminus 
of TM4, found in the GluClα and not the GluClβ receptor, resulted in ~10% regain of 
glutamate-induced response relative to ivermectin.  No deficiency of coupling between 
the Cys-loop and the C-terminus was identified.  These findings indicate that the 
properties of TM4, while distant from both the ligand binding and channel gate domains, 
exert significant effects on receptor function.  Direct interactions with the surrounding 
membrane likely have a strong influence on the structure and dynamics of this helix, 
which is translated to the ligand binding domain and channel gate through unknown 
mechanisms. 
   
 
 
Figure 5.1. Structure of the GluClα 
receptor (PDB ID: 3RIF) with regions of 
interest highlighted. 
!"#$
%&'$"(()$
*+,%$-./01$
*2$)(/.3"45456$
7."48$
%7(".'-./("$$
945:456$0(;<$
 139 
Methods 
Molecular biology.  The mammalian codon optimized GluClα and β receptors from C. 
elegans29 were used in the pcDNA3.1 vector for HEK293T experiments.  The receptors 
were subcloned into the pGEMhe vector and the stop codon of the GluClβ receptor was 
mutated from TAG to TGA for Xenopus laevis oocyte experiments.  Mutagenesis of the 
GluClβ receptor, including amino acid deletions, was performed using the QuikChange 
protocol (Stratagene).  The cDNA was linearized using SbfI (New England Biolabs) and 
mRNA was produced from the linearized plasmids by using the T7 mMessage Machine 
kit (Ambion) for X. laevis oocyte experiments.   
 
Chimeras.  Chimeras were synthesized by mutating in an EcoRI restriction enzyme site 
(GAATTC) in both the GluClα and GluClβ receptors at the desired cut site.  First, the 
inherent EcoRI site in the GluClα M3-M4 loop (ATGAATTCC) was removed using 
silent mutations (ATGAACAGC) to eliminate undesired cutting.  The mutated receptors 
were then cut with EcoRI and HindIII (5’ of the encoded gene) and the fragments were 
separated by gel electrophoresis on a 1% agarose gel.  The resulting bands were isolated 
and purified using a gel extraction kit (Qiagen) and the desired GluClα and GluClβ 
fragments were ligated together using DNA ligase.  The engineered EcoRI restriction site 
was then mutated back to the wild type α/β or β/α sequence and mRNA was produced as 
described above.   
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Oocyte preparation and injection.  Stage V-VI Xenopus laevis oocytes were harvested 
and injected with RNA as previously described30.  For all constructs, 12.5 ng of receptor 
mRNA was injected 48 hours before recording.   
 
Transfection of HEK293T cells. Cells were grown in DMEM:F12 (1:1) media with 
GlutaMAX-I (Gibco). 60-90% confluent HEK293T cells in 35 mm dishes were 
transfected with 2 µg of DNA using the TransIT-mRNA reagent.  Transfection was 
performed by manufacturers instructions using 3.75 µL of Boost Reagent and 7.5 µL of 
TransIT in serum and antiobiotic free media.  The DNA and reagent complexes were 
added directly to the media over the cells and cells were incubated for 24 hours at 37oC 
and 5% CO2.  After 24 hours the cells were harvested and plated in 96-well plates (one 35 
mM dish was used to fill 3 wells in a 96-well plate) and allowed to incubate for an 
additional 24 hours before FlexStation3 recording.   
 
Methyl-β-cyclodextrin removal of cholesterol.  For methyl-β-cyclodextrin (MβCD) 
experiments in X. laevis oocytes, 4 cells were placed in 2 mL of varying concentrations 
of MβCD (50 µM, 500 µM, or 5 mM) in ND96+ for the specified amount of time (0.5, 1, 
1.5, or 2 hours).  Cells were then washed 3X with ND96+ before recording. 
 For HEK293T experiments, media containing 0, 100 µM, 1 mM, and 10 mM 
MβCD were added to cells plated in a 96 well plate.  Cells were incubated in the presence 
of MβCD for 2 hours before the media was exchanged after a PBS wash step. 
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Data Collection and analysis.  All oocyte experiments were performed on an 
OpusXpress 6000A (Axon Instruments) using two-electrode voltage clamp mode.  The 
recording buffer was calcium-free ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5 
mM HEPES, pH 7.5).  The initial holding potential was -60 mV.  Data were sampled at 
125 Hz and filtered at 50 Hz.  A calcium-free ND96 prewash was applied for 30 s (1 
mL/min.) followed by application of agonist for 15 s (4 mL/min.).  Agonist was then 
washed out with calcium-free ND96 buffer for 116 s (3 mL/min.).  Agonist-induced 
currents were measured from the baseline.  Glutamate dose solutions were made in 
calcium-free ND96 buffer from a 50 mM (pH 7.5) stock solution made in the same 
buffer.  A 10 µM solution of ivermectin was made in calcium-free ND96 buffer from a 
50 mM stock solution made in DMSO. 
 All HEK293T experiments were performed using a FlexStation3 (Molecular 
Devices). After a 48 hour incubation period, the media above the cells was removed and 
the cells were washed with Flex Buffer (115 mM NaCl, 1 mM KCl, 1 mM CaCl2, 1 mM 
MgCl2, 10 mM D-glucose, and 10 mM HEPES at pH 7.5)31.  The cells in the 96-well 
plate were incubated with 100 µL/well of a 1:2 dilution of FLIPR Membrane Potential 
Assay Kit (blue) for 30 minutes at 37oC and 5% CO2 and read using the FlexStation3. 
Wells were excited at 530 nm and fluorescence was recorded at 565 nm using a 550 nm 
filter at low photomultiplier tube sensitivity after application of 100 µL of agonist to the 
wells.  Fluorescence data were collected every 1.52 seconds for 180 seconds and data 
were analyzed using the SOFTmax Pro software (Molecular Devices).  The peak values 
for each well in a column of the 96-well plate were normalized to the maximum value. 
 142 
Data were fit to the Hill equation, Inorm = 1/(1 + (EC50/A)) nH, where Inorm is the 
normalized current peak at [agonist] = A, EC50 is the concentration of agonist that elicits a 
half-maximum response, and nH is the Hill coefficient.  EC50 values were obtained by 
averaging the Inorm values for each agonist concentration and fitting those values to the 
Hill equation.  
 
Results and Discussion 
Implication of the M4 helix in GluClα receptor insensitivity to glutamate.  Chimeras 
between GluClα and GluClβ were synthesized to identify regions responsible for GluClα 
insensitivity to glutamate.  A previous study indicated that the GluClα extracellular 
domain possesses sufficient ligand binding elements, as evidenced by the functionality of 
a GluClα/β chimera with an extracellular (EC) GluClα domain and a transmembrane 
(TM) GluClβ domain24.  This finding also suggests that a decoupling of ligand binding 
and channel gating events, originating in the TM domain of the receptor, is the reason for 
glutamate insensitivity in GluClα.  We have duplicated their data here, and have created 
additional receptor chimeras to determine if there are TM regions other than the channel 
gate that contribute to the impaired coupling between ligand binding and channel gating 
in GluClα.  Chimeras are indicated by the order of splicing (α/β indicates N-terminal 
GluClα elements and C-terminal GluClβ elements and the reverse for β/α) and the 
approximate location of splicing.  The exact site of receptor splicing is indicated in 
Figure 5.2.  Because ivermectin is a full allosteric agonist at the wild-type GluClα 
receptor, we can measure the efficacy of glutamate at the mutant receptors as the percent 
response to glutamate relative to ivermectin. 
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Figure 5.2.  Chimeras synthesized in this study.  Red indicates GluClα and blue GluClβ. 
Table 5.1.  Functional data of synthesized chimeras  
  EC50 Glu (mM) Hill n Imax Glu (µA) Imax IVM (µA) 
GluClα No Response 3-7 
GluClα:β (1:1) 0.48 +/- 0.01 3.3 +/- 0.1 7 4-24 7-9 
GluClβ 0.35 +/- 0.01 2.5 +/- 0.2 20 0.4-4 NR 
α/β EC/TM 0.00078 +/- 0.00007 2.1 +/- 0.4 15 0.3-2 NR 
β/α EC/TM No response NR 
α/β M1-M2 No response NR 
β/α M1-M2 No response NR 
α/β M2-M3 No response NR 
β/α M2-M3 No response NR 
α/β M3-M4 loop 0.11 +/- 0.01 2.1 +/- 0.1 22 3-36 2-23 
β/α M3-M4 loop No Response NR 
α/β M4 0.54 +/- 0.03 2.5 +/- 0.3 19 0.4-15 0.1-11 
β/α M4 No Response NR 
GluClα/β C-term 2.8 +/- 0.5 1.4 +/- 0.1 7 0.4-3 3-13 
GluClβ/α C-term No response - 
EC domain M1 M2 M3 M4 
Signal 
peptide Glu (µA) IVM (µA) 
3-14 NR GluCl!/" Sig. 
GluCl!/" EC/TM 
GluCl"/! EC/TM 
GluCl!/" M1/M2 
GluCl"/! M1/M2 
GluCl!/" M2/M3 
GluCl"/! M2/M3 
GluCl!/" M3/M4 
GluCl"/! M3/M4 
GluCl!/" M4 
GluCl"/! M4 
GluCl!/" C-term 
GluCl"/! C-term 
GluCl!/" Sig. + !1 
GluCl"/!/" M3-M4 loop 
0.2-4 NR 
NR NR 
NR NR 
NR NR 
NR NR 
NR NR 
3-36 2-23 
NR NR 
NR NR 
NR NR 
NR NR 
0.4-15 0.1-11 
0.3-2.8 3-13 
GluCl! 
GluCl" 
NR 3-8 
0.4-4 NR 
0.3-2 NR 
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Figure 5.3.  Sites of receptor splicing for chimera synthesis. 
 
 
In addition to the α/β EC/TM chimera, chimeras with the receptors spliced 
between helices for both α/β and β/α were created (Figures 5.2 and 5.3).   While a 
majority of these chimeras were non-functional, chimeras that are primarily GluClα, 
except for the M3-M4 loop and/or M4 helix, demonstrated robust glutamate responses in 
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GluCl! !  MATWIVGKLIIASLILGIQAQQARTKSQDIFEDDNDNGTTTLESLARL----TSPIHIPI!
GluCl"      --------------------------------------MTTPSSFSILLLLLLMPVVTNG!
                                                   **  *   *      *     !
!
!
GluCl! !  EQPQTSDSKILAHLFTSGYDFRVRPPTDN---GGPVVVSVNMLLRTISKIDVVNMEYSAQ!
GluCl"      EYSMQSEQEI-LNALLKNYDMRVRPPPANSSTEGAVNVRVNIMIRMLSKIDVVNMEYSIQ!
            *    *   *        ** *****  *    * * * **   *  *********** *!
!
!
GluCl! !  LTLRESWIDKRLSYGVKGDGQPDF--VILTVGHQIWMPDTFFPNEKQAYKHTIDKPNVLI!
GluCl"      LTFREQWIDPRLAYENLGFYNPPAFLTVPHVKKSLWIPDTFFPTEKAAHRHLIDMENMFL!
            ** ** *** ** *   *   *        *    * ****** ** *  * **  *   !
!
!
GluCl! !  RIHNDGTVLYSVRISLVLSCPMYLQYYPMDVQQCSIDLASYAYTTKDIEYLWKEHSPLQL!
GluCl"      RIYPDGKILYSSRISLTSSCPMRLQLYPLDYQSCNFDLVSYAHTMNDIMYEWDPSTPVQL!
            **  **  *** ****  **** ** ** * * *  ** *** *  ** * *    * **!
!
!
GluCl! !  KVGLSSSLPSFQLTNTS-TTYCTSVTNTGIYSCLRTTIQLKREFSFYLLQLYIPSCMLVI!
GluCl"      KPGVGSDLPNFILKNYTTNADCTSHTNTGSYGCLRMQLLFKRQFSYYLVQLYAPTTMIVI!
            * *  * ** * * *      *** **** * ***     ** ** ** *** *  * **!
!
!
GluCl! !  VSWVSFWFDRTAIPARVTLGVTTLLTMTAQSAGINSQLPPVSYIKAIDVWIGACMTFIFC!
GluCl"      VSWVSFWIDLHSTAGRVALGVTTLLTMTTMQSAINAKLPPVSYVKVVDVWLGACQTFVFG!
            ******* *      ** **********     **  ****** *  *** *** ** * !
!
!
GluCl! !  ALLEFALVNHIANKQGVER-------KARTEREKAEIPLLQNLHNDVPTKVFNQEEKVRT!
GluCl"      ALLEYAFVSYQDSVRQNDRSREKAARKAQRRREKLEMVDAEVYQPPCTCHTFEARETFRD!
            **** * *          *       **   *** *               *   *  * !
!
!
GluCl! !  VPLNRRQMNSFLNLLETKTEWNDISKRVDLISRALFPVLFFVFNILYWSRFGQQNVLF--!
GluCl"      ------KVRRY------FTKPDYLPAKIDFYARFVVPLAFLAFNVIYWVSCLIMSANAST!
                              *         *   *   *  *  **  **            !
!
GluCl! !  -----!
GluCl"      PESLV!
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addition to response to ivermectin (Table 5.1).  Conversely, receptors that were primarily 
GluClβ at the N-terminal end did not respond to glutamate with any C-terminal fragments 
of GluClα.  The GluClα/β-C-term chimera demonstrated functional response to 
glutamate, however the response to glutamate was ~10-20% that of ivermectin.  This 
indicates impaired coupling when the entire GluClα M4 helix is present and suggests that 
properties of both the M4 helix and the C-terminus are responsible for this effect.  
Relative response of the GluClα/β chimeras including or excluding the β M3-M4 loop 
were similar for both glutamate and ivermectin.  These findings indicate that the M3-M4 
loop is not involved in glutamate insensitivity, and that the putative RxR endoplasmic 
reticulum (ER) retention motifs do not prevent export to the membrane in the chimeras.  
It is interesting to note that the GluClβ receptor with the GluClα M3-M4 loop was non-
functional.  This is likely attributed to impaired communication between the GluClα M3-
M4 loop and the GluClβ receptor rather than a problem with the GluClα M3-M4 helix 
itself, as evidenced by the functional response to glutamate of both the GluClα/β-M3-M4 
loop and M4 chimeras.  The EC50 values of the GluClα/β-M3-M4 loop and TM4 
chimeras are comparable to that of the wild type GluCl receptors.  The EC50 of the 
original α/β EC/TM chimera is a ~500-fold gain-of-function compared to the other 
chimeras.  This chimera also demonstrates some constitutive activity as evidenced by 
large leak currents in the absence of agonist and lower current response to applied 
glutamate. 
 
Properties of the C-terminus and M4 helix are responsible for decoupling ligand 
binding and channel gating in GluClα.  Upon identification of the M4 helix as a  
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Figure 5.4.  Sequence and location of residues in the GluClα and β M4 helices. (A) 
Approximate location of residues and shape of TM4, residues 1-16 are highlighted in 
yellow. (B) Cartoon of mutagenesis to GluClα/β-M4 (left) and GluClα/β-M4,1-16 (right). 
(C) Sequence alignment of TM4 and C-terminus residues.  Residues conserved between 
the two receptors are highlighted in yellow.   
 
Table 5.2. Mutagenesis of M4 residues in the GluClα/β-M4 chimera 
  EC50 Glu (mM) Hill n Imax Glu (µA) Imax IVM (µA) 
α/β M4 0.54 +/- 0.03 2.5 +/- 0.3 19 0.4-15 0.1-11 
 1-6 0.46 +/- 0.01 2.1 +/- 0.1 13 5-18 ND 
1-11 0.72 +/- 0.02 1.9 +/- 0.1 7 0.3-19 ND 
1-16 0.78 +/- 0.01 1.7 +/- 0.1 32 1-25 4-5 
1-19 High leak currents, small response (~5% IVM) 0.5-15 
1-22 No response 1-2 
1-30 2.8 +/- 0.5 1.4 +/- 0.1 7 0.4-3 3-13 
19-40 No response NR 
22-40 No response NR 
25-40 No response ~100 nA 
29-40 0.84 +/- 0.01 2.0 +/- 0.1 10 0.5-15 1-4 
36-40 1.3 +/- 0.1 2.5 +/- 0.2 8 1-5 ND 
 -C-term 0.20 +/- 0.01 1.2 +/- 0.1 18 2-18 ND 
1-6, -C-term 7     3 0.1-0.5 0.3-1 
1-11, 36-40 No response NR 
1-16, 29-40 No response 0.02-0.15 
1-6, 29-40 1.3 +/- 0.1 1.9 +/- 0.1 15 0.4-8 (~15%) 5-34 
1-11, 29-40 No response 0.3-2 
1-16, -C-term 7 0.55 +/- 0.02 1.8 +/- 0.1 14 1-16 ND 
1-16,ANAVLF 0.89 +/- 0.03 2.1 +/- 0.1 5 0.2-0.7 ND 
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domain capable of uncoupling ligand binding from gating, mutagenesis was performed to 
narrow the residues involved (Table 5.2).  Numbering for mutations made in the M4 helix 
begin at the N-terminus of the M4 helix as residue 1 (threonine) and continue through to 
the C-terminus of the GluClα receptor and end at residue 40 (phenylalanine) (Figure 5.4).  
The M4 helix is predicted to end at residue 30 in this numbering scheme, and so residues 
31-40 are assumed to be the extracellular C-terminus residues.  It was found that the first 
16 residues of the M4 helix in the GluClα/β-M4 chimera could be mutated to the 
corresponding GluClα residues with no loss of sensitivity to glutamate. Extending the 
chimera to have GluClα residues at the 1-19 and 1-22 positions of the M4 helix led to 
receptors that had little or no response to glutamate, but demonstrated robust response to 
ivermectin.  Some function (10-20%) was regained when the entire M4 helix (residues 1-
30) was mutated to GluClα residues, as was previously mentioned.  These data indicate 
that the nature of amino acids in the 17-C-terminus region of the M4 helix is important 
for determining glutamate sensitivity.  
 In addition to mutating residues from the N-terminus of the M4 helix, residues 
were also mutated from the C-terminus of the receptor in the GluClα/β-M4 chimera to 
further narrow the dysfunctional region.  Because the C-terminus of GluClβ is seven 
residues longer than the C-terminus of GluClα, these extra residues were truncated as a 
first step to receptor mutagenesis.  Truncation of these residues in the GluClα/β-M4 
chimera gave individual oocytes with EC50 values that varied over an order of magnitude 
(Figure 5.5).  Further mutagenesis to make the C-terminus more GluClα-like abolished 
this effect.  We initially supposed this effect could be caused by a partial disruption of an 
N-linked glycosylation motif (NxS) in the C-terminus of GluClβ.  Truncation of the  
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Table 5.3. Removal of and mutagenesis to a putative N-linked glycosylation site on the 
C-terminus of the GluClβ and GluClα/β-M4 and M4,1-16 chimeras.  All constructs have 
the GluClβ C-terminus. 
 
Chimera EC50 (mM) Hill n Imax (µA) Fold shift 
GluClβ 0.35 +/- 0.01 2.5 +/- 0.2 20 0.4-3.9 - 
 NAS (-TPESLV) 0.38 +/- 0.01 2.1 +/- 0.1 12 1.5-20 1 
LAS (-TPESLV) 0.30 +/- 0.01 2.0 +/- 0.2 6 0.07-0.33 1/1.3 
NAS->DAS 0.34 +/- 0.01 2.2 +/- 0.1 15 0.3-16 1 
NAS->LAS 0.20 +/- 0.01 2.4 +/- 0.2 7 5-12 1/1.8 
NAS out  
(-NASTPESLV) No response 
GluClα/β M4 0.54 +/- 0.03 2.5 +/- 0.3 19 0.4-15 - 
 NAS (-TPESLV) Multiple populations 13 6-23 1 
LAS (-TPESLV) Multiple populations 7 1-30   
NAS->DAS 1.0 +/- 0.1 1.8 +/- 0.1 15 0.4-16 1.9 
NAS->LAS Multiple populations 6 6-24   
NAS out  
(-NASTPESLV) Multiple populations 16 5-16 1.9 
GluClα/β 1-16 0.78 +/- 0.01 1.7 +/- 0.1 32 1.5-25 - 
 NAS (-TPESLV) 0.55 +/- 0.02 1.8 +/- 0.1 14 1-16 1/1.4 
LAS (-TPESLV) No data 
NAS->DAS 0.86 +/- 0.04 2.0 +/- 0.2 7 0.9-9 1.1 
NAS->LAS 0.54 +/- 0.04 1.6 +/- 0.1 7 4-17 1/1.4 
NAS out  
(-NASTPESLV) 0.63 +/- 0.01 2.0 +/- 0.1 15 0.4-13 1/1.2 
 
 
Figure 5.5. Location of NAS N-linked glycosylation motif at the C-terminus of GluClβ 
and scatter plot of GluClα/β-M4,(-TPESLV) highlighting the variability of responses in 
different oocytes.   
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seven C-terminal residues removes the serine in this motif, but not the asparagine or the 
subsequent alanine (Nx(A) of the motif), and could therefore lead to altered glycosylation 
efficiencies.  Mutagenesis of asparagine to leucine in the C-terminal truncation GluClα/β-
M4 chimera, which would abolish any glycosylation at this site, did not change the 
variability of oocyte EC50 and did not have an effect on receptor function (Table 5.3).   
Additionally, mutagenesis of the NxS glycosylation motif to DxS, which removes the 
nitrogen of the side chain to be glycosylated, in the chimera lacking the C-terminal 
truncation had no effect on receptor function, further supporting that glycosylation either 
does not occur at this site, or that it is not functionally relevant.  These effects were not 
observed in the wild-type GluClβ receptor and were only observed in the NL, but not 
the ND, mutation in the GluClα/β-M4,1-16 chimera, indicating a potentially important 
electrostatic interaction between the asparagine and another region of the receptor in this 
chimera.  These data provide evidence that properties of both the M4 helix and the C-
terminus of the receptor are dependent on each other, and that altering either can affect 
the ability of the receptor to function properly.  We also conclude that the variability in 
EC50 is likely due to different coupling states of the receptor.  This phenomenon could be 
caused by weakening/changing the interaction(s) between the modified C-termini and the 
receptor that is shown here to be required for activation.  These interactions, if less stable, 
could be more sensitive to variability in membrane environment of the specific oocyte.   
 When the remainder of the C-terminus (residues 29-40) was mutated to be 
GluClα-like, the receptor demonstrated similar functional properties as the parent 
GluClα/β-M4 chimera.  This finding, when combined with previously discussed data, 
indicates that while the composition of the C-terminus is important for receptor function, 
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neither the M4 helix or the C-terminus of the GluClα receptor alone are responsible for 
glutamate insensitivity in the wild-type receptor.  We observe this in the functional 
mutant GluClα/β-M4 chimeras, where the entire receptor is GluClα-like with the 
exception of either the C-terminus (1-16 for fully functional, 1-30 for partially) or the M4 
helix (29-40).  Therefore some combination of properties of the two domains must 
exacerbate impaired coupling of ligand binding and channel gating.  Attempts to mutate 
GluClβ residues to their α counterparts in the GluClα/β-M4,1-16 or 29-40 chimeras were 
unsuccessful.  These data indicate that distant residues on the M4 helix and C-terminus 
are functionally connected through unknown mechanisms.  Two possible hypotheses to 
explain this phenomenon are that either the properties of the M4 helix in the X. laevis 
membrane directly affect the ability of the C-terminus to form necessary interactions, or 
that weaker interactions of the C-terminus prevent the M4 helix from forming important 
interactions with the M1 and M3 helices required for receptor function.  
 
Mutagenesis of the M4 helix.  The GluClα receptor contains a Phe-Pro motif near the 
middle of the M4 helix that is absent in the GluClβ receptor.  This motif has been 
previously shown to affect the cis-trans preference of the proline backbone32, which 
could lead to alternate conformations of the M4 helix in the GluClα and β receptors.  In 
the GluClα crystal structure, this proline initiates a kink in the M4 helix at the i-4 
position, which could provide flexibility of the C-terminal portion of the M4 helix.  To 
determine whether the Phe-Pro motif has a functional role in the GluCl receptors, the 
motif was mutated into GluClβ and out of GluClα.  No change in receptor EC50 or 
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glutamate sensitivity was observed for either mutant, indicating that this motif does not 
play a functional role in receptor activation (Table 5.4). 
Next, residues within the 17-30 amino acid region in the M4 helix were mutated 
one helix turn at a time, from GluClβ-like to GluClα-like, to determine if specific residue 
mismatches were responsible for the impaired gating properties of the receptor.  
Mutations were made in both the GluClα/β-M4 and M4,1-16 chimeras to determine 
whether the effects of mutagenesis were influenced by the properties of the rest of the M4 
helix.  Different batches of cells gave data that were inconsistent, likely due to the large 
leak currents observed (> 1 µA).  Large leak currents indicate either poor cell health or 
constitutive activation (channel opening in the absence of agonist).  These leak currents 
increased steadily with each glutamate application and gave data that did not fit the Hill 
equation.  One healthier batch of cells indicated a biphasic fit for some of the mutants, 
with the appearance of a high-sensitivity component, with an EC50 of ~0.02 mM 
glutamate, that accounted for ~20% of the response.  The current response of these 
mutants to glutamate was ~5-25% that observed with ivermectin application.  These data 
were not reproduced, therefore no interpretation of these mutations is considered. 
 
Table 5.4. Mutagenesis of the Phe-Pro motif in the M4 helix of GluClα.  Residue 
numbering is relative to the start of the M4 helix. 
 
GluCl EC50 (mM) Hill n Fold shift Imax (µA) 
β WT 0.35 +/- 0.01 2.5 +/- 0.2 20 - 0.4-4 
β V18F 0.89 +/- 0.02 1.9 +/- 0.1 7 1.3 1.4-15 
α F18V No response 
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Properties of the receptor, including the M4 helix, determine requirements for the 
length of the C-terminus.  C-terminal truncations were made to the wild-type GluClβ 
receptor and the GluClα/β-M4 and M4,1-16 chimeras to determine requirements for C-
terminus length.  The length of the C-terminus has previously been shown to affect 
receptor trafficking and formation of functional ligand binding sites14,15.  In these studies, 
truncation of the 5-HT3A C-terminus, in either the wild-type receptor or α7 EC binding 
domain chimera, resulted in impaired ligand sensitivity and surface expression with 
results that were independent of the identity of the extracellular binding domain.  Here, 
we show that the GluCl receptors are also sensitive to C-terminal truncation, however the 
amount of truncation that was tolerated was dependent on the identity of the rest of the 
receptor. 
  The wild-type GluClβ receptor was shown to be the most sensitive to C-terminal 
truncation with a complete loss of function upon removal of the last 9 amino acids, which 
results in a C-terminus that is two residues shorter than the wild-type GluClα receptor 
(Figure 5.6 and Table 5.5).  Conversely, truncation of the terminal 9 amino acids on the 
GluClα/β-M4 chimeras had no effect on receptor function.  Removal of an additional two 
amino acids (-11) resulted in a decrease in functional response to glutamate in the 
GluClα/β-M4,1-16 chimera, but not in the GluClα/β-M4 chimera, and truncation to -13 
further reduced the GluClα/β-M4,1-16 response and decreased the response of the 
GluClα/β-M4 chimera as well.  It is important to note that all of the receptors considered 
here in the C-terminal truncations studies have an identical GluClβ-like C-terminal 
domain, but vary in the GluClα-like or GluClβ-like character of the rest of the receptor.  
Therefore, the variations in functionality of the truncated constructs are likely due to  
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Figure 5.6.  Sites of C-terminus truncation.  The GluClα sequence is hidden from residue 
17-40 because all constructs considered in this study have GluClβ-like character in this 
region at a minimum. 
 
 
Table 5.5. C-terminal truncation of GluClβ and GluClα/β-M4 and M4,1-16 chimeras 
  EC50 (mM) Hill n Imax (µA) Fold shift 
WT           
GluClβ 0.35 +/- 0.01 2.5 +/- 0.2 20 0.4-3.9 - 
GluClα/β-M4 0.54 +/- 0.03 2.5 +/- 0.3 19 0.4-15 - 
GluClα/β-M4,1-16 0.78 +/- 0.01 1.7 +/- 0.1 32 1.5-25 - 
C-term 7 out           
GluClβ 0.38 +/- 0.01 2.1 +/- 0.1 12 1-20 1 
GluClα/β-M4 0.56 +/- 0.04 1.2 +/- 0.1 13 6-23 1 
GluClα/β-M4,1-16 0.55 +/- 0.02 1.8 +/- 0.1 14 1-16 1/1.4 
C term 9 out           
GluClβ No response 
GluClα/β-M4 1.0 +/- 0.1 1.1 +/- 0.1 16 5-16 1.9 
GluClα/β-M4,1-16 0.63 +/- 0.01 2.0 +/- 0.1 15 0.4-13 1/1.2 
C-term 11 out           
GluClβ No response 
GluClα/β-M4 0.83 +/- 0.04 2.0 +/- 0.2 15 5-25 1.5 
GluClα/β-M4,1-16 1.6 +/- 0.1 2.2 +/- 0.1 13 0.4-3 2.1 
C-term 13 out 
    
  
GluClβ No response 
GluClα/β-M4 0.75 +/- 0.06 1.8 +/- 0.2 7 0.1-1.2 1.4 
GluClα/β-M4,1-16 3.3 +/- 0.6 1.0 +/- 0.1 8 0.07-0.4 4.2 
 
different functional interactions between the C-terminus and the corresponding receptor.  
This can be interpreted as the two receptors (GluClα and β) having different interactions 
between the C-terminus and its interaction partner or that the two receptors have different 
10 20 30 40 
-7 -13 -11 -9 
!/" !"# !/" $%$&#
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activation mechanisms that have varied requirements for C-terminus coupling to another 
domain of the receptor.  
In the GluClβ receptor, a strong requirement was found for having an extended C-
terminal domain, whereas a lesser requirement was demonstrated for the GluClα-like 
receptors.  One interpretation for this is that the GluClβ receptor needs a longer C-
terminus so that it can interact with residues distal from the M4 helix either through 
specific or global electrostatic interactions.  This is supported by a large loss of functional 
response to glutamate in the NL mutation of the -9 residue (from the end of the C-
terminus) in the GluClβ -7 C-terminal truncation (Table 5.3).  These combined data 
indicate that this residue, potentially in addition to others toward the M4 helix, 
participates in an important electrostatic interaction with another residue in the GluClβ 
receptor.  This effect would not be observed in the chimeras if the partner residue was not 
conserved in the GluClα receptor, if there were other functionally analogous interactions, 
or if the C-terminus was less important in the activation mechanism of GluClα.  The 
difference in truncation sensitivity in the two GluClα/β-M4 chimeras indicates that the C-
terminus is important for activation, and that properties of the M4 helix affect coupling 
interactions between the C-terminal domain and its interaction partner in the receptor.  
These effects could be caused by differences in the dynamics or structure of the M4 helix 
in the membrane, which could affect the placement and flexibility of the C-terminal 
domain.  These interactions in the GluClα receptor may be more global and less specific 
than they are in the GluClβ receptor because of the tolerance of the GluClβ C-terminus.  
A defective GluClα C-terminus or interaction between the C-terminus and its interaction 
partner in the receptor can be ruled out because of the full response to glutamate in the 
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GluClα/β-M4,29-40 chimera, which contains only a GluClβ-like M4 helix.  Instead, 
membrane properties of the M4 helix are likely responsible for the observed glutamate 
insensitivity.  Studies were not performed to determine whether the lack of response to 
glutamate in the C-terminal truncations was due to impaired surface expression or 
receptor activation.  We assume that C-terminal truncation in the GluCl receptors is not 
causing ER retention, as was observed in the 5-HT3A receptors, because no ER retention 
motif is found in the EC or TM regions that would need to be masked by this domain. 
 
Functional interactions between the C-terminus and the extracellular domain of 
GluClα were not identified.  The C-terminal domain of Cys-loop receptors has long 
been predicted to make a functional interaction with the extracellular ligand binding 
domain14,16,17,32.  The interaction partner of the C-terminus has been speculated to be the 
Cys-loop, which is supported by direct contacts observed in the GluClα crystal structure 
(Figure 5.7).  To determine whether there are specific interactions between the Cys-loop 
and the C-terminus in the GluCl receptors, chimeras with matched and mismatched Cys-
loop and C-terminal domains were synthesized (Table 5.6 and Figure 5.8).  Of these 
chimeras, only the GluClα with the β C-terminus and GluClβ with the α Cys-loop were 
functional.  These data further support our findings that glutamate insensitivity in GluClα 
is not caused by a lack of coupling between the C-terminus and Cys-loop.  If it were, 
glutamate sensitivity would be recovered in the GluClα receptor by introducing both the 
β Cys-loop and C-terminus, which should form a functional pair.  The data also suggest 
that the inherent properties of the GluClα Cys-loop are not flawed because incorporation 
of this sequence into GluClβ results in a fully functional receptor.  Despite these findings  
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Figure 5.7.  Crystal structure of the Cys-loop-C-terminus interactions predicted by the 
GluClα crystal structure. Green and purple residues are conserved between the GluClα 
and β receptors, purple residues are located in the 17-34 region of the M4 helix.  Orange 
residues are not conserved between the two receptors. Crystallographic data is not 
available for residues 35-40. (A) Side view of the Cys-loop.  Residue labels indicate the 
corresponding amino acid in GluClβ. (B) Top down view of the Cys-loop and C-
terminus. (C) Side view from the M3 helix of the Cys-loop and C-terminus.  Residues 
predicted to contact each other are shown as space-filling. (D) The same interactions as 
seen from the M1 helix. 
 
 
not providing evidence for a functional interaction between the two domains, the 
chimeras indicate that these regions are important for receptor activation, as shown by a 
lack of response to both glutamate and ivermectin in a majority of the chimeras 
examined.  
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Figure 5.8. Cartoon representation of chimeras examined in this study. 
Table 5.6. Cys-loop and C-terminus chimera data 
Chimera EC50 (mM) Hill n Imax Glu (µA) IVM (µA) 
GluClα β Cys-loop No response NR 
GluClβ α Cys-loop 0.57 +/- 0.01 2.2 +/- 0.1 15 0.4-9 - 
GluClα β C 2.8 +/- 0.5 1.4 +/- 0.1 7 0.4-3 3-13 
GluClβ α C No response - 
GluClα β Cys and C No response NR 
GluClβ α Cys and C No response - 
 
Because we could not confirm a functional interaction between the Cys-loop and 
the C-terminus, we sought to identify other potential sites of interaction between the C-
terminus and the EC domain of the receptor.  Near the Cys-loop on the β9 strand of the 
EC domain is an asparagine residue in an N-linked glycosylation motif in both the 
GluClα and β receptors (Figure 5.9).  Glycosylation of this residue could obstruct 
interaction between the C-terminus and the Cys-loop, or could provide additional polar 
functional groups for the C-terminus to interact with.  To determine the importance of 
glycosylation at this site, the motif was altered or removed.   An NxS motif is found in 
GluClα and an NxT motif in GluClβ, both of which have been shown to encode N-linked 
EC domain M1 M2 M3 M4 
Signal 
peptide Glu (µA) IVM (µA) 
0.4-3 4-15 GluCl! " C terminus 
GluCl! " !"#$ NR NR 
GluCl" ! !"#$ 0.4-9 NR 
GluCl!#
" cys and C term 
NR NR 
GluCl"#
! cys and C term NR NR 
GluCl" ! C terminus NR NR 
Cys loop 
 158 
glycosylation in eukaryotes with varying 
rates and efficiencies33,34.  Therefore, to 
determine whether the two glycosylation 
motifs lead to differences in glycosylation 
patterns or efficiencies in X. laevis oocytes, 
the motifs were swapped in the two 
receptors.  The glycosylation motifs were 
also removed in both receptors by mutating 
the asparagine to alanine.  In both cases, no 
change in receptor function was observed 
(Table 5.7).  These data suggest that the 
GluCl receptors are not glycosylated in X. 
laevis oocytes or that there is no functional 
role for glycosylation at this site in the 
GluClβ receptor.  It is possible that there is a functional role for glycosylation at this site 
in GluClα, and the lack of glycosylation in X. laevis oocytes is involved in glutamate 
insensitivity. 
Because the GluClα receptor could only be crystalized when the six C-terminal 
residues (35-40) were deleted, these residues can be assumed to be unstructured in the 
ligand-bound state (assuming the crystal structure represents a physiologically relevant 
state).  Therefore, any interaction the C-terminus makes with another region of the 
receptor is likely transient or low affinity, and therefore cannot be captured in a static 
snapshot of the receptor.  While the length and composition (in the GluClβ receptor) were  
Figure 5.9.  Interaction of C-terminus 
residues in the GluClα crystal structure 
(3RIF) with the Cys-loop.  The 
asparagine in the N-linked glycosylation 
motif is indicated in cyan. 
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Table 5.7. Modulation and removal of a putative N-linked glycosylation site on the β9 
sheet of the extracellular domain. 
 
  EC50 (mM) Hill n Imax (µA) Fold shift 
GluClα NxSNxT No response to glutamate, response to IVM 
GluClα NxSAxS No response to glutamate, response to IVM 
GluClβ NxTNxS 0.57 +/- 0.01 2.2 +/- 0.1 7 0.2-4 1.6 
GluClβ NxTAxT 0.28 +/- 0.01 2.0 +/- 0.1 8 0.3-1 1/1.25 
 
shown to be important for receptor activation, no binding partner was identified for the 
C-terminus.  REFER analysis also does not indicate that the Cys-loop (or any other 
region of the EC domain) and the M4 helix/C-terminus act as a functional unit because 
both domains move at different, and not subsequent, stages of the activation process4.  
We therefore cannot make any conclusions about the role of the C-terminus in receptor 
activation. 
 
Probing membrane properties: examination of cholesterol-receptor interactions and 
effect of incubation temperature.  The crystal structure of the GluClα receptor shows a 
kink and bulge at approximately the midpoint of the M4 helix.  This kink is likely caused 
by a break in hydrogen bonding of the helical backbone by a proline residue conserved 
amongst the anion-selective Cys-loop receptors and the prokaryotic ligand-gated ion 
channels.  This break in the helix occurs at the i-4 residue from the proline, which in the 
GluClα receptor is an arginine at the 15th residue on the helix.  Along with the kink, a 
bulge occurs at the subsequent alanine residue (residue 16 on the helix) because of a 
partial unwinding of the helix.  The C-terminal region of this helix, following this kink 
and bulge, is the region shown in this study to cause glutamate insensitivity in GluClα as 
indicated by the GluClα/β-M4,1-16 chimera. We hypothesize that either intrinsic 
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properties of this part of the helix or interactions with the surrounding membrane are 
responsible for glutamate insensitivity.   
In the GluClα receptor, a putative cholesterol-binding motif (L/V-X1-5-Y-X1-5-
R/K, where X is between 1 and 5 amino acids of any type35,36) was identified near the C-
terminal end of the M4 helix (Figure 5.10a).  This motif (and its inverted counterpart) is 
found in a number of other Cys-loop receptors37-39, as well as other membrane 
proteins38,40, and is thought to aid in the incorporation of membrane proteins into 
cholesterol-rich lipid domains41.  Indeed, sterol interaction with the M4 helix has been 
shown to modulate function in the Torpedo nAChR42,43 and GABAA receptor44, as well as 
in the TM domains of a number of G protein-coupled receptors. Mutagenesis43, 
computational studies27, and lipid modulation17,45 indicate a lipid-dependent uncoupling 
of ligand-binding and TM domains in Cys-loop receptors displaying cholesterol-binding 
motifs in the M4 helix in the absence of crucial lipid-protein interactions.  Ligand-gated 
ion channels that lack this cholesterol recognition motif have been found to be less 
sensitive to cholesterol modulation46. 
Mutagenesis to remove the cholesterol recognition motif led to a partial regain of 
function in the GluClα receptor (Figure 5.10b).  The Vx4Yx2RAx4Ax2A mutation gave 
glutamate-induced currents with a maximum response that was ~10% the currents 
observed in response to ivermectin.  The YxRAxA mutant also gave similar responses, 
but mutagenesis of individual residues in the motif had little-to-no effect on receptor 
activation.  The relative responses to glutamate and ivermectin varied between cell 
batches, indicating that inherent variability between oocytes can affect receptor activity.   
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Figure 5.10.  Cholesterol binding motif in the GluClα receptor.  (A) Crystal structure of 
residues in the motif (B) dose-response curve of removal of the putative cholesterol 
binding motif. 
 
 
To visualize the putative cholesterol binding site, cholesterol was docked into the 
crystal structure of GluClα (Figure 5.11).  This was performed by dragging the 
coordinates for cholesterol into the binding site predicted by the recognition motif.  No 
energy minimization was performed to optimize cholesterol binding to the receptor.  By 
rough fit, the cholesterol molecule fits well in the predicted binding site.  The hydroxyl of 
cholesterol could easily be bound by the arginine side chain and the planar hydrophobic 
core of cholesterol could be stabilized by stacked aromatic residues formed by TM3/TM4 
helical interactions.  The GluClα M4 helix also differs from the GluClβ receptor in that it 
has larger hydrophobic residues on the periphery of the putative cholesterol binding site.  
These residues, along with the polar and aromatic contacts, could form a hydrophobic 
binding pocket that bound cholesterol with high-affinity.  Mutagenesis of these large 
hydrophobic residues in addition to the VxYxRAxAxA mutations, did not increase  
!" #"
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Figure 5.11. Putative cholesterol binding site.  Residues in cyan are on the M4 helix, 
residues in blue are on the M3 helix, and cholesterol is shown in yellow.  Cholesterol was 
docked into the GluClα structure with no energy minimization.  (A) and (B) front and 
back view of the putative cholesterol binding site, respectively. (C) Surface contour of 
the two helices.  
 
response to glutamate and in most cases, resulted in a non-functional receptor.  These 
findings indicate that the arginine and tyrosine residues are the crucial components of 
cholesterol binding, and that small hydrophobic side chains in the M4 helix disfavor 
receptor activation.   
Attempts to remove cholesterol, using methyl-β-cyclodextrin (MβCD), were not 
effective.  Incubation of oocytes in low concentrations of MβCD (50 or 500 µM) prior to 
data collection did not result in glutamate-induced currents of the wild type receptor.  
Incubation with a higher concentration (5 mM) resulted in cells with large leak currents 
indicative of compromised cell health.  MβCD incubation of oocytes expressing the 
VxYxRAxAxA mutations also resulted in low current responses to applied glutamate, 
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however poor cell health gave data that did not fit the Hill equation (data not shown).  
Similar data were found with GluCl receptors expressed in HEK293T cells. We therefore 
conclude that in the GluClα receptor, cholesterol acts as a negative allosteric modulator, 
which is contrary to the effects observed in the muscle-type nAChR and GABAA 
receptors.  While we are able to see this effect through receptor mutagenesis, cholesterol 
depletion with MβCD has not proved to be an effective way to remove tightly bound 
cholesterol.  This would not be surprising if a high-affinity cholesterol binding site was 
present, because of the large concentration of cholesterol found in the membrane and the 
fact that MβCD is only capable of binding and sequestering free cholesterol molecules. 
Negative allosteric modulation by cholesterol could occur through many different 
mechanisms.  In the crystal structure, which was obtained without cholesterol in the 
crystallization matrix, the arginine residue in the cholesterol binding motif is predicted to 
form a hydrogen bond interaction with a tyrosine on the Cys-loop.  This tyrosine is a 
leucine in the GluClβ receptor, further providing evidence that these receptors do not 
have conserved interactions between the C-terminus and the EC domain.  Mutagenesis of 
this tyrosine to alanine in GluClα resulted in a non-functional receptor that did not 
respond to either glutamate of ivermectin, indicating its importance in the activation 
mechanism.  While we were not able to provide evidence for a functional coupling 
between the Cys-loop and the C-terminus, data were collected in cells with high 
concentrations of cholesterol.  It is possible that the hydroxyl of cholesterol binds the 
arginine, thereby preventing a potentially important interaction between the C-terminus 
and the Cys-loop.  It is also possible that bound cholesterol changes the properties of the 
membrane environment sensed by the receptor.  Cholesterol is known to increase the 
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thickness of the membrane47, which could prevent helical tilting of the M4 helix, thought 
to be part of the activation mechanism48 because of the energetic penalty of burying polar 
residues in the hydrophobic membrane.  Also, bound cholesterol could stabilize M3-M4 
helix interactions and preclude TM helical movement.  Regardless of mechanism, 
cholesterol likely plays a role in receptor activation.  While we are not able to definitively 
prove a direct TM4-cholesterol interaction, data in this study suggest cholesterol as a 
negative allosteric modulator.  The existence and location of the cholesterol recognition 
motif on the M4 helix coincides well with chimera data and removal of this motif results 
in a partial regain of function.  Additional experiments are required to determine the 
nature of this interaction. 
While the “cholesterol as a negative allosteric modulator” hypothesis works for 
experiments in X. laevis oocytes, the hypothesis does not hold for other heterologous 
expression systems.  The GluClα receptor was shown to be functional when expressed in 
HEK293 cells28, which also have a high concentration of cholesterol in the lipid bilayer.  
It is possible, however, that properties of the membrane or the receptor in the membrane 
vary at the different incubation temperatures of the expression systems (18oC for X. laevis 
oocytes and 37oC for HEK293 cells).  Because we couldn’t incubate or record on oocytes 
at 37oC, HEK293T cells expressing wild-type GluClα were assayed at 25oC and 37oC to 
determine whether a decrease in temperature had an effect on response to applied 
glutamate.  While some days of recording indicated a slight loss of receptor response at 
the lower temperature, the data were not consistent between trials.  It is also possible that 
the observed slight loss of signal was due to cell health issues. 
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Appendix A 
Light-induced modulation of a voltage-gated potassium channel by a Ru(bpy)2-
polyunsaturated fatty acid derivative 
 
Intent 
 The goal of this project was to shift the I-V curve of the Shaker potassium 
channel in X. laevis oocytes toward the left (gain-of-function) upon incubation with and 
irradiation of Ru(bpy)2-polyunsaturated fatty acid derivatives.  This appendix provides 
initial data about the effects of the first of these compounds, Ru(bpy)2-linoleic acid. 
 
Results and Discussion 
Effect of polyunsaturated fatty acids on channel function.  It has previously been 
shown that polyunsaturated fatty acids (PUFAs) interact with a variety of membrane 
proteins either through direct allosteric interactions or by alteration of the physical 
properties of the surrounding membrane1-7.  Specifically, in voltage-gated potassium 
channels, PUFAs have been shown to shift the current-voltage (I-V) relationship of the 
channel in an electrostatic and pH dependent manner8,9.  In these studies, 
docosahexaenoic acid (DHA), an ω-3 PUFA with six units of unsaturation, was shown to 
shift the conductance vs. voltage curve in a dose-dependent manner toward the left on the 
voltage axis indicating that PUFAs can lead to hyperpolarization of the membrane.  This 
effect was more dramatic at higher pH values, pH 9 vs. pH 7.5.  Conversely, a rightward 
shift was observed when the negatively charged carboxylate group was replaced with a 
positively charged amino group, and no shift was observed for the neutral methyl ester, 
 170 
  
 
Figure A1. Dose-dependent electrostatic effect of linoleic acid on Shaker potassium 
channels. (A and C) I-V curve of Shaker IR upon application of buffer and buffer + 
ethanol used to make the highest concentration LOA solution: pH 7.5 or pH 9, 
respectively. (B and D) I-V curve of Shaker IR upon application of buffer and increasing 
concentrations of LOA: pH 7.5 and pH 9, respectively. 
 
implying an electrostatic effect.  These studies were repeated here with linoleic acid 
(LOA), an ω-6 PUFA with two unsaturations.  A similar leftward shift was observed 
upon addition of LOA to X. laevis oocytes overexpressing the Shaker IR potassium 
channel, which was both dose-dependent and more pronounced at higher pH values 
(Figure A1).  These data therefore support the previous studies and indicate that LOA 
behaves similarly to DHA.  Small concentrations of ethanol from the LOA stock solution 
(up to 0.5%) had no effect on channel function at pH 7.5 or pH 9. 
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A light-absorbing Ru(bpy)2 group alters the effect of LOA on channel function. A 
100 µM dose of Ru(bpy)2LOA 
and a <100 µM dose of 
Ir(bpy)2LOA were applied 
separately to cells 
overexpressing Shaker IR and 
were irradiated with 455 nm light for 15 seconds after a 1 minute incubation (Figure A3).  
While a 100 µM dose of LOA gave no shift in the I-V curve of the channel at pH 7.5, a 
100 µM dose of Ru(bpy)2LOA resulted in a large rightward (loss-of-function) shift and 
cell death before irradiation could be performed.  No shift was observed for Ir(bpy)2LOA  
 
 
Figure A3.  Shifts in I-V curve of Shaker IR in response to decreasing doses of 
Ru(bpy)2LOA before and after irradiation with 455 nm light. (A) 100 µM Ru(bpy)2LOA 
(B) 50 µM Ru(bpy)2LOA, (C) 25 µM Ru(bpy)2LOA, (D) 25 µM Ru(bpy)2LOA 
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(data not shown).  This may be due to the lesser charge of the complex, +1 vs. +2, or 
because of the potentially low concentration of the drug solution.   
Ascorbic acid was used as an electron donor to favor reduction of the Ru2+ 
complex upon light absorption to Ru1+ over oxidation to Ru3+. It was thought that upon 
irradiation of light, favoring the redox chemistry of the complex toward reduction would 
result in a leftward shift of the I-V curve relative to the Ru2+ complex because of the 
electrostatic effects previously observed with PUFAs.  Because application of 100 µM of 
the complex led to rapid cell death, lower concentrations were applied to X. laevis 
oocytes and were tested for their effects on channel function.  Minimal cell death was 
observed upon application of 50 µM, 25 µM, and 10 µM Ru(bpy)2LOA.  However, 
irradiation with 455 nm light lead to reduced cell health in both the 50 µM and 25 µM 
dose, indicated by leak currents at low membrane potentials (< -20 mV).  We therefore  
 
 
Figure A4.  Shifts of the I-V curve of Shaker IR.  Data are shown before application of 
Ru(bpy)2LOA, after application of the complex, after a 1 minute incubation period, after 
irradiation with 455 nm light, and after a 1 minute post-irradiation dark incubation. 
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determined that 10 µM was an ideal concentration for maintaining cell health and 
observing the effects of the complex on receptor function. 
Application of Ru(bpy)2LOA led to a rightward shift of the I-V curve, with more 
dramatic shifts observed at higher concentrations of the complex.  This shift, opposite of 
what was observed with LOA, is likely due to the +2 charge of the complex compared to  
the -1 charge of LOA.  Upon irradiation, contrary to our expectations, the I-V curve 
shifted further to the right, indicating either that oxidation of the complex was observed 
or that another mechanism was responsible for the observed shift.  After a one-minute 
post-irradiation period in the dark, the large rightward shift observed upon irradiation did 
not decrease, and a slight shift further to the right was observed instead (Figure A4). 
Concurrent studies performed by our collaborators with a Ru(bpy)2C17 complex 
in HEK293 and INS cells showed that irradiation of cells incubated with the complex led 
to an increase in action potential firing10.  This effect increased in the presence of 
reducing compounds (ascorbic acid and ferrocyanide) and decreased in the presence of 
oxidizing compounds (ferricyanide).  It was concluded that the Ru(bpy)2C17 complex 
induced depolarization of the membrane in the presence of reducing compounds (more 
negative at the extracellular surface) and hyperpolarization of the membrane in the 
presence of oxidizing compounds (more positive).  Therefore, instead of demonstrating 
effects similar to PUFAs, irradiation led to a change in the bulk charge of the 
extracellular space near the membrane, therefore affecting the opening and closing of 
voltage-gated ion channels.  These results provide evidence that what we observed with 
the Ru(bpy)2LOA complex at the Shaker IR channel was not due to oxidation of the 
complex upon irradiation, but instead due to changes in membrane polarization. 
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Methods 
Molecular Biology and electrophysiology.  The Shaker potassium channel (inactivation 
domain removed) was in the pBSTA plasmid.  Plasmid DNA was linearized with NotI 
restriction endonuclease and in vitro transcribed mRNA was created using runoff 
transcription and Ambion’s T7 mMessage Machine Enzyme kit.  100 mM stock solutions 
of linoleic acid and Ru(bpy)2LOA were made in ethanol and stored at -80oC.  The mass 
of the iridium complex was unknown and assumed to be less than the ruthenium 
complex.  A stock solution was made with an equal volume of ethanol and was further 
diluted identically to the ruthenium complex to make the drug solution that was used.  
We therefore report the concentration as <100 µM, however it is likely to be <<100 µM.  
For Shaker IR overexpression, 5 ng of mRNA was injected into stage V-VI X. laevis 
oocytes 24 hours prior to recording. 
 Data were collected with an OpusXpress6000A (Axon Instruments) using two-
electrode voltage clamp mode.  Recording buffers were ND96 pH 7.5 (96 mM NaCl, 2 
mM KCl, 1 mM MgCl2, 5 mM HEPES, 1.8 mM CaCl2, pH 7.5) or ND96 pH 9 (96 mM 
NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM CHES, 1.8 mM CaCl2, pH 9.0).  Initial holding 
potential was -80 mV, and currents were measured as the voltage was jumped 
between -80 mV and +70 mV in 10 mV increments.  Cells were irradiated with a 455 nm 
LED for 15 seconds prior to and throughout the duration of data collection for the 
irradiation curve. 
 
Synthesis.  Ru(bpy)2LOA and Ir(bpy)2LOA molecules were synthesized by Melanie 
Pribisko-Yen in the Grubbs group.   
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Appendix B 
Screening of physostigmine analogs against ligand-gated ion channels* 
 
*Work done in collaboration with Christopher Marotta 
 
Abstract 
 The goal of this project was to screen novel compound synthesized by the 
Reisman group for activation or inhibition of a variety of ligand-gated ion channels.  
These molecules were synthesized using their group’s novel methodology and 
demonstrate structural similarity to physostigmine, a positive allosteric modulator of 
nicotinic acetylcholine receptors (nAChRs) and a clinically used inhibitor of 
acetylcholinesterase.  In this study, five compounds were screened for their activity at 
seven ligand-gated ion channels: the α7, α4β2, and muscle-type nAChRs and the 5-HT3A, 
GABAA(αβγ), glycine, and GluR2 receptors.  Most compounds were channel blockers of 
the nAChRs at moderate concentrations, however, one compound, 86, demonstrated 
positive allosteric modulation of the GABAαβγ receptor in addition to channel block of 
the nAChRs. 
 
Results and discussion 
Compound screening against ligand-gated ion channels.  Five novel physostigmine 
analogs were screened against a panel of ligand-gated ion channels (Figure B1).  These 
compounds were tested for their ability to activate the receptor alone (agonist) or for their 
ability to activate or inhibit the receptor in the presence of the native agonist (allosteric 
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Figure B1.  Chemical structures of physostigmine and the five novel compounds tested 
in this screen. 
   
 
modulator, antagonist, or channel blocker).  All compounds were tested at a 
concentration of 20 µM and were tested in combination with an EC50 concentration of the 
native agonist.  Therefore, the percent increase or decrease in signal reported is relative to 
the response elicited by an EC50 value of the agonist.  While these compounds might have 
shown stronger effects at higher concentrations, we were limited by the amount of many 
of the compounds that we had and the solubility of the compounds in buffer.  We were 
also only interested in determining “hits” at moderate concentrations that could 
potentially be used physiologically.   
Of the five compounds tested at seven receptors, only compound 86 at GABAA 
showed any response to application of the compound in the absence of agonist.  The 20 
µM dose of 86 at GABAA elicited a current response that was approximately 5-10% that 
of the current observed with the EC50 agonist dose, however the compound was not 
sufficiently soluble in buffer to determine a dose-response curve or relative efficacy.  
1 71 
98 86 100 
Physostigmine 
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Table B1.  Percent change in current observed upon co-application of an EC50 dose of 
agonist and 20 µM of the indicated compound relative to the agonist alone.  Negative 
values represent a decrease of observed current and positive values represent an increase. 
 
  1 71 86 98 100 
 
Muscle (9') -21 +/- 0.6 -29 +/- 3 -53 +/- 3 -7 +/- 3 -81 +/- 6 
α4β2 (9') -28 +/- 2 -47 +/- 4 -29 +/- 6 -11 +/- 2 -44 +/- 2 
α7 (6') -62 +/- 4 -68 +/- 7 -92 +/- 4 -57 +/- 10 -96 +/- 3 
5-HT3A -3 +/- 2 -23 +/- 4 -3 +/- 5 3 +/- 12 -11 +/- 8 
GABAAαβγ -27 +/- 4 -27 +/- 11 52 +/- 10 -27 +/- 21 10 +/- 5 
GluR2 -6 +/- 0.7 -0.2 +/- 2 -9 +/- 6 -11 +/- 5 -12 +/- 5 
Glycine -6 -9 +/- 9 3 +/- 7 18 +/- 10 -16 +/- 6 
 
When the compounds were co-applied with an EC50 dose of the respective agonist, a 
variety of responses were observed in the different receptors (Table B1).  The most 
common phenotype was a decrease in observed current relative to the EC50 dose alone, 
indicating an inhibitory role for these compounds.  It is likely that this inhibition of 
current is due to open channel block, which is observed with high concentrations of 
physostigmine (>20 µM)1.  This effect was most pronounced in the nAChRs, specifically 
the α7 receptor, with between 57% and 96% block for all compounds tested.  Current 
inhibition was also observed in the GABAA and 5-HT3A receptors in response to some of 
the compounds (-27% for 1, 71, and 98 at GABAA and -23% for 71 at the 5-HT3A 
receptor).  No significant inhibition or activation was observed (<-20% or >20%, 
respectively) upon application of any of the compounds to the GluR2 or glycine 
receptors.  Interestingly, in addition to slight agonist activity at the GABAA receptor, 86 
elicited a significant increase in current when combined with an EC50 dose of GABA, 
indicating the compound can act both as an agonist and as a positive allosteric modulator.  
Similar studies at the GABAA(αβ) receptor were inconclusive.  Agonist activity or positive 
allosteric modulation was not observed at any of the other receptors.  All compounds 
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resulted in different levels of inhibition/activation of the receptors examined, indicating 
some level of specificity of each compound for certain receptors over others. 
 
Characterization of the binding interaction of the physostigmine analogs.  An IC50 
curve for compound 1, the most water soluble and plentiful compound we had for study, 
was determined against acetylcholine (ACh) at the α7 (T6’S) and the α43β22 receptors 
(Figure B2).  Large variability was observed between cells at low compound 
concentrations (<10 µM) indicating that the compound may have a slow on-rate and that 
full inhibition was not achieved in the drug application time used.  The IC50 of 1 at α7 
was determined to be approximately 5 µM with a Hill coefficient of -0.8 indicating that 
there is likely a single binding site in the receptor, thus favoring these compounds as 
channel blockers.  Because of the presence of five identical subunits in α7, this receptor 
has five identical agonist binding sites, and so a competitive inhibitor could have multiple 
molecules bound and a Hill coefficient greater than 1.  Values were similar for the α4β2 
receptor with an IC50 of 8 µM and a Hill coefficient of -1.2.  At the maximum dose of 
100 µM nearly full inhibition of current is observed in both receptors.   
To provide evidence that the physostigmine analogs are acting through an open 
channel blocking mechanism, voltage jump experiments were performed (Figure B3).  
The goal of these experiments was to indicate a voltage-dependence of the channel 
blockers by observing a difference between the negative to positive and the positive to 
negative voltage jumps.  This has previously been performed on the open channel blocker 
hexamethonium at α4β2 nAChRs2.  While we did not observe the same voltage-
dependence as in the hexamethonium studies, this is likely due to our molecule being a  
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Figure B2. IC50 curve of 1 at the (A) α7 and (B) α43β22 nAChRs.  m2 is the IC50 value 
and m3 is the Hill coefficient. 
 
 
Figure B3. Voltage jump of α43β22 in the presence of ACh and ACh+1 jumped 
from -110 to +70 mV and subsequently +70 to -110 mV.   
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net neutral molecule and theirs a positively charged molecule, rather than ours not being 
an open channel blocker.  Performing these experiments on the other positively charged 
physostigmine agonists would likely have shown a larger effect.  The Hill coefficients 
they observed were similar to what we observed for our molecule (-0.7 to -0.9), as were 
the IC50 values (3-19 µM). 
 
Conclusions 
 The physostigmine analogs examined here demonstrate properties similar to 
physostigmine itself.  At low concentrations of physostigmine, it acts as a weak agonist 
and positive allosteric modulator of nAChRs (similar to 86 at GABAA) and at higher 
concentrations exhibits open channel blocking activity1.  We observe an inhibition of 
current of the various nAChRs tested here by a co-application of 20 µM of the 
physostigmine analogs and an EC50 dose of the native agonist.  This is also observed to a 
lesser extent in the GABAA and 5-HT3A receptors.  The IC50 and Hill coefficient values 
for these novel compounds are similar to what is observed for other nAChR open channel 
blockers, providing evidence for a channel blocking mechanism of these compounds. 
Perhaps at lower ligand concentrations the compounds would have exhibited channel 
activation and positive allosteric modulation, however these tests were not performed.  It 
would be interesting to examine more closely the properties of 86 at the GABAA 
receptor, for example, an EC50 value, whether channel blocking is observed at higher 
concentrations, and determination of the binding site of the compound. However, 
solubility in buffer will likely be a problem for these studies.  
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Methods 
 Percent inhibition/activation of receptors by the compounds was determined by 
the methods shown in Figure B4.   First, three consecutive EC50 doses of the native 
agonist were applied with a 3-5 minute washout in between applications.  This was 
followed by a 20 µM concentration of the ligand being tested and a subsequent 20 µM 
ligand + agonist EC50 dose with no washout in between to test for agonist and antagonist, 
allosteric modulation, and channel block activity, respectively.  The second and third 
current responses were averaged together and the compound and compound+agonist 
responses were normalized to this value to give a percent change.  The ability for the 
ligand to be washed out of the receptor was then measured by two successive agonist 
applications.  Agonist EC50 values used in these experiments were: 100 µM ACh (α7 
T6’S), 1.2 µM ACh (muscle-type L9’A), 0.5 µM ACh (α43β22 L9’A), 110 µM glycine 
(glycine receptor), 3 µM 5-HT (5-HT3A), 14 µM glutamate (GluR2), and 11 µM GABA 
(GABAAαβγ).  ND96 Ca2+ free buffer was used for the muscle-type and α4β2 nAChRs, 
the glycine, 5-HT3A, and GluR2 receptors.  ND96 was used for the GABAA and α7 
nicotinic acetylcholine receptors. 
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Figure B4.  Protocol used for testing novel compounds against ligand-gated ion channels 
for agonist, antagonist, allosteric modulator, and channel blocker properties. 
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